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ABSTRACT 
Thyroid cancer is the most common endocrine malignancy and its 
incidence is increasing worldwide. We previously found that normal rat thyroid 
cells, transduced with papillary thyroid cancer (PTC)-related oncogenes, 
display an inflammatory signature, that includes cytokines, chemokines and 
their receptors (Melillo at al., 2005). One of the chemokine receptors we 
identified, CXCR4, is frequently up-regulated in thyroid cancer and the 
chemokine SDF-1, a CXCR4 ligand, induces proliferation, survival and 
invasive ability of PTC cells; moreover, CXCR4 blocking compounds inhibit 
thyroid cancer growth (Castellone et al., 2004; De Falco et al., 2007).  
In order to better understand the molecular mechanisms of the biological 
effects of CXCR4/SDF-1? in thyroid carcer, we performed a global genome 
expression profile, through DNA microarrays, of CXCR4-expressing human 
papillary thyroid carcinoma cells (TPC-1) treated or not with SDF-1?. We 
identified, as transcriptional targets of CXCR4/SDF-1?, two tyrosine-kinase 
receptors: TYRO3 and AXL. These proteins belong to a small Protein Tyrosine 
Kinase (PTK) subfamily of receptors that includes three members: TYRO3, 
AXL and MER, from which this family is named TAM; they can be activated 
by two ligands, GAS6 and Protein S, are involved in the regulation of immune 
response, and are overexpressed in some epithelial cancers (Linger et al., 
2008). We found that TPC-1 cells, derived from a human PTC, constitutively 
express TYRO3 and AXL receptors, but SDF-1? stimulation increased their 
protein level and tyrosine phosphorylation. We found that most of the available 
thyroid cancer cell lines express both the receptors, albeit to different extent, 
and AXL was always much more abundant than TYRO3. In most cell lines, the 
two receptors display high levels of tyrosine-phosphorylation, due to 
constitutive expression of GAS6. An exception to this rule was the TPC-1 cell 
line, in which AXL was highly phosphorylated despite the fact that GAS6 is 
absent. AXL and its ligand GAS6 are also overexpressed in human thyroid 
carcinoma samples with respect to normal thyroid, as assessed by IHC. The 
inhibition of TYRO3 and AXL by blocking reagents or RNA interference 
targeting each receptor or the ligand decreased cell proliferation and resistance 
to apoptotic stimuli in different thryoid cancer cell lines. In cell lines that 
expressed both receptors and ligand, the simultaneous blockade of these 
molecules dramatically affected cell viability. Accordingly, we showed that the 
stimulation of GAS6-negative TPC-1 cells with exogenous  GAS6 increased 
their proliferation and survival. Finally, we found that the blockade of AXL 
receptor consistently impaired thyroid carcinoma cell line invasiveness 
through Matrigel and, moreover, it inhibited tumor growth in nude mice.  
In this thesis project, we provide evidences that targeting CXCR4/SDF-1 
or TYRO3/AXL/GAS6 axis might be exploited as novel anticancer therapyes 
for human thyroid carcinomas. 
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1. BACKGROUND 
 
1.1 Thyroid cancer 
The thyroid gland develops in the embryo as a tubular evagination of the 
pharyngeal endoderm at the basis of the tongue. It is located in the neck, beside 
the trachea. The functional thyroid unit consists of the follicle, a hollow 
spheroid lined by a single layer of columnar epithelial (follicular) cells, filled 
with colloid containing thyreoglobulin secreted by these cells. A small 
minority of follicles includes a second epithelial cell type, the C or 
parafollicular cells, which arise from the neuroectoderm of the neural crest and 
produce calcitonin.  
Thyroid cancer is the most frequent endocrine malignancy with an 
incidence of about 9-100.000 cases/year; moreover, the incidence increases 
with age, reaching a plateau at 50 years. Thyroid cancer can derive from both 
the follicular and the parafollicular cells. 
 
1.1.1 Classification, etiopathogenesis, clinical features of thyroid 
carcinoma 
 
Thyroid carcinoma is responsible for about 60% of deaths secondary to 
endocrine cancer (Sherman 2003).  Malignant thyroid tumors can derive from 
any of the gland cell populations, although those deriving from the epithelial 
cells are most frequent. The most common carcinomas deriving from thyroid 
follicular cells are: (1) the well-differentiated thyroid carcinomas (WDTC), 
including the papillary carcinoma (PTC), and the follicular carcinoma (FTC); 
(2) the recently identified poorly differentiated carcinomas, (PDC), 
hystologically between the un- and the differentiated tumors; (3) the 
undifferentiated or anaplastic carcinomas (ATC) (Rosai 2004).  
PTC is the most common thyroid malignancy; it accounts for 75 to 80% 
of all thyroid cancers, showing an incidence peak at 40-50 years. A well-
established cause of PTC is the exposure to ionizing radiations, especially in 
the neck region; in fact, about 2-4% of the patients irradiated to treat deseases 
such as acne or enlarged thymus, develop a differentiated thyroid carcinoma 
after about 20-30 years. Accordingly, the frequency of PTC is dramatically 
increased in the children exposed to the massive release of radionuclides that 
followed the explosion of the nuclear reactor in Chernobyl in 1986. 
Immunohistochemically, PTC features distinctive architectural pattern and cell 
nuclei morphology, and is usually associated with good therapeutic response 
and prognosis. However, PTC can usually metastasize to the cervical 
lymphonodes; distant metastasis are uncommon, but lung and bone are the 
most frequent sites. The solid/follicular, tall-cell and diffuse/follicular variants 
of PTC have been associated with increased malignancy (Rosai et al. 1992).  
FTC is less frequent than PTC and represents about 10-30% of thyroid 
cancers; it is particularly linked to dietary iodine deficiency (Williams et al., 
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1997) and both iodine and iodine deficiency and genetic influences could 
account for its link with a history of nodular goiter (Ron E et al., 1987). 
ATC is one of the most aggressive solid tumors in humans. ATC cancer 
cells are extremely undifferentiated and spread rapidly to other parts of the 
body; ATC makes up only about 1% of all thyroid cancers. Metastasis to 
regional lymph-nodes are quite common as well as distant ones; no effective 
therapy is available for ATC and prognosis is extremely negative, with a mean 
survival of six months after diagnosis (Giuffrida et al. 2000). 
Finally, the medullary thyroid carcinoma (MTC) derives from the 
calcitonin-secerning parafollicular C cells. About 5 to 7% of all thyroid cancers 
are medullary; of the four types of thyroid cancers, only MTC has a clear 
genetic predisposition that can be passed on in families; in fact, together with 
pheochromocytoma, parathyroid adenoma and other tumor types, MTC can be 
inherited in the context of autosomal dominant MEN 2 (multiple endocrine 
neoplasia type 2) syndromes, MEN 2A and MEN 2B, and FMTC (familial 
medullary thyroid carcinoma) (Cote et al. 2003). 
(Fig.1) 
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Figure 1: Features of thyroid tumors (Modified from Williams 2002). 
 
 
1.1.2 Molecular genetics of thyroid tumors 
 
PTC 
Several studies on thyroid tumors have allowed the identification of 
many genetic alterations. In particular, four genetic lesions, at the somatic 
level, are associated with PTC. They include chromosomal aberrations 
targeting the RET or TRKA tyrosine kinase receptors and point mutations in 
RAS or BRAF genes.  
???
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In a sizeable fraction of papillary thyroid carcinomas, the kinase domain 
of the tyrosine kinase receptor for the GDNF (Glial-Derived Neurotrophic 
Factor), c-Ret (REarranged during Transfection), is fused with the N-terminal 
region of constitutively expressed, heterologous genes, such as H4 (in 
RET/PTC1) or RFG (in RET/PTC3) (Manie et al., 2001). In RET/PTC 
rearrangements, fusion with protein partners, possessing protein-protein 
interaction domains, provides RET/PTC proteins with coiled-coil domains, 
thereby resulting in ligand-independent activation of c-Ret tyrosine kinase 
activity (Santoro et al. 1995). RET/PTC1, the H4-RET fusion, and RET/PTC3, 
the RFG-RET fusion, are the most prevalent variants. RET/PTC3 is frequently 
found in radiation-associated-PTC occurred after the Chernobyl accident 
(Fagin 2002). RET/PTC-transgenics develop PTC, proving that RET/PTC 
oncogenes are able to initiate thyroid carcinogenesis (Santoro et al., 1996). 
RET/PTC oncogenes are detected with a high frequency in clinically-silent 
small PTC, confirming that they can be early events in thyroid tumorigenesis 
(Fusco et al. 2002). Similar rearrangements of the high affinity receptor for 
NGF (Nerve Growth Factor), TRKA, can be also found, at a low prevalence in 
human PTC (Alberti et al., 2003). As a member of the tyrosine kinases receptor 
family (RTK), and thanks to its intrinsic kinase activity, RET activates many 
intracellular signaling pathways. Upon binding to ligand, it dimerizes and 
autophosphorylates various cytoplasmic tyrosines. The phosphorylated 
tyrosines thus become binding sites for intracellular molecules containing 
phosphotyrosine-binding motifs, thereby initiating a diverse array of signaling 
pathways (Santoro et al. 2004). In RET/PTC rearrangements, the fusion with 
protein partners possessing protein-protein interaction motifs provides 
RET/PTC kinases with dimerizing interfaces, thereby resulting in ligand-
independent autophosphorylation. The RET intracellular domain contains at 
least 12 autophosphorylation sites, 11 of which are maintained in RET/PTC 
proteins (Kawamoto et al. 2004). Phosphorilated tyrosine 905 (Y905) is a 
binding site for SH2-containing proteins, such as Grb7/10 adaptors (Pandey et 
al. 1996). Phosphorilated tyrosines 1015 and 1096 are responsible for binding 
of phospholipase C? and GRB2, respectively (Borrello et al. 1996, Jhiang S.M. 
2000; Hansford et al. 2000; Airaksinen M.S. et al. 1999; van Weering et al. 
1998), and phosphorilated tyrosine 981 for c-Src (Encinas et al. 2004). The 
multi-docking site tyrosine 1062 is the binding site for several proteins 
including the Shc family proteins (Shc and N-Shc/RAI), IRS1/2, FRS2, 
DOK1/4/5 and Enigma (Ichihara et al. 2004). Binding to Shc and FRS2 
mediates recruitment of Grb2-SOS complexes, leading to GTP exchange on 
RAS and RAS/ERK stimulation (Asai et al. 1996; Melillo et al. 2001); 
moreover, it is responsible for the activation of the phosphatidylinositol 3-
kinase (PI3K)/AKT and the c-Jun amino-terminal protein kinase (JNKs) and 
the p38MAPK (Jhiang S.M. 2000; Hansford et al. 2000; van Weering et al. 
1998).  
(Fig. 2). 
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Figure 2: Signaling pathways activated by RET (modified by Drosten 2006).  
 
 
Activating point mutations in RAS small GTPases are found roughly in 
10% of PTC, mainly in those belonging to the follicular variant (PTC-FV) 
(Zhu et al. 2003). Point mutations in BRAF are the most common genetic 
lesions found in PTC (up to 50% of the cases) (Kimura et al. 2003; Xu et al. 
2003; Soares et al. 2003; Fukushima et al. 2003; Cohen et al. 2003). BRAF is a 
member of the RAF family of serine/threonine kinases and it is a component of 
the RAF-MEK-ERK signaling module. Activation of the RAF proteins is 
mediated through binding of RAS in its GTP-bound state. Once activated, RAF 
kinases phosphorylate MEK which in turn phosphorylates and activates ERK 
(Malumbres et al. 2003). A Glutamine for Valine substitution at residue 600 
(V600E) in the activation segment accounts for more than 90% mutations of 
BRAF in PTC (Kimura et al. 2003; Cohen et al. 2003; Soares et al. 2003). This 
mutation enhances BRAF activity through disruption of the autoinhibited state 
of the kinase.  (Fig. 3). 
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Figure 3. Structure of BRAF gene. CR: conserved regions; triangles denote the common oncogenic mutations. RBD: 
Ras Binding Domain. CRD: Cystein Rich Domain. (Modified from Cohen 2003). 
 
In human PTC, the genetic alterations of RET/PTC, RAS and BRAF are 
mutually exclusive, suggesting the existence of a common signaling cascade; 
moreover, mutations at more than one of these sites are unlikely to provide an 
additional biological advantage (Kimura et al. 2003, Cohen et al. 2003, Soares 
et al. 2003). 
  
FTC 
Follicular thyroid carcinoma (FTC) is also a well-differentiated cancer 
developing from thyroid cells. In this carcinoma the presence of K-, H-, and N-
RAS mutations is quite common. More recently, it has been shown that a quite 
high proportion of FTC carries the PAX8/PPAR? rearrangement (Nikiforova 
MN et al. 2003). PAX8 encodes a thyroid-specific transcription factor, while 
PPAR? is a nuclear receptor involved in lipid metabolism and tumorigenesis. 
The resulting fusion protein has dominant negative activity on wild type 
PPAR? (Kroll et al. 2000). 
 
PDC and ATC 
Point mutations in the RAS oncogene and in the tumor suppressor p53 
have been described in PDC and ATC (Garcia-Rostan et al. 2003, Donghi et al. 
1993, Fagin 1993). It is well known that p53 safeguards the cell cycle, the 
DNA repair and the apoptotic processes; thus, mutations in its sequence can 
account for the progression from a more differentiated to an anaplastic 
carcinoma, according to a model already described for the colon carcinoma by 
Vogelstein (Vogelstein et al., 1988). Garcia-Rostan and colleagues found 
somatic mutations within the PI3K catalytic subunit in 23% of analyzed ATC 
as well as activating point mutations of ?-catenin?(Garcia-Rostan et al. 2005). 
Mutations of BRAF gene have been detected in anaplastic carcinomas??
suggesting that some ATC may arise from a preexisting WDTC, while others 
may arise de novo (Nikiforova MN et al. 2003). 
 
MTC 
Germline point mutations in RET cause the dominantly inherited cancer 
syndromes: multiple endocrine neoplasia (MEN) 2A and 2B, and familial 
medullary thyroid carcinoma (FMTC). MEN2 patients are invariably affected 
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by Medullary Thyroid Carcinoma (MTC), a malignant tumour arising from 
calcitonin-secerning C cells of the thyroid. Additional features can be present 
in MEN2A (pheochromocytoma and parathyroid adenoma) and MEN2B 
(pheochromocytoma, mucosal neuroma and ganglioneuroma of the intestine) 
(Brandi et al. 2001). Most MEN2B patients carry the M918T substitution in the 
P+1 loop in the kinase domain. In MEN2A and most FMTC patients, 
mutations affect one cysteine of the extracellular cysteine-rich domain of RET 
(609, 611, 618, 620, 630, 634) that can change to different residues. A 
significant genotype-phenotype correlation is observed. In particular, about 
90% of MEN2A patients have Cys634 mutation, and this mutation is highly 
predictive of the presence of pheochromocytoma and parathyroid hyperplasia. 
(Santoro et al. 1995; Carlomagno et al. 1997). RET activation by mutations 
targeting the intracellular domain is less understood (Santoro et al. 1995, 
Iwashita et al. 1999) but it can be envisaged that a modification of the structure 
of the kinase may switch on its enzymatic function. 
 
1.2 Inflammation and cancer 
 
Inflammation is a physiological, protective response organized by the 
organism in response to tissue damages. Several chemical signals initiate and 
sustain the inflammatory response whose aim is repairing the damage. Several 
cells migrate in the sites of tissue damage, thanks to the action of chemotactic 
and adhesion proteins, including the integrin and selectin family members 
(Coussens et al., 2002). Resident cells, such as macrophages and mast cells, 
and migrating cells, such as neutrophils, secrete ROS, vasoactive proteins, such 
as histamine and leukotrienes, and several other factors, such as cytokines, 
chemokines and proteases that remodel the extracellular matrix (de Visser et 
al., 2006). 
(Fig. 4) 
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Figure 4 A model of innate and adaptative immune-cell function during inflammation-associated cancer 
development (modified from De Visser 2006). 
 
Inflammation is an auto-limiting process; however, the abnormal 
persistence of the stimuli that first induced the inflammatory response or the 
failure of the mechanisms determining its termination cause chronic 
inflammation (Coussens et al., 2002). A functional relationship between 
chronic inflammation and cancer has been envisaged long ago. In 1863, 
Virchow hypothesized that the origin of cancer was at sites of chronic 
inflammation (Virchow 1863), in part based on the hypothesis that some 
classes of irritants, together with the tissue injury and ensuing inflammation 
they cause, enhance cell proliferation (Balkwill and Mantovani 2001). 
Although it is now clear that proliferation of cells alone does not cause cancer, 
sustained cell proliferation in an environment rich in inflammatory cells, 
growth factors, activated stroma, and DNA-damage-promoting agents, 
certainly potentiates and/or promotes neoplastic risk. Leukocytes 
physiologically secrete ROS and RNS, to eliminate the pathogens. However, 
these highly reactive metabolites induce the production of peroxynitrite and 
other mutagenic agents; therefore, they can induce “DNA damage”, i.e. 
mutations in proliferating cells (Coussens et al., 2002). Thus, in the case of a 
persistent tissue damage of O2 and N highly reactive metabolites secreted by 
the inflammatory cells induce point mutations, rearrangements and double 
strand breaks in the DNA of proliferating cell. This results in a higher 
probability of oncogene activation or tumor suppressor loss of function 
(Colotta et al., 2009). 
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1.3 Thyroid cancer and inflammation 
 
An association between Hashimoto’s thyroiditis (HT) and thyroid cancer 
has been reported in about the 30% of the cases (Di Pasquale, 2001; 
Wirtschafter.et al., 1997; Mechler et al., 2001; Segal et al., 1985; Eisemberg et 
al., 1989; Ott et al., 1987; Sclafani et al., 1993; Pisanu et al., 2003) and the 
increased incidence of carcinomas in patients with thyroiditis suggests it might 
be a precancerous condition. The vast majority of thyroiditis-associated 
carcinomas are papillary; however, also follicular and anaplastic, medullary 
carcinomas have been reported (Guarino et al., 2009). Hashimoto thyroiditis is 
an autoimmune disorder in which the immune system is activate to react 
against a variety of thyroid antigens. HT is characterized by a progressive 
depletion of thyroid epithelial cells (thyrocytes), mononuclear cell infiltration 
and fibrosis, which ultimately leads to thyroid functional insufficience. 
Sensitization of autoreactive CD4+ T-helper cells to thyroid antigens appears 
to be the initiating event, but multiple immunological mechanisms might 
contribute to thyreocyte death in HT. This disease is also characterized by 
proliferating nodules as well as cytological alterations and nuclear 
modifications similar to those of the papillary carcinomas (Weetman et al., 
2004). The thyroid follicular cells in HT may have chromosomal defects, such 
as the RET/PTC1 rearrangement, the hallmark of many papillary thyroid 
carcinomas. Several other evidences suggest a role for RET/PTC in the 
association between thyroiditis and cancer. In fact, patients exposed to 
radiation from the Chernobyl nuclear power plant disaster often develop not 
only RET/PTC-induced papillary tumors but also an associated autoimmune 
thyroiditis (Williams et al 2002). Transgenic mice engineered to express 
RET/PTC develop papillary carcinomas and chronic thyroiditis (Powell et al. 
1998). Finally, Wirtschafter and colleagues have detected RET/PTC expression 
in about the 90% of the HT they have analyzed (Wirtschafter et al., 1997). 
These data are, however, partially in contrast with the report by Rhoden and 
colleagues. These authors have found only few follicular cells expressing very 
low levels of the rearranged PTC protein in HT, thus suggesting that RET/PTC 
expression does not necessarily predicts the development of a papillary 
carcinoma in patients with thyroiditis (Rhoden et al., 2006). Two models have 
been hypothesized to explain the association between Hashimoto’s thyroiditis 
and RET/PTC. The first one suggests that inflammation might facilitate the 
rearrangement. According to this hypothesis, free radicals production, cytokine 
secretion, cellular proliferation as well as other phenomena correlated with 
inflammation might predispose to the rearrangement in follicular cells. Another 
hypothesis suggests that it is the rearrangement that promotes thyroid 
inflammation. Accordingly, RET/PTC induces a severe inflammatory response 
in animal models and the synthesis of many inflammatory proteins in epithelial 
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thyroid cells (Powell et al., 2003; Melillo et al., 2005; Puxeddu et al., 2003; 
Guarino et al., 2009).  
 
1.4 Chemokines and chemokine receptors 
 
Chemokines are a group of small (~8-14 KDa) secretory proteins; they 
belong to a family of chemotactic cytokines which possess a relatively high 
degree of specificity for chemoattraction of specific leukocyte populations; 
they are involved in the recruitment of downstream effector cells and dictate 
the natural evolution of the inflammatory response. The profile of 
cytokine/chemokines persisting at an inflammatory site is important in the 
development of chronic disease. Chemokines can be produced not only by 
leukocytes but also by fibroblasts, endothelial and epithelial cells. Chemokine 
production is induced by inflammatory cytokines and growth factors 
(Mantovani et al. 2004; Balkwill 2004). More than 50 chemokines and 18 
chemokine receptors have been discovered. They are subdivided into four 
groups based on the relative position of cysteine residues: CC, CXC, XC and 
CX3C, with the CC and CXC groups being by far the most common ones. 
(Fig. 5). 
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Figure 5: Chemokine families (From Luster 1998). 
 
 
Corresponding groups of CCR, CXCR, XCR and CX3CR receptors of 
the GPCR (G protein coupled receptor) family (seven-transmembrane 
receptors) mediate the functions of those chemokines on their target cells. 
Several chemokines can bind the same receptor and one chemokine can bind to 
several receptors, creating multiple combinations and, therefore, multiple 
biological outcomes (Balkwill 2004).  
(Fig. 6). 
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Figura 6: The chemokine wheel. This illustration explains the ligand-binding patterns of the seven-transmembrane 
domain G-protein-coupled human chemokine receptors. Receptors CXCR1–CXCR3, CCR1–CCR5, CCR7, CCR8, 
CCR10 and CXCR1 all bind several chemokines. By contrast, CCR6, CCR9, CX3CR1 and CXCR4–CXCR6 bind only 
one ligand each. Duffy and D6 are considered to be ‘deceptors’, as they bind ligands but do not signal, thereby acting 
as a negative feedback for chemokine responses.(Modified by Balkwill, 2004). 
 
Chemokine receptors are coupled to heterotrimeric G proteins of the G?i 
class and can be inhibited by Bordetella pertussis toxin (PTX). Their activation 
leads to a cascade of cellular events, including the generation of diacylglycerol 
and inositol triphosphate, release of intracellular calcium, inhibition of adenyl 
cyclase, and activation of several signaling proteins including Janus tyrosine 
kinase/signal transducers and activators of transcription (Jak/STAT), protein 
kinase C, phospholipase C, phosphatidylinositol 3-kinase (PI3K) and small 
GTPases of the Ras and Rho families. This results in activation of AKT and 
ERK and in cell polarization, adhesion and migration (Luster et al. 1998).  
(Fig. 7). 
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Figure 7: Signaling pathways activated by chemokines binding to their receptors and promoted 
biological activities (Modified from Mellado et al. 2001). 
 
1.4.1 Chemokines and cancer 
 
Initially, chemokines have been functionally defined as soluble factors 
able to control the directional migration of leukocytes, in particular during 
infection and inflammation. Although originally identified on leukocytes, 
functional chemokine receptors are also found on epithelial cells, particularly 
on those that have undergone malignantly transformation. Therefore it appears 
that the biological effects mediated by chemokines are by far more complex 
and that virtually all cells, including many tumor cell types, can express 
chemokines and chemokine receptors (Rollins 1997; Rossi et al. 2000). 
Accordingly, one of the most interesting aspects of the relationship between 
inflammation and cancer is the fact that several tumors may use molecules of 
the innate immune sytem, such as chemokines and their receptors, not only to 
recruit leukocytes, but also for growth, survival and metastasis (Balkwill and 
Mantovani 2001). It can be envisaged that a mixture of chemokines are 
produced in the tumor microenvironment and act in an autocrine or paracrine 
fashion on neighboring homotypic cells. 
New informations indicate that chemokines can influence metastatic 
potential and site-specific spread of cancer cells (Muller et al. 2001; Kang et al. 
2003). Therefore, chemokines can have a two-sided effect in cancer as they can 
influence both leukocyte infiltration in tumor sites and the malignant 
phenotype of neoplastic cells. It is becoming now clear that different 
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chemokines produced locally in the tumor can strongly influence the 
composition of inflammatory infiltrate that can be composed by macrophages, 
endothelial cells, fibroblasts, but also by mast cells, NK and B cells (Brigatti et 
al., 2002; Coussens et al., 2002; Poliard et al 2004).?In particular, we observed 
that mast cells are present into thyroid carcinomas and that they can promote 
proliferation, survival and invasive ability of thyroid cancer cells in culture 
(Melillo et al., submitted to Oncogene). These evidences suggest that 
leukocytic tumoral infiltrate is able to promote cancer progression; 
furthermore, the local production of chemokines, that are the typical and most 
important chemotactic proteins for leukocytes in the tumoral site, can be 
considered as a very poor prognostic factor (Luboshits et al., 1999; Azenshteen 
et al., 2002; Saji et al., 2001). 
 
1.4.2 Role of CXCR4 in human cancer 
 
CXCR4 is one of the chemokine receptors higly expressed in tumors of 
epithelial and non epithelial origin. CXCR4 is the receptor for the chemokine 
CXCL12/SDF-1? (Stromal Derived Factor-1). It is broadly expressed in cells 
of both the immune and the central nervous system and can induce migration 
of CXCR4-positive cells in response to its ligand. Mice lacking CXCR4 exhibit 
hematopoietic and cardiac defects identical to those of SDF1-deficient mice 
(Nagasawa et al., 1996), suggesting that CXCR4 may be the only receptor for 
SDF-1. SDF-1 is a chemokine that belongs to the CXC family, characterized 
by the presence of 4 conserved cysteines, which form 2 disulfide bonds. The 
SDF-1 protein is produced in two forms, SDF-1? and SDF-1? by alternate 
splicing of the same gene. These chemokines activate leukocytes and are often 
induced by proinflammatory stimuli such as lipopolysaccharide, TNF or IL1. 
SDF-1 is generally expressed at high levels by tumoral stroma, thus generating 
a paracrine loop which sustains the malignant phenotype of cancer cells 
(Orimo et al., 2006). Several studies have demonstrated the implication of 
CXCR4/SDF-1? couple in tumor progression. In particular, the chemokine 
receptor CXCR4 and its ligand SDF-1/CXCL12 have been implicated in the 
metastatic spread of breast cancer cells. SDF-1 induces endothelial expression 
of VEGF-A; VEGF-A in turn upregulates CXCR4 on endothelial cells (Homey 
et al. 2002). Studies by Muller and co-workers (2001) suggest that chemokine 
expression is particularly high in target organs for breast cancer metastasis 
(Muller et al., 2001). The involvement of CXCR4 in metastasis is not limited to 
breast cancer, as CXCR4 is expressed in several tumour cell lines (for example, 
prostate carcinomas, B-cell lymphomas, astrogliomas and chronic lymphocytic 
leukaemias) that also respond to SDF-1 (Moore 2001). Moreover, it has been 
shown that the CXCR4-SDF-1 axis has an important role in promoting cell 
growth, invasiveness and survival in thyroid cancer cell cultures (Castellone et 
al., 2004). These data suggest that CXCR4 is one of the most important 
chemokine receptor for cancer cells. 
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1.5 TAM receptors 
 
In a screening for SDF-1-induced genes in thyroid cancer cells, we 
identified Tyro3 and Axl, two tyrosine kinase receptors (RTK). These receptors 
belong to a small Protein Tyrosine Kinase (PTK) subfamily of receptors, that 
includes three members, Tyro3, Axl and Mer, from which this family was 
named TAM. The three TAM receptors were identified as a distinct receptor 
PTK subfamily in 1991. They share a common structure, that includes an 
extracellular, ligand-binding region which contains two immunoglobulin-
related domains and two fibronectin type III repeats, each in tandem; a single-
pass transmembrane domain; a catalytically competent, cytoplasmic PTK 
domain (Lemke and Rothlin, 2008). The TAM receptors are most closely 
related to RON (also known as CD136), the PTK receptor for macrophage-
stimulating protein, and to MET, the hepatocyte growth-factor receptor 
(Manning et al., 2002). Similar to all others RTKs, the TAMs seem to function 
as dimers (Sasaki et al., 2006). TAM receptors are frequently co-expressed in 
vascular, reproductive, nervous and mature immune system in adults, but they 
seem to have a pivotal role in innate immunity; TAM receptors inhibit 
inflammation in dendritic cells and macrophages, promote the phagocytosis of 
apoptotic cells and membranous organelles, and stimulate the maturation of 
natural killer (NK) cells (Lemke and Rothlin, 2008). Their expression is not 
indispensable for life, since knockout of each receptor produces viable and 
fertile mice. Interestingly, when all the three receptors are deleted, several 
phenotypes arise few weeks after birth. Indeed, TAM-deficient mice are 
unfertile (Lu et al., 1999), display retinal degeneration, and develop a systemic 
autoimmune disease (Lu et al., 2001). 
 
1.5.1 TAM receptors and their ligands 
 
TYRO3 (also named Tif/Sky/Dtk/Rse/Brt) was first cloned from a human 
myelogenous leukemia cell line. Its expression is widely distributed, but it 
appears to be higher in the central nervous system (Funakoshi et al., 2002) and 
brain (Ohashi et al., 1994); TYRO3 is also overexpressed in osteoclasts in 
bone, indicating a role in bone resorption (Nakamura et al., 1998). 
AXL (alternatively named Ufo/Ark/Tyro7) was originally identified in 
patients with chronic mielogenous leukemia (Liu et al., 1988) and chronic 
myeloproliferative disorder (Janssen et al., 1991; O’Bryan et al., 1991); it is 
ubiquitously expressed, being detected in cell lines of epithelial, mesenchymal 
and haematopoietic origins. It is also overexpressed in several cancer types and 
its levels correlate with cancer progression in some epithelial neoplasia. 
MER (alternatively named Eyk/Nym/Tyro12) was firstly identified as the 
homologue of the avian retroviral v-eyk oncogene (Jia et al., 1994). Human 
MER is named after its original reported expression pattern (monocytes and 
epithelial and reproductive tissues) (Graham et al., 1994). It displays tissue 
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specific expression, almost exclusively in the monocytic cell lineage, and has a 
role in the phagocytosis of apoptotic cells by macrophages and in the 
homeostasis of the retina and of the immune system; finally, MER appears able 
to induce the cytoskeletal remodelling that is required for engulfment during 
phagocytosis (Todt et al., 2004; Jennings et al., 2005).  
The two physiological ligands that bind to and activate the TAM 
receptors are two closely related proteins, GAS6 (Growth-Arrest-Specific 6) 
(Manfioletti et al., 1993) and Protein S (Stitt et al., 1995). Both of them are 
highly similar vitamin K-dependent proteins. Gas6 was identified as a gene up-
regulated in NIH3T3 fibroblasts upon serum deprivation and can bind, with 
distinct affinities, the three receptors (Nagata et al., 1996). Protein S has been 
identified as a negative regulator of the blood coagulation process (Rezende et 
al., 2004) and has a role in the engulfment of apoptotic bodies by phagocytic 
cells. It has been shown that Protein S can act as an agonist for Tyro3 and Mer, 
while there are no data available sustaining Axl/Protein S interaction; 
moreover, it is not clear whether ligands can bind as heterodimers and how 
receptor homo-heterodimers eventually respond to different combinations of 
ligands. The two ligands display 42% aminoacid identity; each protein has a 
~60 aminoacid Gla domain at its amino terminus, a region rich in glutamic acid 
residues that are ?-carboxylated in a vitamin-K-dependent reaction (Gla-
domain-containing proteins are prominent components of the blood 
coagulation cascade). These Gla domains bind the phospholipid 
phosphatidylserine on apoptotic cells (Huang et al., 2003) and this is an 
important feature of the in vivo function of GAS6 and Protein S (Nakano et al., 
1997; Anderson et al., 2003). The Gla domain is followed by a loop region 
constituted by four epidermal growth factor (EGF)-like-repeats and by a C-
terminal globular sex hormone binding globulin (SHGB)-like domain (Sasaki 
et al., 2006). This last region is both necessary and sufficient for receptor 
activation and biological activity (Sasaki et al., 2002). 
(Fig. 8). 
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Figure 8: TAM receptors and their ligands. Tam receptors dimers bind to their ligands, GAS6 and Protein S, 
through interaction between the two N-terminal immunoglobulin-like domains of the receptors and the SHBG (Sex 
Hormon Binding Globulin) domain  of the ligands. Via their  N-terminal Gla domains, GAS6 and Protein S can bind to 
phosphatidylserine  that is dispayed on the extracellular surface of the plasma membranes of apoptotic cells or on the 
outer segment of photoreceptors. EGF: epidermal growth factor; FNIII: fibronectine type III. (Modified from Greg 
Lemke and Carla V. Rothlin 2008). 
 
 
1.5.2. TAM receptors and cancer 
 
It has been highlighted that TAM receptors are endowed with 
transforming ability and also play an important role in cancer development and 
progression; together, these receptors regulate many processes, such as cell 
proliferation, survival, cell adhesion, migration, inflammation and cytokine 
release, thus suggesting their implication in human cancerogenesis (Linger et 
al., 2008). 
Axl was originally identified as a transforming gene in chronic myeloid 
leukemia patients and in a chronic myeloproliferative disorder wherein it was 
suggested to be capable of transforming cells without intrinsic activating 
mutations (Liu et al., 1991). Moreover, Axl has been shown to be 
overexpressed and to have mitogenic and prosurvival roles in a broad spectrum 
of human malignancies, including colon (Craven et al., 1995), oesophageal 
(Nemoto et al., 1997), thyroid (Ito et al., 2002), breast (Zantek et al., 2001), 
lung (Shieh et al., 2005), renal (Gustafsson et al., 2009) and ovarian (SunW et 
al., 2004) carcinomas. Recently, Axl was shown to mediate glioma cell 
proliferation, migration, and invasion (Vajkoczy et al., 2006), and in human 
gliomas, both Axl and its ligand Gas6 are frequently overexpressed and this 
predicts poor prognosis (Hutterer et al., 2008). Moreover, Axl affects multiple 
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cellular behaviors required for neovascularization, such as endothelial cell 
proliferation, migration, survival, and tube formation in vitro, and regulates 
angiogenesis in vivo (Holland et al., 2005). 
Although able to induce cell transformation experimentally (Lan et al., 
2000), information about TYRO3 expression in human cancer is still scant. To 
date, TYRO3 has been detected in several human leukaemic cell lines and 
blasts of acute myeloid leukaemia patients (Crosier et al., 1995), and 
overexpressed in myeloma cells compared to autologous B-lymphoblastoid cell 
lines (De Vos et al., 2001). 
As with TYRO3, very little has been reported about the 
expression/activity of MER in cancer. Experimentally, both the transforming 
and antiapoptotic abilities of this receptor have been observed through at least 
its intracellular region (Georgescu et al., 1999). One microarray study has 
shown MER to be overexpressed in an ACTH-secreting adenomas compared 
with normal pituitary gland (Evans et al., 2001). Also, since its original 
detection in neoplastic B- and T-cell lines (Graham et al., 1999), MER up-
regulation has been observed in mantle cell lymphomas as compared to normal 
B cells (Ek et al., 2002). Finally, Gas6 is frequently co-expressed with Axl or 
Tyro3 in cancer cells; in some cancer types its expression levels correlate with 
a poor prognosis (Hutterer et al., 2008). 
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2. AIM OF THE STUDY 
 
 
This thesis project was aimed at understanding the biological role of 
chemokines and chemokine receptors in thyroid cancerogenesis. In particular 
we analyzed the role of the CXCR4/SDF1? receptor/ligand couple in thyroid 
cancer. Moreover, we studied the role of two CXCR4/SDF-1 transcriptional 
targets, the tyrosine kinase receptors Tyro3 and Axl, in thyroid cancer. 
Specifically, our focus was as follows: 
 
 
 
1. Evaluation of the the biological role of CXCR4 and of its ligand 
SDF-1? in thyroid cancer. 
 
2. Identification of SDF-1??induced transcriptional targets in thyroid 
cancer cells. 
 
 
3.  Study of the biological role of the tyrosine kinase receptors AXL and 
TYRO3 in thyroid cancer cells through deletion and overexpression 
approaches. 
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3.MATERIALS AND METHODS 
 
3.1 Cell cultures 
 
Human primary cultures of normal thyroid and ATC cells were obtained 
from F. Curcio (Dipartimento di Patologia e Medicina Sperimentale e Clinica, 
University of Udine, Udine, Italy;) P5, P5-2N, P5-3N, P5-4N (hereafter “NT”) 
and U-HTH83/U-HTH7, and cultured as described previously (Salvatore et al., 
2006). Human thyroid papillary cancer cell lines TPC1 , BcPAP and NIM have 
been described previously (Carlomagno et al., 2003; Inokuchi et al., 1995). 
TPC1 cells harbor a RET/PTC1 rearrangement; BCPAP cells harbor a 
BRAF(V600E) mutation in homozygosis; NIM cells harbor a BRAF(V600E) 
mutation in heterozygosis. The anaplastic cells FB1 cells harbor a 
BRAF(V600E) mutation in heterozygosis; 8505C and FRO harbor a 
BRAF(V600E) mutation in homozygosis (Salvatore et al., 2006); CAL62 cells 
express wild-type BRAF but mutant NRAS allele (Q61K);? U-HTH83 cells 
express wild-tipe BRAF but mutant HRAS allele (Q61R) ; C643 cells express 
wild-type BRAF but mutant HRAS allele (G13R); SW1736 cells harbor a 
BRAF(V600E); U-HTH7 cells express wild-type BRAF but mutant NRAS 
allele (Q61R); OCUT-1 cells harbor a BRAF(V600E) mutation in 
heterozygosis; ACT-1 cells express a wild-type BRAF but mutant NRAS 
(Q61K). (Guida et al., 2005). Continuous cell lines were maintained in DMEM 
supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 
1% glutamine. PC Cl 3 (hereafter "PC") is a differentiated thyroid follicular 
cell line derived from 18-month-old Fischer rats. PC cells were cultured in 
Coon’s modified Ham F12 medium supplemented with 5% calf serum and a 
mixture of 6 hormones (6H), including thyrotropin (TSH, 10 mU/ml), 
hydrocortisone (10 nM), insulin (10 μg/ml), apo-transferrin (5 μg/ml), 
somatostatin (10 ng/ml) and glycyl-histidyl-lysine (10 ng/ml) (Sigma Chemical 
Co., St. Louis, MO) (Fusco et al 1987). 
 
3.2 Tissue samples and immunohistochemistry 
 
Retrospectively-collected archival thyroid tissue samples from patients 
affected by ATCs were retrieved from the files of the Pathology Department of 
the University of Pisa, on informed consent, and tested for CXCR4 expression 
with a mouse monoclonal antibody against CXCR4 (clone 12G5; R&D 
Systems). Retrospectively-collected archival frozen thyroid tissue samples 
from 26 patients affected by thyroid carcinomas (8 PTCs, 10 FTCs and 8 
PDCs/ATCs) were retrieved from the files of the Struttura Complessa di 
Anatomia Patologica, Istituto Nazionale Tumori, Fondazione G. Pascale, of 
Naples, upon informed consent, and analysed for AXL and GAS6 expression, 
by using anti-AXL (R&D Systems) and anti-GAS6 antibodies for the staining( 
R&D Systems). Sections (4-8 μM thick) of paraffin-embedded samples were 
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stained with hematoxylin and eosin for histological examination to ensure that 
the samples fulfilled the diagnostic criteria required for the identification of 
PTC, FTC, PDC/ATC. Normal thyroid tissue samples were also retrieved from 
the Pathology Department of the University of Pisa and from Struttura 
Complessa di Anatomia Patologica, Istituto Nazionale Tumori, Fondazione G. 
Pascale of  Naples, as well. 
 
3.3 RNA interference  
 
Small inhibitor duplex RNAs targeting human CXCR4 were chemically 
synthesized by Proligo. Transfection was performed using 5 to 15 μg of duplex 
RNA and 6 μL of?Oligofectamine reagent (Invitrogen). For silencing of Axl, 
Tyro3 and Gas6, the SMARTpool (custom-synthesized siRNA) system by 
Dharmacon was used. As transfection reagent, DharmaFECT was used. 
Transfection was performed by using 100nM of SMARTpool and 6 μl of 
DharmaFECT (Dharmacon). ?
 
3.4 RNA extraction and reverse transcription polymerase chain reaction  
 
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley, West 
Sussex, UK) and subjected to on-column DNase digestion with the RNase-free 
DNase set (Qiagen) according to the manufacturer’s instructions. The quality 
of RNA was verified by electrophoresis through 1% agarose gel and visualized 
with ethidium bromide. Random-primed first strand cDNA was synthesized in 
a 50 μl reaction volume starting from 2 μg RNA by using the GeneAmp RNA 
PCR Core Kit (Applied Biosystems, Warrington, UK). Quantitative (real-time) 
reverse transcription polymerase chain reactions (QRT- PCR) were performed 
by using the SYBR Green PCR Master mix (Applied Biosystems) in the 
iCycler apparatus (Bio-Rad, Munich, Germany). Fluorescent threshold values 
were measured in triplicate and fold changes were calculated by the formula: 2-
(sample 1 ?Ct - sample 2 ?Ct), where ?Ct is the difference between the 
amplification fluorescent thresholds of the mRNA of interest and the ß actin 
mRNA. 
 
3.5 Generation of stable shRNA-expressing cell lines 
 
 We obtained 5 lentiviral constructs (pLKO.1puro) containing custom 
synthesized, 21-mer short hairpin RNA (shRNA) directed to various coding 
region of AXL cDNA and with puromycin resistance locus (Mission shRNA, 
pLKO.1 puro) from Sigma-Aldrich, Inc. (Stewart et al., 2003). We transfected 
8505-C the plasmid shAxl pool or a pool of non-targeting vectors (control, 
shCTR) by electroporation. Stable transfectants were clonally selected in 
medium with 500ng/ml puromycin for 15 days, and cell colonies were screened 
for Axl silencing by Western blot analysis. 
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3.6 Protein studies 
 
Protein extractions and immunoblotting experiments were performed 
according to standard procedures. Briefly, cells were harvested in lysis buffer 
(50 mM HEPES, pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 
mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 
mM Na3VO4, 10 μg of aprotinin/ml, 10 μg of leupeptin/ml) and clarified by 
centrifugation at 10,000 x g for 30 min. Protein concentration was estimated 
with a modified Bradford assay (Bio-Rad, Munich, Germany). Immune 
complexes were detected with the enhanced chemiluminescence kit (ECL, 
Amersham). Recombinant human SDF-1? was from Peprotech (Princeton 
Business Park, Rocky Hill, NJ). Anti-AXL for Western Blot and 
immunoprecipitation analysis was from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA); anti-phosphorilated AXL, specific for the active AXL 
phosphorilated at tyrosine 779, was from R&D Systems; anti-GAS6 for 
Western Blot was from R&D Systems. Anti-TYRO3 (NB 100-2311) for 
Western Blot and immunoprecipitation was from Novus Biologicals. Anti-
CXCR4 was from Abcam Ltd. Anti-AKT and antiphosphoAKT, specific for 
the active AKT phosphorylated at serine 473, were from Cell Signaling 
(Beverly, MA). Anti-phosphorylated p44/42 MAPK, specific for the active 
MAPK phosphorilated at threonins 202 and 204, and anti-p44/42 MAPK were 
from Cell Signaling (Beverly, MA). Monoclonal anti-?tubulin was from Sigma 
Chemical Co. Secondary anti-mouse and anti-rabbit antibodies coupled to 
horseradish peroxidase were from Bio-Rad; secondary antibodies coupled to 
horseradish peroxidase were from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA) and from Biorad. Anti-phosphotyrosine antibodies were from Upstate 
Biotechnology Inc., (Lake Placid, NY, USA). 
 
3.7 Flow cytometric analysis.  
 
Subconfluent cells were detached from culture dishes with a solution of 
0.5 mmol/L EDTA and then washed thrice in PBS buffer. After saturation with 
1 μg of human IgG/105 cells, cells were incubated for 20 min on ice with 
phycoerythrin (PE)-labeled antibodies specific for human CXCR4 (R&D 
Systems) or isotype control antibody. After incubation, unreacted antibody was 
removed by washing cells twice in PBS buffer. Cells resuspended in PBS were 
analyzed on a FACSCalibur cytofluorimeter using the CellQuest software 
(Becton Dickinson). Analyses were performed in triplicate. In each analysis, a 
total of 10
4 
events were calculated. 
 
 
3.8 ELISA assay 
 
Thyroid cells plated in 6-well dishes were allowed to grow to 70% 
confluency and then serum-deprived for 24h. Gas6 levels in culture 
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supernatants were measured using a quantitative immunoassay ELISA kit 
(QuantiKine colorimetric Sandwich assay ELISA, R&D Systems, UK), 
following the manufacturer’s instructions. Triplicated samples were analyzed 
at 490 nM with an ELISA reader (Model 550 microplate reader, Bio-Rad). 
ELISA results were validated on cell lysates by Western Blotting analysis by 
using an anti-GAS6 antibody (R&D Systems). 
 
3.9 Matrigel invasion 
 
In vitro invasiveness through Matrigel was assayed using transwell cell 
culture chambers according to described procedures. Briefly, confluent cell 
monolayers were harvested with trypsin/EDTA and centrifuged at 800xg for 10 
min. The cell suspension (1x10
5
 cells/well) was added to the upper chamber of 
a pre-hydrated polycarbonate membrane filter of 8 μM pore size (Costar, 
Cambridge, MA, USA) coated with 35 μg Matrigel (Collaborative Research 
Inc., Bedford, MA, USA). The lower chamber was filled with complete 
medium or 2.5% FCS (as indicated). After having plated stably-AXL-silenced 
cells on matrigel, cells were then incubated at 37°C in a humidified incubator 
in 5% CO2 and 95% air for 24h and 48h. Nonmigrating cells on the upper side 
of the filter and Matrigel were wiped off and migrating cells on the reverse side 
of the filter were stained with 0.1% crystal violet in 20% methanol for 15 min, 
and photographed. The stained cells were lysed in 10% acetic acid. Triplicated 
samples were analyzed at 570 nM with an ELISA reader (Model 550 
microplate reader, Bio-Rad). The results were expressed as the percentage of 
8505-C sh-Axl migrating cells with respect to the controls. 
 
3.10 Cell proliferation 
 
S-phase entry was evaluated by BrdU incorporation and indirect 
immunofluorescence. Cells were serum deprived for 12 h and BrdU was added 
at a concentration of 10 μM for the last 2h before the reaction was stopped. 
Subsequently, cells were fixed in 3% paraformaldehyde and permeabilized 
with 0.2% Triton X-100. BrdU-positive cells were revealed with Texas-Red-
conjugated secondary antibodies (Jackson Immuno Research Laboratories, Inc. 
Philadelphia, PA). Cell nuclei were identified by Hoechst staining. 
Fluorescence was visualized with a Zeiss 140 epifluorescent microscope.  
For growth curves, cells were plated at a density of 0.5 x 10
5
 with complete 
medium or in low serum conditions (2.5%) (as shown) and counted at the 
indicated time-points. 
 
3.11 TUNEL assay 
 
For terminal deoxynucleotidyl transferase-mediated. deoxyuridine 
triphosphate nick end-labeling (TUNEL), an equal number (5 x 10
3
) of thyroid 
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carcinoma cells from the different lines was seeded onto single-well Costar 
glass slides. Cells were fixed in 4% (w/v) paraformaldehyde and permeabilized 
by the addition of 0.1% Triton X-100/0.1% sodium citrate. Slides were rinsed 
twice with PBS, air-dried and subjected to the TUNEL reaction (Roche). All 
coverslips were counterstained in PBS containing Hoechst 33258, rinsed in 
water and mounted in Moviol on glass slides. The fluorescent signal was 
visualized with an epifluorescent microscope (Axiovert 2, Zeiss) (equipped 
with a 100X objective) interfaced with the image analyzer software KS300 
(Zeiss). 
 
3.12 Tumorigenesis in immunodeficient mice 
 
Mice were housed in barrier facilities and in 12-hour light-dark cycles 
and received food and water ad libitum at the Dipartimento di Biologia e 
Patologia Cellulare e Molecolare (University of Naples “Federico II”, Naples, 
Italy). This study was conducted in accordance with Italian regulations for 
experimentation on animals. All manipulations were performed while mice 
were under isoflurane gas anesthesia. No mouse showed signs of wasting or 
other signs of toxicity. BHT101 cells (5 x 10
6
 per mouse) were inoculated s.c. 
into the right dorsal portion of 4-week-old male BALB/c nu/nu mice (The 
Jackson Laboratory). When tumors measured 40 mm3, mice were randomized 
to receive AMD3100 (n = 10; 1.25 mg/kg/twice daily) or vehicle alone (n = 10; 
PBS) by i.p. injection for 5 consecutive days per week for 3 to 4 weeks. 
Moreover, three groups of mice (4-week-old male BALB/c nu/nu mice, 
Jackson Laboratories, Bar Harbor, ME) were inoculated subcutaneously into 
the right dorsal portion with 8505-C shCTR cells (10x10
6
/mouse), 8505-C 
shAXL CL1(1x10
6
/mouse), 8505-C shAXL CL2 (1x10
6
/mouse). Tumor 
diameters were measured at regular intervals with a caliper. Tumor volumes 
(V) were calculated with the formula: V= A x B2/2 (A=axial diameter; B= 
rotational diameter). Tumors were excised and fixed overnight in neutral 
buffered formalin and processed by routine methods. 
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4.RESULTS and DISCUSSION 
 
4.1 CXCR4 is overexpressed in surgical samples of human ATC. 
 
To evaluate CXCR4 expression in ATC, we analysed a set of human 
samples (n = 13) and normal thyroids (n=6) by quantitative Real-Time PCR. 
As shown in Fig. 9A, CXCR4 mRNA was found to be up-regulated in most of 
the tumor samples (10 of 13) with respect to samples of normal thyroid tissue. 
The statistical analysis showed that the differences in the expression levels of 
CXCR4 between tumors and normal thyroid tissues were statistically 
significant (P = 0.0084; Fig. 9A). Then, we performed a Western Blot analysis 
to verify whether CXCR4 overexpression also resulted in an increase in the 
protein levels; to this aim, we used protein extracts from a different set of 
human ATC samples and three normal thyroid tissues and analysed CXCR4 
protein levels by using a CXCR4-specific antibody. As shown in Fig. 9B, 
CXCR4 protein levels were higher in ATC samples than in normal thyroid. As 
a positive control for CXCR4 expression, we used a human colon carcinoma 
cell line, the ARO cells, which were previously shown to feature high CXCR4 
levels (Hwang et al., 2003). Finally, we evaluated CXCR4 expression, by 
immunohistochemical experiments, in a set of 33 ATC samples and in normal 
thyroid tissues. As shown in Fig. 9C, we found that normal thyroid tissues were 
completely negative for CXCR4 expression, but 13 (39%) of the ATC samples 
presented a strong positivity for CXCR4. These data suggest that a relevant 
fraction of human ATCs features the overexpression of CXCR4 receptor and 
that this overexpression is probably due to a transcriptional mechanism. 
(Fig 9). 
 
 
Figure 9. A) Expression levels of CXCR4 in human ATC samples versus six normal thyroid tissues by real-time RT-
PCR. CXCR4 expression levels of tumors (Y axis) are calculated relative to the mean CXCR4 level of normal human 
thyroid tissues (NT). All experiments have been performed in triplicate and the average value of the results was plotted 
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on the diagram. P value was calculated with the two-tailed, non-parametric Mann-Whitney test. B) Protein lysates (100 
μg) extracted from the indicated samples underwent Western blotting with anti-CXCR4-specific antibodies. 
Immunocomplexes were revealed by enhanced chemiluminescence. Equal protein loading was ascertained by anti-
tubulin immunoblot. C) Immunohistochemical staining for CXCR4 of formalin-fixed, paraffin-embedded ATCs. 
Tissue samples from normal thyroid (NT) or ATC were incubated with a mouse monoclonal anti-CXCR4 antibody. 
ATCs show a strong immunoreactivity for CXCR4,whereas normal thyroid tissue is negative. Representative pictures 
of normal and pathologic positive samples are shown. Isotype control was also performed (data not shown). 
 
 
4.2 CXCR4 is overexpressed in thyroid cancers of transgenic mice. 
 
Several transgenic mice model of thyroid cancer are available, developed 
by using various oncogenes under the transcriptional control of the thyroid-
specific thyroglobulin bovine promoter. Carcinomas developed by these mice, 
according to the specific transgene, can be assimilated to human PTC, FTC or 
ATC, both cytologically and histologically. In particular, mice expressing 
either RET/PTC3 (TGPTC3) or TRK/T1 (TGTRK) oncogene develop PTC-
like tumors (Powell et al., 1998; Russell et al., 2000). NRAS transgene 
expression induces follicular tumors that progress to poorly differentiated 
carcinomas (TGNRAS; Vitagliano et al., 2006). Finally, animals expressing the 
SV40 large T antigen (TGSV) feature aggressive thyroid cancer very similar to 
human ATC (Ledent et al., 1991). We decided to evaluate the expression of 
CXCR4 in carcinomas developed in these animal models by performing 
Western blot analysis with anti-CXCR4 antibodies. As shown in Fig. 10, all 
tumors derived by transgenic mice expressed CXCR4, but, it was much more 
expressed in ATC models with respect to well-differentiated thyroid cancer 
models. These data, together with previously published data (Hwang et al., 
2003; Castellone et al., 2004), suggest that CXCR4 up-regulation is a frequent 
event in thyroid tumorigenesis and that, in the mice models, there is a strong 
correlation between the malignancy of lesions and the overexpression of 
CXCR4.  
 
Figure 10. The expression levels of CXCR4 protein were analyzed in thyroid tumor samples from transgenic mice 
models. Tumor tissues were snap frozen and immediately homogenized by using the Mixer Mill apparatus in lysis 
buffer. Equal amounts of proteins were immunoblotted and stained with anti-CXCR4 polyclonal antibodies (Abcam). 
ATC-like samples displayed a more intense immunoreactivity for CXCR4. As a control for equal loading,the anti-a-
tubulin monoclonal antibody was used. 
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4.3 CXCR4 is overexpressed in human ATCs cell lines  
 
We analysed a panel of different human ATC cell lines; as shown in Fig. 
11A and B, normal thyroid cultures displayed undetectable CXCR4 expression 
levels. PTC cell lines expressed CXCR4, but most (7 of 10) of ATC cell lines 
expressed high levels of the receptor both at the protein and at the mRNA 
levels, as verified by Western blot (Fig 11A and B) and quantitative Real-Time 
PCR analysis (Fig. 11C). We then asked whether this receptor was expressed 
on the cell surface. To this aim, we performed flow cytometry experiments 
using a PE-conjugated mouse monoclonal anti-CXCR4 antibody. We 
determined the percentage of CXCR4-positive cells. Normal thyroid cells did 
not express CXCR4 as analyzed by FACS analysis (data not shown), while 
almost all the ATC cell lines tested, with the exception of the FB1, expressed 
CXCR4; the ARO cells were used as a positive control (Fig 12). Interestingly, 
SDF-1, the CXCR4 ligand, was not expressed by ATC cells as assessed by 
quantitative PCR or ELISA assay (data not shown). 
 
 
 
Figure 11. Overexpression of CXCR4 in human ATC cell lines. A) CXCR4 up-regulation in cell lines derived from 
human thyroid carcinomas was evaluated by Western Blot with a polyclonal anti-CXCR4 antibody. The expression 
levels of CXCR4 protein were analyzed in the P5 human primary thyroid cells and in the indicated cell lines derived 
from human PTCs (NIM,TPC1, FB2) or from human ATCs (8505C, CAL62, BHT101, FRO and FB1). ARO cells, a 
CXCR4-expressing human colon carcinoma cell line, was used as positive control B) ATC-derived (S11T,S77T, S14T, 
HTU8) and normal thyroid primary cultures (P5) were screened for CXCR4 expression by Western blot analysis with 
the polyclonal anti-CXCR4 antibody. As a control for equal loading, the anti-tubulin monoclonal antibody was used. 
C) Expression levels of CXCR4 mRNA in human ATC cells versus the P5 normal thyroid culture were evaluated by 
real-time RT-PCR analysis. CXCR4 expression levels of ATC cell lines (Y axis) are calculated relative to the 
expression level in the normal human cell culture P5. All experiments were performed in triplicate, and the average 
value of the results was plotted on the diagram. SDs were smaller than 25% in all cases (data not shown).  
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Figure 12. FACS (fluorescence-activated cell sorting analysis) of surface-expressed CXCR4 in ATC cells. 
Subconfluent cells were detached from culture dishes and incubated with PE-labeled antibodies specific for human 
CXCR4. ARO cells were used as positive control of CXCR4 expression.  
 
 
4.4 CXCR4 is activated by SDF-1?  in human ATC cells  
 
 It is already known that the stimulation of CXCR4 is able to induce the 
activation of different kinase cascades, specifically through the activation of 
the G subunit of the Gi protein (Gangu et al., 1998; Peng et al., 2005). We 
asked whether CXCR4 receptor was also functional in human thyroid 
carcinoma cell lines. Particularly, we tested the phosphorylation of two 
downstream effectors, extracellular signal-regulated kinase (ERK) 1/2 and 
AKT, using specific phosphorylated antibodies. To this aim, we selected S11T 
and BHT101 cells. Cells were serum deprived for 12 h and then stimulated 
with SDF-1? for different time-points. As shown in Fig. 13A and B, the 
activation of ERK1/2 both in S11T and BHT101 was evident from the first 
minute after the stimulation with SDF-1? and proceeded in a time-dependent 
way; instead, AKT activation was a later event of the stimulation with SDF-1? 
and was less pronounced in S11T cells. Taken together, these data indicate that 
CXCR4 is a functional receptor in ATC cells. Activation of ERK1/2 and AKT 
was observed in virtually all the ATC cell lines expressing CXCR4, whereas 
normal thyroid cells, which do not express CXCR4, did not display these 
effects (data not shown). 
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Figure 13. A) and B) protein extracts from the indicated cell lines were subjected to immunoblotting with anti-
phosphorylated p44/42 MAPK (apMAPK) and with anti-phosphorylated AKT (apAKT) antibodies. The blots were 
reprobed with anti-p44/42 and anti-AKT antibodies for normalization. 
 
4.5 CXCR4 induces S-phase entry of human ATC cell lines. 
 
In order to evaluate whether SDF-1? was able to induce cell proliferation 
in ATC cells, we performed  BrdU incorporation assays on BHT101 and S11T. 
Cells were maintained in low-serum (2.5%) growth conditions for 24 h and 
then either left untreated or stimulated with SDF-1? for 12 h. As a measure of 
DNA synthesis, we counted BrdU-positive cells on a 1-h BrdU pulse. As 
shown in Fig. 14 A, both the cell lines presented an increased percentage of 
BrdU incorporation under SDF-1? treatment. We then used a specific CXCR4 
inhibitor, AMD3100, to block this effect. AMD3100 is a competitive 
antagonist of SDF-1?, but it also displays partial agonist activity (De Clerq, 
2005). Normal thyroid cells were insensitive to SDF-1? stimulation and to the 
effect of AMD3100 (data not shown). As shown in Fig. 14A, in the presence of 
AMD3100, SDF-1?–mediated DNA synthesis in ATC cells was blocked. To 
evaluate whether SDF-1? could stimulate ATC cell growth, we also performed 
growth curves in low-serum (2.5%) conditions. As shown in Fig. 14B, the 
stimulation of BHT101 with SDF-1? increased their proliferation rate, and 
AMD3100 reverted this effect. SDF-1? was also able to increase the 
proliferative rate of different ATC cell lines, which express CXCR4, BHT101 
and CAL62, but was unable to do so on FB1 cells, which we previously 
reported to be devoid of CXCR4; AMD3100 alone did not have any effect on 
ATC cells (data not shown). To exclude off-target effects of AMD3100 and to 
directly determine the role of CXCR4 on ATC cell proliferation, we used small 
duplex RNA oligos to knock down CXCR4. We then transfected CXCR4 
siRNAs into BHT101, CAL62, and 8505C cells. CXCR4 RNA interference 
was verified by Western blot analysis in BHT101 cells (Fig. 15A and B). 
CXCR4 silencing substantially impaired SDF-1?–induced S-phase entry in all 
the ATC cells but had no effect on BrdU incorporation in the absence of the 
chemokine, as shown in Fig. 15. When we used the control scrambled siRNA, 
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this inhibitory effect was not observed. Furthermore, scrambled oligos had no 
effect on CXCR4 protein levels (Fig. 15A). These data confirm the role of 
CXCR4 and of its specific ligand SDF-1?, in the proliferation of human ATC 
cells, thus suggesting the possibility to neutralize this pro-proliferative effect 
by inhibiting this chemokine receptor. 
 
 
 
Figure 14. A) BrdU incorporation was measured to evaluate S-phase entry of BHT101 and S11T cells treated with 
SDF-1? in the presence or absence of the CXCR4 inhibitor AMD3100. Columns, average results of three independent 
experiments; bars, SD. P < 0.05. B) The indicated cell lines were plated at the same density (5 x 104) in 2.5% serum, 
harvested, and counted at the indicated time points. Columns, average results of at least three independent 
determinations; bars, SD. 
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Figure 15. A) CXCR4 RNA interference was used to transiently suppress CXCR4 expression in ATC cells. BHT101, 
CAL62 and 8505C  cells were transfected with siRNAs against CXCR4 (siRNA CXCR4) or control non-specific small 
duplex RNA containing the same nucleotides, but in scrambled fashion (siRNA SCR), and harvested 48 and 72 h later.   
CXCR4 RNA interference (siRNA CXCR4) inhibited SDF-1?–stimulated S-phase entry as evaluated by BrdU 
incorporation assay. Control siRNA (siRNA SCR) did not inhibit DNA synthesis. Unstimulated cells were not affected 
by siRNA transfection. B) Protein lysates were subjected to immunoblotting with anti-CXCR4 and anti-tubulin 
antibodies. Control siRNA did not affect CXCR4 protein levels. 
 
4.6 CXCR4 reduces the growth of ATC xenografts in nude mice. 
 
It has been previously shown that the CXCR4/SDF-1 axis plays an 
important role in the growth and in the metastatic ability of several epithelial 
cancers (Balkwill et al., 2004). According to our in vitro results regarding the 
possibility to reduce the proliferation of human anaplastic cell lines by 
blocking CXCR4 with its specific antagonist, AMD3100, and because it has 
been shown that this chemokine is secreted by stromal tumoral cells (Orimo et 
al., 2005), we hypothized that the drug could represent a real therapeutical 
possibility for the treatment of human ATCs. In order to demonstrate that, we 
selected BHT101 cells for their ability to respond to SDF-1? and their ability 
to form tumors in vivo with high efficiency. We then injected nude mice, s.c., 
with 5 x 10
6
 cells. After about 10 days, when tumors measured 40 mm
3
, we 
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randomized mice (n = 20) in two groups to receive AMD3100 (1.25 
mg/kg/twice daily i.p.) or vehicle 5 days per week for 3 to 4 weeks. We 
measured tumor diameters at regular times with caliper. After 21 days, the 
mean volume of BHT101 tumors in mice treated with AMD3100 was 48 mm
3
, 
whereas that of mice treated with vehicle was 620 mm
3
. No mice expressed 
signs of toxicity due to the drug. We show representative experiments in Fig. 
16A and B. These data confirmed the critical role of CXCR4 in the tumoral 
growth and, most importantly, suggest the possibility to consider CXCR4 as 
potential therapeutical target for the treatment of human anaplatic thyroid 
carcinoma, that represents one of the most aggressive human malignancy. 
 
 
 
Figure 16. Antitumorigenic effects of AMD3100 in BHT101 xenografts.  A) Excised and photographed tumors. 
Two representative examples of BHT101 xenografts untreated (right) or AMD3100 treated (left) are shown. B) 
Antitumorigenic effects of AMD3100 in BHT101xenografts. BHT101 cells (5 x  106 per mouse) were injected s.c. into 
the right dorsal portion of BALB/c athymic mice. When tumors measured 40 mm3, mice were randomized to two 
groups to receive AMD3100 or vehicle (PBS) by i.p. injection. Treatment was given for 5 consecutive days per week 
for 3 to 4 wk (day 1 is the treatment starting day). Tumor diameters were measured with calipers and tumor volumes 
were calculated. Unpaired Student’s t test (normal distributions and equal variances) was applied. All P values were 
two sided, and differences were statistically significant at P < 0.05(*).  
 
4.7 The Tyro3 and Axl receptors are transcriptional targets of the 
CXCR4/SDF-1?  axis and are overexpressed in thyroid cancer cells. 
 
To characterize the molecular mechanisms of the SDF-1/ CXCR4 
biological activity in thyroid cancer cells, we performed a global gene 
expression profiling experiment, by using, as a model system, TPC1 cells, a 
human PTC-derived cell line that has been previously characterized for the 
expression and the functional activity of CXCR4 (Castellone et al., 2004). 
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Cells were serum-deprived and then stimulated for 24 h with human 
recombinant SDF-1? (100ng/ml). To perform microarray analysis, the GE 
Healthcare software and the codelink gene expression bioarray platform (based 
on an oligonucleotide array representing the entire human genome) was used. 
Statistical analysis on triplicate experiments, data mining and differential 
expression were evaluated by using the GeneSpring analysis platform. Several 
groups of SDF-1?-regulated genes were identified based on statistical analysis, 
whose activity, according to data available in literature, is related to different 
biological processes. Consistent with the biological activities of SDF-1?, genes 
involved in cell adhesion and motility, cell proliferation, survival and signal 
transduction resulted up-regulated. Genes with functions related to interferon 
activity, mRNA processing and ribosome biosynthesis were also identified. 
Genes with at least 1,5 fold change and a P value < 0.05 were considered.  
Among the different genes induced by SDF-1?, we found TYRO3 and 
AXL, two tirosine kinase receptors belonging to the TAM family. To confirm 
these data, we first analysed Tyro3 and Axl levels both at mRNAs and protein 
levels respectively by Real-time (RT-PCR) (data not shown) and by Western 
blot analysis in TPC1 cells treated with SDF-1?. Tyro3 basal levels were much 
lower than those of Axl in TPC1 cells, but under SDF-1?  treatment , both Axl 
and Tyro3 protein levels increased, as shown by the time-course experiments in 
fig. 17A. SDF-1? treatment also increased their tyrosine phosphorylation 
levels (data not shown). Then, Tyro3 and Axl protein levels were evaluated by 
Western blot analysis in a panel of thyroid cancer cell lines and in primary 
cultures of thyroid normal cells. As shown in Fig. 17B, Tyro3 and Axl protein 
levels were not expressed in normal thyroid cells, but most of the cancer cell 
lines presented high levels of the two receptors, being Axl consistently more 
expressed than Tyro3. This was also confirmed by RT-PCR experiments (data 
not shown). We also analysed the expression of both the receptors in a rat 
thyroid cell line (PC Cl3) and in PC Cl3-derived cell lines transduced with 
different oncogenes. While we could not detect endogenous Tyro3, we were 
able to show that two RET/PTC isoforms, RET/PTC1 and RET/PTC3, the 
cooperation between E1A and RAF, and the v-mos oncogenes were able to 
induce Axl overexpression in these cells. Since it has been reported that TAM 
receptors are activated in different cancer histotypes (Craven et al.,1995; 
Nemoto et al., 1997; Ito 2002; Zantek et al., 2001; Shieh et al., 2005; 
Gustafsson et al., 2009), we asked whether Axl receptor was also tyrosine-
phosphorylated in our cell lines. To verify this, we performed 
immunoprecipitation experiments by using an anti-Axl antibodies followed by 
Western blot analysis with either anti-phosphotyrosine antibodies or an anti-
phospho-Axl antibody, which specifically recognizes phosphorylated Tyr 779 
(Y779), a residue of the carboxy-terminal tail that is phosphorylated upon Axl 
stimulation. As shown in fig. 17C, we found that all the cell lines tested 
displayed Axl activation, being phosphorylation levels higher in Cal62, 8505-C 
and NIM with respect to OCUT-1 and ACT1. The TPC1 cells, derived from a 
human PTC featuring a spontaneous RET/PTC1 rearrangement, showed the 
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highest levels of phospho-Axl relative to total Axl. We also evaluated Axl 
activation in Axl-expressing PC Cl3 rat cell lines, PC PTC3, PC663 and PC 
E1A RAF. As shown in fig. 17C, Axl phosphorylation was very low in PC663 
and PC E1A/RAF, while PC PTC3, consistently, displayed the highest levels. 
(Fig. 17). 
 
 
 
 
Figure 17: A)?Analysis of Tyro3 and Axl protein levels by western blot analysis on TPC1 cells stimulated with SDF-
1? at different time-points. B) Evaluation of Tyro3 and Axl protein levels by western blot in a panel of human thyroid 
cancer cell lines and in primary cultures of thyroid normal cells (NT). Axl levels were also evaluated in PC rat thyroid 
cell lines transduced with the indicated oncogenes. Equal amounts of proteins (50 μg) were immunoblotted with anti-
TYRO3 and anti-AXL polyclonal antibodies. Anti-tubulin monoclonal antibody was used as a control for equal 
loading. C) Analysis of Axl tyrosine-phosphorylation by anti-phosphotyrosine and phospho-AXL western blot in a 
panel of human PTC and ATC cell lines. AXL-phosphorylation levels were evaluated. 
 
These data show that thyroid cancer cells express both Axl and Tyro3 
receptors. Moreover, in most cell lines Axl is also activated, as demonstrated 
by the high levels of phosphotyrosine content of the receptor. 
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4.8 Thyroid cancer cell lines express Gas6, one of the Tyro3/Axl ligands. 
 
Since it has been reported that Axl activation in tumor cells is due to 
autocrine or paracrine loops, we asked whether thyroid cancer cell lines 
expressed one of the Axl/Tyro3 ligands, Gas6 and Protein S. We first 
performed RT-PCR experiments to evaluate whether our cells expressed these 
ligands and we found that only Gas6, but not Protein S, was produced (data not 
shown). To confirm these results, we analysed Gas6 levels by using both 
ELISA immunoassay and Western blot analysis. As shown in Fig. 18A, among 
the cell lines we tested, 8505-C, NIM, CAL62 and SW1736, produced 
detectable levels of Gas6, while OCUT-1 and TPC1 did not. When we 
performed a Western blot analysis with a specific anti-Gas6 antibody, we 
found again that all the cell lines produced Gas6, with the exception of TPC1. 
Recombinant human Gas6 was used as a positive control. Silencing of Gas6 in 
NIM cells (NIM siGAS6) and overexpression of Gas6 in OCUT-1 cells 
(OCUT-1 Gas6) were used to confirm antibody specificity (Fig. 18B).  
(Fig. 18). 
 
 
 
Figure 18: A) Evaluation of Gas6 levels by using ELISA immunoassay. B) Western blot analysis with specific anti-
Gas6 antibody. Anti-tubulin monoclonal antibody was used as a control for equal protein loading. 
 
In summary, with these experiments, we identified cell lines, such as 
CAL62and SW1736, that produce Gas6, but inefficiently release it in the 
culture medium; cell lines, such as NIM and 8505-C, that produce and secrete 
high levels of Gas6; cell lines, such as TPC1, that did not produce detectable 
levels of Gas6, but, despite this, display high levels of Axl phosphorylation. 
Taken together, these data suggest that receptor activation is probably due to an 
autocrine effect, since all the cell lines, with the exception of the TPC1, express 
variable levels of the ligand, Gas6. 
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4.9 Human thyroid cancer specimens express Axl and its ligand Gas6 
 
To confirm our results, we evaluated Axl and Gas6 expression in human 
thyroid cancer specimens. We analysed a panel of 26 thyroid carcinoma 
samples (8 PTCs, 10 FTCs and 8 PDC/ATCs) and 2 normal thyroid by using 
immunohistochemical staining with specific anti-human Axl and Gas6 
antibodies. The 73% (19/26) of all the tested carcinoma presented positivity for 
Axl expression (Table 1). 
 
 
Table 1: This Table summarizes the percentage of AXL and GAS6 positivity in the panel of human thyroid cancer 
specimens analysed by immunohistochemistry. 
 
As shown in Fig.19, Axl positivity was observed mainly in the epithelial 
tumoral cells. Most of the samples showed membrane positivity, but a small 
number of specimens were characterized by cytosolic staining. In the last case, 
Axl was particularly found in the perinuclear vescicles probably representing 
the Golgi apparatus, pattern that is sometimes observed for overexpressed 
proteins. Tumoral stroma and non tumoral adjacent tissues were negative for 
Axl staining, with the exception of endothelial and red blood cells, that were 
strongly recognized by anti-Axl antibody, as previously reported (Tang et al., 
2009). To confirm whether thyroid carcinomas feature autocrine/paracrine 
loops involving Axl and its ligand, we also performed IHC experiments to 
evaluate Gas6 expression in the same human sample set. As summarized in 
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Table 1 and shown in fig. 19, 74% of analysed samples scored positive for 
Gas6 expression and 55% of these were positive for both receptor and ligand 
expression. Gas6 staining was cytosolic and was mainly found in carcinoma 
cells; some samples also presented stromal positivity, suggesting that ligand 
can also be provided by other cells of the tumor microenvironment. 
(Fig. 19). 
 
 
 
Figure 19: Immunohistochemistry on human thyroid cancer specimens with anti-AXL and anti-GAS6 antibodies. 
Axl positivity was observed mainly in tumoral cells. Gas6 staining was cytosolic and was mainly found in carcinoma 
cells but also a stromal positivity was observed. 
 
 
4.10 Axl/Tyro3-Gas6 axis blockade inhibits papillary thyroid cancer 
(PTC) cell proliferation.  
 
To investigate whether the Axl/Gas6 axis could influence thyroid cancer 
cell proliferation, we performed BrdU-incorporation experiments. To this aim, 
we first selected two PTC cell lines, TPC-1 and NIM. As shown above, TPC1 
cells express high levels of activated Axl in the absence of the ligand; NIM 
cells express both Axl receptor and Gas6 ligand. We analysed the levels of 
DNA synthesis by BrdU incorporation assays both in basal conditions (serum 
deprivation) and in the presence of exogenous Gas6. As shown in Fig. 20A, 
under serum-deprivation, 10% of TPC1 incorporated BrdU; when Gas6 was 
added, the percentage of BrdU incorporation increased to 20%. Then, we used 
a blocking compound, a chimaeric protein (Dtk/FC) which is composed by the 
extracellular domain of Tyro3 receptor fused to the FC portion of an IgG that is 
able to sequester and then to inhibit Gas6-mediated biological effects. In the 
presence of Dtk/Fc, we found that the percentage of BrdU-positive cells after 
Gas6 stimulation decreased. To confirm the role of Axl in TPC1 cell 
proliferation, we decided to silence the receptor by using transient RNA 
interference. Axl silencing was verified by Western blot analysis (Fig 20C). As 
shown in Fig. 20B, when Axl was silenced, there was only a modest reduction 
of BrdU incorporation in basal conditions. This reduction was more dramatic in 
the presence of Gas6: the percentage of BrdU-positive cells strongly decreased 
from 27% to 13%. Consistently, Gas6 silencing did not modify TPC1 DNA 
synthesis, as we expected, according to the observation that Gas6 is not 
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produced by TPC1 cells (data not shown). Since the additon of Gas6 partially 
recovered the effects of Axl blockade in this cell line, we evaluated whether 
Tyro3 was responsible for this effect. To this aim, Tyro3 was silenced in TPC1 
cells through RNA interference and DNA synthesis was evaluated. As shown 
in Figure 20B, Tyro3 silencing also induced a reduction of BrdU incorporation, 
but when we silenced both Tyro3 and Axl receptors, we obtained a dramatic 
decrease of the percentage of BrdU-positive cells to 5%; finally, Gas6 
treatment did not modify the effect of the double silencing. Tyro3 and Axl 
silencing was confirmed by Western blot analysis (Fig 20C). 
 
 
 
Figure 20. Axl/Tyro3  blockade inhibits TPC1 cell proliferation? A) TPC1 cells were serum-deprived and, where 
indicated, treated with GAS6 (200ng/ml) and/or the blocking chimaeric protein Dtk/FC for 24h. The results are 
expressed as percentage of BrdU incorporation with respect to NT (untreated) TPC1 cells. Gas6 stimulated BrdU 
incorporation of TPC1 cells and this effect was blocked by the Dtk/FC protein. The average results and the standard 
deviations of three independent experiments in which at least 400 cells were counted are reported. B) TPC1 were 
silenced for AXL or TYRO3 receptors; after 24h of silencing, cells were serum-deprived for 12h and treated or not 
with GAS6. AXL and TYRO3 silencing inhibited TPC1 BrdU incorporation. The results are expressed as percentage 
of BrdU incorporation with respect to  sictr-silenced TPC1 cells (sictr). C) Western blot analysis with anti-AXL and 
anti-TYRO3 antibodies was peformed to verify Axl- Tyro3 silencing. Anti-tubulin monoclonal antibody was used as a 
control for equal protein loading. 
 
Moreover, we performed similar experiments by using another PTC cell 
line, NIM, that, as already shown above, expresses both Axl and Gas6. As 
indicated in Fig 21, the addition of exogenous ligand did not modify BrdU 
incorporation. Instead, the blockade of both endogenous Axl and Gas6 by 
using Dtk/FC or RNAi inhibited NIM DNA synthesis (Fig 21A and B), and 
exogenous Gas6 addition partially reverted these effects. These data suggested 
that the presence of Tyro3 could also affect NIM proliferation. In fact, as 
shown in Fig 21B, Tyro3 silencing induced a reduction of BrdU incorporation; 
Tyro3/Axl silencing was more effective than single knockdown. In this 
condition, exogenous Gas6 was not able to modify the percentage of BrdU 
incorporation. Gas6 silencing was as effective as Axl/Tyro3 double silencing. 
Gas6, Tyro3 and Axl knockdown was verified by Western blot analysis (Fig 
21).  
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Figure 21. Axl/Tyro3  blockade inhibits NIM cell proliferation. A)  NIM cell lines were serum-deprived and then 
treated with GAS6 and Dkt/FC as indicated. BrdU incorporation was evaluated in presence or absence of human 
recombinant GAS6. Dtk/FC inhibited DNA synthesis of NIM cells. B) AXL, Gas6 and TYRO3 silencing affected NIM 
BrdU incorporation. C) Western blot analysis verified Axl, Tyro3, GAS6 silencing. Anti-tubulin monoclonal antibody 
was used as a control for equal protein loading. 
 
4.11 Axl/Tyro3-Gas6 axis blockade inhibits papillary thyroid cancer cell 
survival.  
To evaluate whether Axl/Tyro3-Gas6 axis blockade could also influence 
PTC cell lines resistance to apoptotic stimuli, we performed TUNEL assays, 
both in basal conditions or in the  presence of exogenous Gas6. To this aim, we 
used again TPC1 and NIM cells. In these experiments, we first induced 
apoptosis by exposing cells to a pro-apoptotic substance, DEM 
(DiEthylMaleate), or to serum-deprivation. As shown in Fig 22A, upon DEM 
treatment, 48% of TPC1 cells displayed TUNEL positivity, that was 
dramatically decreased in the presence of exogenous Gas6. The blockade of 
exogenous Gas6 with Dtk/FC completely reverted this effect. Consistently, 
Dtk/FC did not modify the percentage of apoptotic cells when used in the 
absence of Gas6. We also performed apoptosis assays after Axl- or Gas6-
silencing. In this case, apoptosis was induced by 24h of serum deprivation. In 
this condition, 10% of apoptotic cells were observed. This percentage 
decreased to 5% when Gas6 was added. Axl silencing dramatically increased 
the rate of apoptotic cells to 30%. Interestingly, when Gas6 was added to Axl-
silenced cells, the pro-apoptotic effects of Axl silencing were consistently 
inhibited (Fig 22B). These results can be considered as a further confirm that 
the other tyrosine-kinase receptor, Tyro3, can contribute to Axl biological 
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functions. In fact, when Tyro3 was knocked down in TPC1 cells through RNA 
interference, we found an increase of apoptotic rate and, particularly, the 
silencing of the two receptors together resulted in further decrease of TPC1 
survival, not modified by the addition of exogenous Gas6 (Fig 22B). Finally, 
again Gas6 silencing did not modify TPC1 apoptosis rate both in presence and 
in absence of Gas6 (data not shown). Axl and Tyro3 silencing was verified by 
Western blot analysis (Fig 22C). 
 
 
 
Figure 22. Axl/Tyro3 blockade inhibits TPC1 cell survival. A) TPC1 cell line was treated with a proapoptotic 
sunstance DEM (DiEthylMaleate) for 12h and then with Gas6 and/or Dtk/FC. Gas6 decreased the percentage of TPC1 
apoptotic cells and Dtk/FC reverted this effect. The percentage of apoptotic cells was evaluated with the TUNEL 
reaction. The average results and S.D. of three independent experiments in which at least 400 cells were counted is 
reported. B) TPC1 were serum-deprived and AXL, TYRO3 or both were silenced. In these conditions, the percentage 
of apoptotic cells increased. C) Western blot analysis with anti-AXL and anti-TYRO3 antibodies was perfprmed to 
verify Axl- Tyro3 silencing. Anti-tubulin monoclonal antibody was used as a control for equal protein loading. 
 
We obtained similar results when we performed TUNEL assays on NIM 
cell lines. As shown in Fig 23A, DEM treatment of NIM cells induced 40% of 
apoptotic cells, and the blockade of Gas6 with DtkFC increased to 62% this 
percentage; when cells were serum deprived (Fig 23B), we observed 18% of 
apoptotic cells. This percentage was slightly changed by Gas6 treatment. Axl 
or Gas6 silencing strongly enhanced NIM apoptotic rate, and these effects were 
again reverted by exogenous Gas6. Tyro3 silencing also affected NIM survival. 
The silencing of the two receptors resulted in a dramatic increase of the 
apoptotic rate, and the addition of Gas6 could not revert this phenotype.  
(Fig 23). 
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Figure 23. Axl/Tyro3 blockade inhibits NIM cell survival. A) NIM cell line was treated with the proapoptotic 
substance DEM (DiEthylMaleate) for 12h and then with Gas6 and Dtk/FC. The percentage of apoptotic cells was 
evaluated with the TUNEL reaction. The average results and S.D. of three independent experiments in which at least 
400 cells were counted is reported. Gas6, as expected, did not modify  NIM apoptotic rate, while the Dtk/FC protein 
increased the percentage of apoptotic cells and the addition of exogenous Gas6 reverted this effect. B) NIM cells were 
serum deprived after AXL, TYRO3 (individually or together) and Gas6 silencing. In these conditions,the perncentage 
of apoptotic cells increased and exogenous Gas6 reverted this effect. C) Western blot analysis was performed to verify 
Axl, Tyro3, GAS6 silencing. Anti-tubulin monoclonal antibody was used as a control for equal protein loading. 
 
 4.12 Axl/Tyro3-Gas6 axis blockade inhibits anaplastic thyroid cancer 
(ATC) cell proliferation and survival 
 To verify whether Axl knockdown could impair proliferation and 
survival of human ATC cell lines, we also used siRNA directed against Axl. 
To this aim, we used 8505-C cells, derived from human ATCs. As shown in 
figure 24A and B, Gas6 stimulated cell proliferation and inhibited apoptosis of 
8505-C. Consistently, Axl silencing inhibited BrdU incorporation and 
enhanced apoptotic rate of 8505C and exogenous Gas6 partially reverted these 
effects. Axl silencing was verified by Western blot analysis. We obtained the 
similar results when another ATC cell line, Cal62, was used (data not shown). 
(Fig 24). 
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Figure 24. Axl/Tyro3-Gas6 axis blockade also inhibits 8505-C cell proliferation and survival. A) 8505-C were 
silenced for AXL and  BrdU incorporation was evaluated. Gas6 stimulated 8505C BrdU incorporation while siAXL 
inhibeted. Gas6 reverted this effect.  B) 8505C cells were  subjected to AXL silencing and serum-deprivation. The 
percentage of apoptotic cells was evaluated with the TUNEL reaction. AXL silencing increased the percentage of 
apoptotic cells and Gas6 reverted this effect. C) Western blot analysis was performed to verify Axl silencing with an 
anti-AXL antibody. Anti-tubulin monoclonal antibody was used as a control for equal protein loading. 
 
4.13 Stable silencing of Axl reduces growth, proliferation, survival and 
invasiveness of 8505-C. 
 
To confirm that Axl silencing effectively inhibited the viability of thyroid 
cancer cells, we stably transfected 8505-C cells with two pools of vectors 
expressing, respectively, five different shRNAs directed to Axl or five different 
control non-targeting shRNAs. After antibiotic selection, cell clones were 
isolated and screened by Western blot analysis for Axl expression. As shown in 
Fig. 25A, we identified several clones in which Axl expression was strongly 
reduced (shAxl Cl 1-2) or completely repressed (shAxl Cl3-6). We first 
verified whether Axl knockdown could impair cell growth both in optimal 
serum (10% FCS) or in low serum (2,5% FCS) conditions by performing 
growth curves. As shown in Fig. 25B, shRNA-mediated Axl silencing showed 
mild effects on cell proliferation in complete culture medium, while it was 
significantly more effective in low serum conditions. To assess whether 
reduced cell growth was due to decreased DNA synthesis or increased cell 
death, 8505c shAxl clones 3-6 were selected. Cells were serum-starved for 12h 
and we evaluated the percentage of BrdU- and TUNEL-positive cells. As 
shown in Fig 25C, all shAxl clones displayed a significant reduction of BrdU 
incorporation and a significant increase in apoptosis when compared to control 
clones.  
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(Fig. 25). 
 
 
 
Figure 25. Biological effects of stable silencing of Axl in 8505-C ATC cells??A) Screening of cell clones (8505-C 
shAXL) by Western blot analysis with an anti-AXL antibody. B) Growth curves on 8505-C shAXL and shCTR  
clones. Cells were plated at a density of 0.5 x 105 in complete (10% FCS) (left panel) or in low serum conditions (2.5% 
FCS) (right panel), harvested and counted at the indicated time points. The average results of at least three independent 
determinations were reported. C) BrdU-incorporation was measured to evaluate S-phase entry of stably silenced 
clones. AXL silencing decreased the percentage of BrdU-positive cells. D) TUNEL reaction was performed on cell 
clones to evaluated the proapoptotic effect of AXL stable silencing. Cells were serum-deprived for 12h and then 
processed for TUNEL assay. AXL silencing increased the percentage of apoptotic cells. 
 
 
Moreover, we asked whether stable AXL silencing on ATC cell lines 
could impair cell invasiveness through Matrigel. Invasive ability of cells was 
verified both in optimal (10%FCS) or in low-serum (2,5%FCS) conditions. As 
indicated in Fig. 26, shAXL clones showed a clear decrease of invasive ability 
with respect to shCTR, but only in low-serum conditions (Fig. 26). 
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Figure 26. Matrigel invasion on 8505-C shAXL. A) Cells were added to the upper chamber of a pre-hydrated 
polycarbonate membrane filter of 8 μM pore size coated with Matrigel. The lower chamber was filled with complete 
medium or 2.5% FCS (as indicated). Triplicated samples were analyzed at 570 nM with an ELISA reader (Model 550 
microplate reader, Bio-Rad). The results were expressed as percentage of migrating cells with respect to the unsilenced 
ones. B) Densitometric analysis of Matrigel invasion assay was reported. AXL silencing inhibited Matrigel invasion in 
low-serum conditions. 
 
 
4.14 Axl silencing inhibits experimental tumor growth 
 
Finally, we evaluated the role of Axl in tumor growth by using 
xenografts of ATC cells into (nu/nu) immunodeficient mice. To this aim, we 
choose 8505-C as a model cell line because it expresses Axl and it is able to 
efficiently form tumors when injected into nude mice. To study the role of Axl 
in tumor growth, we injected animals with parental, shCTR-transfected 
(shCTR Cl1) and shAxl (shAxl CL4 and CL6) 8505-C cell lines, and compared 
their growth rate. Parental cells formed tumors with the same efficiency as 
shCTR-transfected cells did (data not shown). As shown in Fig. 28, the 
tumorigenicity of 8505-C shAxl CL4 and CL6 was dramatically reduced when 
compared with 8505-C shCTR cells. At three weeks, shCTR tumor median 
volume was 34 mm
3
, while shAXL was < 10 mm
3
. At four, five and six weeks, 
shCTR tumors continued to grow, reaching a final median volume of ~150 
mm
3. 
shAXL tumors did not grow or regressed. At the end of the experiment, 
no shAXL tumors were available. This precluded histological analysis. 
(Fig. 27). 
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Figure 27.Tumorigenicity of 8505-C shCTR and shAxl clones in ATC cell xenografts. Three groups of mice (4-
week-old male BALB/c nu/nu mice) were inoculated subcutaneously into the right dorsal portion with 8505-C shCTR 
cells (10x106/mouse), 8505-C  shAXL CL1 (10x106/mouse) or 8505-C shAXL CL2 (10x106/mouse), respectively. 
Tumor diameters were measured at regular intervals with a caliper. Tumor volumes (V) were calculated with the 
formula: V= A x B2/2 (A=axial diameter; B= rotational diameter). 8505C tumor growth was strongly impaired in 
shAXL clones with respect to shCTR.  Unpaired Student’s T test (normal distributions and equal variances) was 
applied. All P values were two sided, and differences were statistically significant at P < 0.05. 
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5.CONCLUSIONS 
 
In this thesis, we show that CXCR4, receptor for the chemokine  SDF-
1?, is involved in the pathogenesis and progression of human anaplastic 
thyroid carcinoma and can also be considered a potential therapeutical target 
for this disease. We previously reported functional expression of CXCR4 in 
human papillary thyroid carcinomas (Castellone et al., 2004). In this report, we 
observed that CXCR4 is overexpressed in human anaplastic thyroid carcinoma 
samples and also in a large panel of human ATC established and primary cell 
cultures, both at the mRNA and at the protein level. Neither normal thyroid 
tissue samples nor normal thyroid cell cultures expressed this chemokine 
receptor. In contrast, SDF-1 was not detected in cancer cells. We also show 
that the CXCR4 expressed on ATC cell lines is functional. In fact, stimulation 
of ATC cells with human recombinant SDF-1? activated ERK1/2 and AKT 
pathways. Moreover, stimulation with SDF-1? was able to increase S-phase 
entry of ATC cells, feature that has also been observed in small cell lung 
cancer cells (Kijima et al., 2002). By using a small CXCR4 inhibitor, 
AMD3100 (De Clerq, 2003), it is possible to revert this phenotype. We found 
that the treatment of immunodeficient mice with AMD3100 significantly 
suppressed the development of tumors in different xenograft models of ATC 
cells. These data suggest the possibility to use CXCR4 inhibitors in thyroid 
cancer therapy and eventually to potentiate the effects of conventional anti-
cancer therapies (Muller et al., 2001; Rubin et al., 2003). 
Then, we identified two tyrosine-kinase receptors, Tyro3 and Axl, as 
transcriptional targets of the CXCR4/SDF-1 axis in thyroid cancer. We showed 
that both the receptors, were expressed at basal levels in TPC-1 cells, but under 
SDF-1 stimulation, their protein level and tyrosine phosphorylation increased. 
We found that most of the thyroid cancer cell lines available express both the 
receptors, being AXL more expressed than TYRO3. In particular, in most cell 
lines we tested, AXL receptor was also activated, as demonstrated by an 
increase of tyrosine phosphorilation levels, and this phosphorilation was 
mainly due to the presence of endogenous GAS6. The only exception to this 
rule was represented by TPC-1 cell line, in which AXL was highly 
phosphorylated despite the fact that GAS6 is absent. All these in vitro-
expression results were confirmed by IHC on human thyroid carcinoma 
samples; in fact, we found that most of the human samples we analysed 
presented a strong positivity for AXL and its ligand GAS6, with respect to 
normal thyroid. Then, we showed that the inhibition of TYRO3 and AXL by 
using blocking reagents or RNA interference targeting each receptor or the 
ligand decreased the two main properties of malignant thyroid cells, cell 
proliferation and resistance to apoptotic stimuli. In particular, we found that 
cell lines that expressed both receptors and ligand, after the simultaneous 
blockade of these molecules, presented a dramatic reduction of their cell 
viability. Accordingly, we show that the stimulation of  GAS6-negative TPC-1 
cells with exogenous GAS6 increased their proliferation and survival. 
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Moreover, we found that stable silencing of Axl reduces thyroid cancer cells 
invasiveness and inhibits experimental tumor growth in nude mice. These 
results suggest that TYRO3 and AXL play a critical role in promoting 
proliferation and survival of these neoplasias. For these reasons, targeting the 
Axl-Tyro3/Gas6 axis may represent an important new therapeutic strategy for 
the treatment of thyroid cancer. 
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Abstract
Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer
type with an extremely poor prognosis. Despite appropriate
treatment, which includes surgery, radiotherapy, and chemo-
therapy, this cancer is invariably fatal. CXCR4 is the receptor
for the stromal cell–derived factor-1 (SDF-1)/CXCL12 chemo-
kine and it is expressed in a variety of solid tumors, including
papillary thyroid carcinoma. Here, we show that ATC cell lines
overexpress CXCR4, both at the level of mRNA and protein.
Furthermore, we found that CXCR4 was overexpressed in ATC
clinical samples, with respect to normal thyroid tissues by
real-time PCR and immunohistochemistry. Treatment of ATC
cells with SDF-1 induced proliferation and increase in
phosphorylation of extracellular signal–regulated kinases
and protein kinase B/AKT. These effects were blocked by the
specific CXCR4 antagonist AMD3100 and by CXCR4 RNA
interference. Moreover, AMD3100 effectively reduced tumor
growth in nude mice inoculated with different ATC cells.
Thus, we suggest that CXCR4 targeting is a novel potential
strategy in the treatment of human ATC. [Cancer Res
2007;67(24):11821–9]
Introduction
Thyroid cancer accounts for the majority of endocrine neo-
plasms worldwide (1). Malignant tumors derived from the thyroid
gland include well-differentiated thyroid carcinomas (WDTC;
papillary and follicular) and undifferentiated or anaplastic thyroid
carcinomas (ATC). Another group of cancers falls between these
two types, the so-called poorly differentiated thyroid carcinomas
(PDC). WDTC represents >90% of all thyroid cancers, whereas
ATC accounts for approximately 2% to 5% of them (2–4). WDTC
management requires surgery and adjuvant radioactive iodine
(5, 6). Whereas most of the patients with WDTC have an excellent
prognosis, those that present with PDC or ATC have a poor
prognosis. PDC displays intermediate biological and clinical
features between WDTC and ATC. Indeed, these tumors display
high propensity to recur and metastasize. Furthermore, they tend
to a progressive dedifferentiation, which leads to the decrease in
the levels of the sodium iodide symporter. As a consequence of this,
these tumors are unable to concentrate iodine and become
resistant to radiometabolic therapy (4, 7). ATC is the most
malignant thyroid tumor and one of the more fatal human
malignancy with a median survival from the time of diagnosis of
only 4 to 12 months (8, 9). ATC is more frequent in iodine-deficient
areas and can be associated with other thyroid disorders. These
tumors arise at a mean age of 55 to 65 years, are more common in
women, and present usually as a rapidly growing mass, localized in
the anterior neck area, which rapidly metastasizes at lungs, bone,
and brain. Treatment of ATC with surgery, radiotherapy, and
chemotherapy, alone or in combination, shows little or no effect on
patient’s survival (10). For these reasons, novel treatment strategies
are urgently needed. Unlike the WDTC, the molecular mechanisms
underlying the development of human ATC are largely unknown.
Genetic rearrangements of the RET and TRKA tyrosine kinase
receptors, point mutations of the BRAF serine-threonine kinase or,
less frequently, RAS mutations, are typically found in papillary
thyroid carcinoma (PTC). Rearrangements of PPARg or RAS point
mutations are instead found in human FTC (11, 12). Among these
genetic alterations, RAS or BRAF point mutations are detected at
low frequency in ATC, suggesting that some ATC may arise from a
preexisting WDTC, whereas others arise de novo (12, 13).
Inactivating point mutations of the p53 tumor suppressor and
activating point mutations of the b-catenin or the PIK3CA are also
found in ATC (13–15).
In the attempt to better characterize human ATC at the
molecular level, we aimed to study the involvement of chemokine
and chemokine receptors in these tumors. Chemokines are small
secretory proteins that were initially reported to control the
recruitment and the activation of immune cells in inflammation
(16). These molecules exert their action through binding to a group
of seven-transmembrane G protein–coupled receptors. All chemo-
kine receptors initiate signal transduction by activating a member
of the Gi family of G proteins which, on receptor activation,
dissociates into a and hg subunits. The Ga subunit inhibits
adenylyl cyclase, whereas the Ghg dimer activates the phospho-
lipase Ch and the phosphatidylinositol 3-kinase pathways, with the
activation of downstream signaling. It has becoming clear recently
that chemokines are also involved in cancer cell migration,
survival, and growth (17). Not only chemokines regulate some
important features of cancer cells but are also involved in the
regulation of tumor angiogenesis and leukocyte recruitment (17).
In particular, the chemokine receptor CXCR4 and its ligand stromal
cell-derived factor-1 (SDF-1)/CXCL12 have been implicated in the
metastatic spread of breast cancer cells (18). CXCR4 is one of the
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most important chemokine receptors for cancer cells. Indeed, it is
expressed in a great number of human solid and hematologic
cancers, including breast, prostate, brain, colon, and lung cancer
(19, 20). We and others previously reported the overexpression and
functional activity of CXCR4 in thyroid cancer (21, 22). In this
report, we show that human ATC cells express high levels of CXCR4
and that the CXCR4-SDF-1/CXCL12 axis sustains the growth of
ATC cells. Finally, we provide evidences that targeting CXCR4
might be exploited as a novel anticancer therapy for human ATC.
Materials and Methods
Cell lines. Human primary cultures of normal thyroid and ATC cells
were obtained from F. Curcio (Dipartimento di Patologia e Medicina
Sperimentale e Clinica, University of Udine, Udine, Italy; P5, P5-2N,
P5-3N, P5-4N, and HTU8) and H. Zitzelsberger (Institute of Molecular
Radiobiology, GSF-National Research Center for Environment and Health
GmbH, Neuherberg, Germany; S11T, S77T, and S14T) and cultured as
described previously (23). Primary cultures of ATC were also a kind gift of
H. Zitzelsberger. Of these, only the S11T displays a BRAF(V600E) mutation
in heterozygosis.4 Human thyroid papillary cancer cell lines TPC1, FB2, and
NIM have been described previously (24–26). TPC1 and FB2 cells harbor a
RET/PTC1 rearrangement. NPA87 cells derive from a PDC and harbor a
BRAF(V600E) mutation in homozygosis (23). The anaplastic cells ARO,
KAT4, BHT101, and FB1 cells harbor a BRAF(V600E) mutation in
heterozygosis; 8505C and FRO harbor a BRAF(V600E) mutation in
homozygosis (23); and CAL62 cells express wild-type BRAF but mutant
NRAS allele. Continuous cell lines were maintained in DMEM supplemented
with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% glutamine.
RNA extraction and reverse transcription PCR. Total RNA was
isolated by the RNeasy kit (Qiagen) and subjected to on-column DNase
digestion with the RNase-free DNase set (Qiagen) according to the
manufacturer’s instructions. The quality of RNA was verified by electro-
phoresis through 1% agarose gel and visualized with ethidium bromide.
RNA (1 Ag) from each sample was reverse transcribed with the QuantiTect
Reverse Transcription (Qiagen) using an optimized blend of oligo(dT) and
random primers according to the manufacturer’s instructions. To design
a quantitative reverse transcription-PCR (RT-PCR) assay, we used the
Human ProbeLibray system (Exiqon). Briefly, Exiqon provides 90 human
prevalidated Taqman probes (8–9 nucleotides long) that recognizef99% of
human transcripts in the RefSeq database at the National Center for
Biotechnology Information. The ProbeFinder assay design software
(available online)5 was used to design primer pairs and probes. All
fluorogenic probes were dual labeled with FAM at 5¶-end and with a black
quencher at the 3¶-end. Primer pairs and PCR conditions are available on
request. Quantitative RT-PCR was performed in a Chromo 4 Detector (MJ
Research) in 96-well plates using a final volume of 20 AL. For each PCR, 8 AL
of 2.5 RealMasterMix Probe ROX (Eppendorf AG), 200 nmol/L of each
primer, 100 nmol/L probe, and cDNA generated from 50 ng of total RNA
were used. PCRs were performed in triplicate and fold changes were
calculated with the following formula: 2(sample 1 DC t  sample 2 DC t), where
DCt is the difference between the amplification fluorescent thresholds of
the mRNA of interest and the mRNA of RNA polymerase 2 used as an
internal reference.
Immunohistochemistry. Retrospectively collected archival thyroid
tissue samples from patients affected by ATCs were retrieved from the
files of the Pathology Department of the University of Pisa on informed
consent. Sections (4 Am thick) of paraffin-embedded samples were stained
with H&E for histologic examination to ensure that the samples fulfilled the
diagnostic criteria required for the identification of ATC. Normal thyroid
tissue samples were also retrieved from the files of the Pathology
Department of the University of Pisa.
For immunohistochemistry, paraffin sections (3–5 Am) were dewaxed in
xylene, dehydrated through graded alcohols, and blocked with 5%
nonimmune mouse serum in PBS with 0.05% sodium azide for 5 min.
Mouse monoclonal antibody against CXCR4 (clone 12G5; R&D Systems)
was added at 1:1,000 dilution for 15 min. After incubation with biotinylated
anti-mouse secondary antibody for 15 min followed by streptavidin-biotin
complex for 15 min (Catalyzed Signal Amplification System, DAKO), sections
were developed for 5 min with 0.05% 3,3¶-diaminobenzidine tetrahydro-
chloride and 0.01% hydrogen peroxide in 0.05 mol/L Tris-HCl buffer (pH 7.6),
counterstained with hematoxylin, dehydrated, and mounted.
Protein studies. Immunoblotting experiments were performed accord-
ing to standard procedures. Briefly, cells were harvested in lysis buffer
[50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1% Triton
X-100, 1 mmol/L EGTA, 1.5 mmol/L MgCl2, 10 mmol/L NaF, 10 mmol/L
sodium pyrophosphate, 1 mmol/L Na3VO4, 10 Ag/mL aprotinin, 10 Ag/mL
leupeptin] and clarified by centrifugation at 10,000  g . For protein
extraction from human tissues, snap-frozen samples were immediately
homogenized in lysis buffer by using the Mixer Mill apparatus (Qiagen).
Protein concentration was estimated with a modified Bradford assay (Bio-
Rad). Antigens were revealed by an enhanced chemiluminescence detection
kit (Amersham). Anti-CXCR4 antibodies were from Abcam Ltd. For the
evaluation of mitogen-activated protein kinase (MAPK) and AKT activity on
SDF-1a triggering, BHT101 and S11T cells were serum deprived for 12 h and
then stimulated with human recombinant SDF-1a (R&D Systems) for the
indicated time. Anti-phosphorylated p44/42 MAPK, anti-p44/42 MAPK,
anti-phosphorylated AKT, and anti-AKT antibodies were from New England
Biolabs. Anti-tubulin monoclonal antibody was from Sigma Chemical.
Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish
peroxidase were from Bio-Rad.
Flow cytometric analysis. Subconfluent cells were detached from
culture dishes with a solution of 0.5 mmol/L EDTA and then washed thrice
in PBS buffer. After saturation with 1 Ag of human IgG/105 cells, cells were
incubated for 20 min on ice with phycoerythrin (PE)-labeled antibodies
specific for human CXCR4 (R&D Systems) or isotype control antibody. After
incubation, unreacted antibody was removed by washing cells twice in PBS
buffer. Cells resuspended in PBS were analyzed on a FACSCalibur cyto-
fluorimeter using the CellQuest software (Becton Dickinson). Analyses were
performed in triplicate. In each analysis, a total of 104 events were calculated.
Cell proliferation. S-phase entry was evaluated by bromodeoxyuridine
(BrdUrd) incorporation and indirect immunofluorescence. Cells were grown
on coverslips, kept in 2.5% serum for 24 h, and then treated with
recombinant SDF-1a (100 ng/mL) for 48 h. BrdUrd was added at a
concentration of 10 Amol/L for the last 1 h. Subsequently, cells were fixed in
3% paraformaldehyde and permeabilized with 0.2% Triton X-100. BrdUrd-
positive cells were revealed with Texas red–conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Inc.). Cell nuclei were
identified by Hoechst staining. Fluorescence was visualized with a Zeiss 140
epifluorescent microscope.
For growth curves, cells were plated at a density of 0.5  105 in low-
serum conditions (2.5%) and counted at the indicated time points.
RNA interference. Small inhibitor duplex RNAs targeting human CXCR4
have been described previously and were chemically synthesized by Proligo.
Sense strand for human CXCR4 small interfering RNA (siRNA) targeting was
the following: 5¶-GAGGGGAUCAGCAGUAUAUAC-3¶.
Small duplex RNAs containing the same nucleotides, but in scrambled
fashion (siRNA SCR), were used as a negative control. For siRNA transfection,
ATC cells were grown under standard conditions. The day before
transfection, cells were plated in six-well dishes at 50% to 60% confluency.
Transfection was performed using 5 to 15 Ag of duplex RNA and 6 AL of
Oligofectamine reagent (Invitrogen). Cells were harvested at 48 and 72 h after
transfection and analyzed for protein expression and biological activity.
Xenografts in nude mice. Mice were housed in barrier facilities and
12-h light-dark cycles and received food and water ad libitum at the
Dipartimento di Biologia e Patologia Cellulare e Molecolare (University of
Naples ‘‘Federico II’’, Naples, Italy). This study was conducted in accordance
with Italian regulations for experimentation on animals. All manipulations
were performed while mice were under isoflurane gas anesthesia. No mouse
4 G. Salvatore, unpublished observation.
5 http://www.probelibrary.com
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showed signs of wasting or other signs of toxicity. BHT101, ARO, or KAT4
cells (5  106 per mouse) were inoculated s.c. into the right dorsal portion
of 4-week-old male BALB/c nu/nu mice (The Jackson Laboratory). When
tumors measured 40 mm3, mice were randomized to receive AMD3100
(n = 10; 1.25 mg/kg/twice daily) or vehicle alone (n = 10; PBS) by i.p.
injection for 5 consecutive days per week for 3 to 4 weeks. Tumor diameters
were measured at regular intervals with calipers. Tumor volumes (V ) were
calculated with the following formula: V = A  B2 / 2 (A = axial diameter;
B = rotational diameter). Tumors were excised and fixed overnight in
neutral buffered formalin and processed by routine methods.
Statistical analysis. To compare CXCR4 mRNA levels in normal thyroid
tissues versus ATC samples, we used the Mann-Whitney nonparametric test
and the GraphPad Instat software, v.3.0b. To compare ATC xenograft
growth in AMD3100-treated versus untreated animals, we used the
unpaired Student’s t test (normal distributions and equal variances) and
the GraphPad Instat software, v.3.0b. All P values were two sided, and
differences were considered statistically significant at P < 0.05.
Results
CXCR4 is overexpressed in surgical samples of human ATC.
We compared CXCR4 mRNA levels in a set of ATC samples (n = 13)
versus different samples of normal thyroid tissue (n = 6). As shown
in Fig. 1A , CXCR4 mRNA was found to be up-regulated in most of
the tumor samples (10 of 13). When we performed statistical
analysis, the differences in the expression levels of CXCR4 between
tumors and normal thyroid tissues were statistically significant
(P = 0.0084; Fig. 1A).
To verify whether CXCR4 mRNA overexpression resulted in an
increase in the protein levels, we used protein extracts from a
different set of ATC samples and three normal thyroid tissues in an
immunoblot experiment with CXCR4-specific antibodies. As shown
in Fig. 1B , CXCR4 protein levels were higher in ATC samples than
in normal thyroid. As a positive control for CXCR4 expression, the
ATC cell line ARO was used.
Finally, CXCR4 antibodies were used in immunohistochemical
experiments. We evaluated CXCR4 expression in normal thyroid
tissues and a set of ATC samples (n = 33). Whereas no CXCR4
expression was detected in normal thyroid tissues, 13 (39%) of the
ATC samples scored positive for CXCR4. A representative CXCR4
immunostaining is shown in Fig. 1C . These data indicate that a
significant fraction of human ATCs, similarly to other epithelial
Figure 1. A, expression levels of CXCR4 in human ATC samples versus six normal thyroid tissues by real-time RT-PCR. CXCR4 expression levels of tumors (Y axis )
are calculated relative to the mean CXCR4 level of normal human thyroid tissues (NT). All experiments have been performed in triplicate, and the average value of the
results was plotted on the diagram. P value was calculated with the two-tailed, nonparametric Mann-Whitney test. B, protein lysates (100 Ag) extracted from the
indicated samples underwent Western blotting with anti-CXCR4-specific antibodies. Immunocomplexes were revealed by enhanced chemiluminescence. Equal protein
loading was ascertained by anti-tubulin immunoblot. C, immunohistochemical staining for CXCR4 of formalin-fixed, paraffin-embedded ATCs. Tissue samples from
normal thyroid or ATC were incubated with a mouse monoclonal anti-CXCR4 antibody. ATCs show a strong immunoreactivity for CXCR4, whereas normal thyroid
tissue is negative. Representative pictures of normal and pathologic positive samples are shown. Isotype control was also performed (data not shown). D, the
expression levels of CXCR4 protein were analyzed in thyroid tumor samples from transgenic mice models. Tumor tissues were snap frozen and immediately
homogenized by using the Mixer Mill apparatus in lysis buffer. Equal amounts of proteins were immunoblotted and stained with anti-CXCR4 polyclonal antibodies
(Abcam). ATC-like samples displayed a more intense immunoreactivity for CXCR4. As a control for equal loading, the anti-a-tubulin monoclonal antibody was used.
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cancers, features high expression levels of the CXCR4 receptor.
Furthermore, they suggest that the increase in CXCR4 levels occurs
at the transcriptional level.
CXCR4 is highly expressed in animal models of ATC. Several
transgenic mice model of thyroid cancer have been developed by
using various oncogenes under the transcriptional control of the
thyroid-specific thyroglobulin bovine promoter. Depending on the
specific transgene, these mice develop carcinomas that resemble,
for cytologic and histologic features, human PTC, FTC, or ATC.
In particular, mice expressing either RET/PTC3 (TGPTC3) or
TRK/T1 (TGTRK) oncogene develop PTC-like tumors (27, 28).
NRAS transgene expression results in follicular tumors that
progress to poorly differentiated carcinomas (TGNRAS; ref. 29).
Finally, animals expressing the SV40 large T antigen (TGSV) present
aggressive thyroid cancer with features similar to human ATC (30).
To evaluate the expression of CXCR4 in these animal models, we
extracted proteins from different tumor samples of the different
transgenic lines and performed Western blot analysis with CXCR4
antibodies. Histologic diagnosis of the thyroid lesions was verified
before processing of the samples. As shown in Fig. 1D , CXCR4
levels were higher in ATC models than in normal mouse thyroid
tissue. PTC samples displayed intermediate levels of CXCR4. These
data, together with previously published data (21, 22), suggest that
CXCR4 up-regulation is a frequent event in thyroid tumorigenesis
and that it correlates with the malignancy of the disease.
CXCR4 is a functional receptor in human ATC cells. To study
the role of CXCR4 in human ATC, we first needed to identify a
suitable cell model. To this aim, various normal thyroid and ATC-
derived primary cultures and continuous cell lines were tested for
CXCR4 expression by Western blot analysis. As shown in Fig. 2A
and B , whereas normal thyroid cultures displayed low or unde-
tectable CXCR4 expression levels, several ATC cell lines featured
high levels of the CXCR4 receptor. In particular, of 10 ATC cell
lines, 7 displayed high expression levels of CXCR4. In the case of
ATC cells, the increased levels of CXCR4 proteins were associated
to an increase in CXCR4 mRNA levels as assessed by quantitative
PCR analysis (Fig. 2C). We then asked whether this receptor was
expressed on the cell surface. To this aim, we performed flow
cytometry experiments using a PE-conjugated mouse monoclonal
anti-CXCR4 antibody. The percentage of CXCR4-positive cells was
Figure 2. A, CXCR4 up-regulation in cell lines derived from human thyroid carcinomas was evaluated by immunoblot with a polyclonal anti-CXCR4 antibody.
The expression levels of CXCR4 protein were analyzed in the P5 human primary thyroid cells, and in the indicated cell lines derived from human PTCs (NIM, TPC1,
FB2, and NPA) or from human ATCs (8505C, ARO, CAL62, BHT101, FRO, and FB1). B, ATC-derived (S11T, S77T, S14T, HTU8 and ARO) and normal thyroid
primary cultures (P5) were screened for CXCR4 expression by Western blot analysis with the polyclonal anti-CXCR4 antibody. As a control for equal loading, the
anti-a-tubulin monoclonal antibody was used. C, expression levels of CXCR4 in human ATC cells versus the P5 normal thyroid culture were evaluated by real-time
RT-PCR analysis. CXCR4 expression levels of ATC cell lines (Y axis ) are calculated relative to the expression level in the normal human cell culture P5. All
experiments were performed in triplicate, and the average value of the results was plotted on the diagram. SDs were smaller than 25% in all cases (data not shown).
D, flow cytometric analysis (fluorescence-activated cell sorting) of surface-expressed CXCR4 in ATC cells. Subconfluent cells were detached from culture dishes
and incubated with PE-labeled antibodies specific for human CXCR4.
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determined. As shown in Fig. 2D , CXCR4 was expressed in almost
all the ATC cell lines tested, with the exception of the FB1 cells. The
ARO cells, which in a previous report were shown to feature high
CXCR4 levels (21), were included as a positive control. In contrast,
normal thyroid cells did not express CXCR4 (data not shown).
SDF-1, the CXCR4 ligand, was not expressed by ATC cells as
assessed by quantitative PCR or ELISA assay (data not shown).
We selected two cell lines, S11T and BHT101, for further
experiments. First, we tested the ability of recombinant SDF-1a to
stimulate signal transduction in ATC cells. It has been previously
reported that stimulation of CXCR4 induces the activation of
several kinase cascades mainly through the activation of the Ghg
subunit of the Gi protein (31, 32). We therefore tested the
phosphorylation of two downstream effectors, extracellular sig-
nal-regulated kinase (ERK) 1/2 and AKT, using phosphorylated-
specific antibodies. To this aim, cells were serum starved for 12 h
and then stimulated with SDF-1a for different time points. As
shown in Fig. 3A and B , SDF-1a induced rapid and sustained
activation of ERK1/2 in both cell lines. AKT activation was also
achieved in BHT101 cells on SDF-1a treatment, whereas it was less
evident in S11T cells. Together, these data indicate that CXCR4 is
functional in ATC cells. Activation of ERK1/2 and AKT was
observed in virtually all the ATC cell lines expressing CXCR4,
whereas normal thyroid cells, which do not express CXCR4, did not
display these effects (data not shown).
Biological activity of CXCR4 in ATC cells. To further test the
functional responsiveness of CXCR4 in ATC, we stimulated these
cells with SDF-1a and evaluated its ability to induce cell
proliferation. To this aim, BHT101 and S11T cells were maintained
in low-serum (2.5%) growth conditions for 24 h and then either left
untreated or stimulated with SDF-1a for 12 h. As a measure of DNA
synthesis, we counted BrdUrd-positive cells on a 1-h BrdUrd pulse.
As shown in Fig. 4, SDF-1a consistently enhanced DNA synthesis in
both BHT101 and S11T cells. We then used a specific CXCR4
inhibitor, AMD3100, to block this effect. AMD3100 is a competitive
antagonist of SDF-1a, but it also displays partial agonist activity
(33). Normal thyroid cells were insensitive to SDF-1a stimulation
and to the effect of AMD3100 (data not shown). As shown in
Fig. 4A , AMD3100 inhibited SDF-1a–mediated BrdUrd incorpora-
tion in ATC cells. The positive effect of SDF-1 on cell proliferation,
measured as S-phase entry, was also observed in other ATC cell
lines (Fig. 5C). To evaluate whether SDF-1a could stimulate ATC
cell growth, we also performed growth curves in low-serum (2.5%)
conditions. As shown in Fig. 4B , the stimulation of BHT101 with
SDF-1a increased their proliferation rate, and AMD3100 reverted
this effect. SDF-1a was also able to increase the proliferation rate
of three different ATC cell lines, KAT4, CAL62, and ARO, which
express CXCR4, but was unable to do so on FB1 cells, which we
previously reported to be devoid of CXCR4 (Fig. 4B). AMD3100
alone did not have any effect on ATC cells (data not shown).
To exclude off-target effects of AMD3100 and to directly
determine the role of CXCR4 on ATC cell proliferation, we used
small duplex RNA oligos to knock down CXCR4. CXCR4 RNA
interference was verified by Western blot analysis in BHT101 cells
(Fig. 5A). We then transfected CXCR4 siRNAs into BHT101, KAT4,
CAL62, and 8505C cells. CXCR4 silencing substantially impaired
SDF-1a–induced S-phase entry in all the ATC cells but had no
effect on BrdUrd incorporation in the absence of the chemokine, as
shown in Fig. 5. When we used the control scrambled siRNA, this
inhibitory effect was not observed. Furthermore, scrambled oligos
had no effect on CXCR4 protein levels (Fig. 5A).
AMD3100 inhibits ATC tumor formation in nude mice. It has
been previously shown that the CXCR4/SDF-1 axis plays an
important role in the growth and in the metastatic ability of
several epithelial cancers (20). Because we had shown that CXCR4
inhibition blocked SDF-1a–mediated ATC cell growth in culture,
and because it has been shown that this chemokine is secreted by
stromal tumoral cells (34), we reasoned that SDF-1a-CXCR4 axis
blockade by AMD3100 might inhibit ATC tumor growth. To this
aim, we selected BHT101, ARO, and KAT4 cells for their ability to
respond to SDF-1a and their ability to form tumors in vivo with
high efficiency. Nude mice were injected s.c. with 5  106 cells.
When tumors measuredf40 mm3, mice (n = 20 for each cell line)
were randomized to receive AMD3100 (1.25 mg/kg/twice daily
i.p.) or vehicle 5 days per week for 3 to 4 weeks. Tumor diameters
were measured at regular intervals with caliper. After 21 days, the
mean volume of BHT101 tumors in mice treated with AMD3100
was 48 mm3, whereas that of mice treated with vehicle was
620 mm3. Representative experiments are shown in Fig. 6A and B .
Tumors induced by ARO and KAT4 reached the volume of 40 mm3
in only 1 week. In addition, in this case, AMD3100 was able to
inhibit tumor growth, although to a lesser extent. In fact, ARO-
induced tumor mean volume at the end of treatment with
AMD3100 was 220 mm3, whereas that of mice treated with vehicle
was 625 mm3. Similar results were also obtained when KAT4 cells
were used. In this case, the difference between the mean volume
of AMD3100-treated versus vehicle-treated tumors was not
statistically significant after 3 weeks. However, when treatment
Figure 3. A andB, protein extracts from the
indicated cell lines were subjected to
immunoblotting with anti-phosphorylated
p44/42 MAPK (apMAPK) and with
anti-phosphorylated AKT (apAKT)
antibodies. The blots were reprobed with
anti-p44/42 and anti-AKT antibodies for
normalization.
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was extended for 1 additional week, AMD3100-treated tumor mean
volume was 180 mm3, whereas that of mice treated with vehicle
was 690 mm3, and the P value was 0.039 (Fig. 6A). These data,
taken together, show that treatment with AMD3100 strongly inhi-
bits ATC tumor growth.
Discussion
Despite ATC is a rare disease, it is one of the most aggressive
human cancers (9). Although various therapeutic strategies have
been exploited to slow down the growth of this tumor, none of
these treatments improved survival (10). The molecular pathways
implicated in this disease are poorly understood, and this hampers
the application of novel rational therapeutic strategies. Genetic
alterations found in ATC are inactivating mutations of the p53
tumor suppressor and activating mutations of b-catenin, RAS,
BRAF, and PIK3CA (11). Recently, molecular genetic alterations of
FHIT have been also detected in ATC (35). Among the genes
involved in ATC, BRAF serine-threonine kinase has been exploited
as a potential therapeutic target (23).
Most epithelial cancers feature high levels of expression of the
chemokine receptor CXCR4 (20). This receptor has been widely
Figure 4. A, BrdUrd incorporation was measured to evaluate S-phase entry on treatment of BHT101 and S11T cells with SDF-1a in the presence or absence of
the CXCR4 inhibitor AMD3100. Columns, average results of three independent experiments; bars, SD. P < 0.05. B, the indicated cell lines were plated at the same
density (5  104) in 2.5% serum, harvested, and counted at the indicated time points. Columns, average results of at least three independent determinations; bars, SD.
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studied because its expression contributes to several phenotypes of
cancer cells, such as the ability to grow, survive, and spread
throughout the body. On the contrary, most epithelial cancers do
not express SDF-1, the unique CXCR4 ligand, whereas SDF-1 is
produced in high amounts in specific body districts. It has been
suggested that the role of this chemokine in cancer is mainly to
attract cancer cells to these districts (18). In support of this
hypothesis, it has been shown that SDF-1 is produced in several
metastatic sites. Recently, it has also been suggested that tumoral
stroma secretes high amounts of SDF-1, supporting the concept
that this chemokine is pivotal in sustaining local protumorigenic
events, such as growth and survival of cancer cells (34). Further-
more, the expression of SDF-1 by stromal cancer cells directly
recruits endothelial progenitors that are required for tumor
angiogenesis (19). As most epithelial and hematopoietic malignan-
cies, also thyroid cancer expresses high levels of CXCR4.
We previously reported functional expression of CXCR4 in
human papillary thyroid cancer (22). Furthermore, Hwang et al.
(21) showed that an anaplastic cell line, ARO, expressed high levels
of functional CXCR4. In this report, we analyzed human ATC
samples for CXCR4 expression. We also screened a large panel of
human ATC established and primary cell cultures for CXCR4
expression. We show that, both at the mRNA and at the protein
level, this receptor is overexpressed in ATC with respect to normal
thyroid samples. In contrast, SDF-1 was not detected. The
molecular mechanisms underlying CXCR4 up-regulation in ATC
are currently unknown. Because we had previously shown that
CXCR4 expression was under the control of the RET/PTC-RAS-
BRAF-ERK pathway in PTCs (22), and because this pathway is also
activated in ATC, we asked whether CXCR4 expression correlated
with the BRAF status in ATC. The ATC cell lines that we used in
this study had been previously characterized for BRAF mutations.
Figure 5. A, CXCR4 RNA interference was used to transiently suppress CXCR4 expression in BHT101 cells. BHT101 cells were transfected with siRNAs against
CXCR4 (siRNA CXCR4) or control nonspecific small duplex RNA containing the same nucleotides, but in scrambled fashion (siRNA SCR ), and harvested
48 and 72 h later. Protein lysates were subjected to immunoblotting with anti-CXCR4 and anti-tubulin antibodies. Control siRNA did not affect CXCR4 protein levels.
B, CXCR4 RNA interference (siRNA CXCR4 ) in BHT101 cells inhibited SDF-1a–stimulated S-phase entry as evaluated by BrdUrd incorporation assay. Control
siRNA (siRNA SCR ) did not inhibit DNA synthesis. Unstimulated BHT101 cells were not affected by siRNA transfection. C, CXCR4 RNA interference (siRNA CXCR4 )
inhibited S-phase entry in SDF-1a–stimulated KAT4, CAL62, and 8505C. ATC cells were transfected with siRNAs against CXCR4 (siRNA CXCR4 ) or control
siRNA (siRNA SCR ) and harvested 48 h later. Control siRNA did not inhibit DNA synthesis. Unstimulated cells were not affected by siRNA transfection.
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Furthermore, human ATC samples were screened for the presence
of BRAF mutations.6 We found that most of the samples expressed
CXCR4, and this expression was present in both the BRAF-positive
and in the BRAF-negative tumors and cell lines. These data suggest
that CXCR4 up-regulation in ATC is not necessarily linked to the
BRAF pathway and that it can be possibly achieved through
different mechanisms. The mechanisms of CXCR4 up-regulation in
cancer thus far described are various and complex. It has been
shown that nuclear factor-nB (NF-nB) positively regulates the
expression of CXCR4 (36) in breast cancer cells. Interestingly,
NF-nB is activated in human thyroid cancer cells (37, 38).
Transduction of human thyroid cancer cells with the mutant
BRAF(V600E) allele induced an increase in NF-nB DNA-binding
activity (39). Thus, it is possible that CXCR4 expression in ATC is
sustained by high NF-nB activity, which can be the result either of
BRAF activation or of the activation of other still undiscovered
pathways.
We also show that the CXCR4 expressed on the ATC cell surface
is able to transduce biochemical signals into the cell. Indeed,
stimulation of ATC cells with recombinant human SDF-1a
activated ERK1/2 and, less consistently, AKT pathways in ATC
cells. Moreover, we found that SDF-1a stimulated cell growth of
different ATC cell cultures, which was inhibited by the small
CXCR4 inhibitor AMD3100. Given the high rate of mortality of this
cancer and the lack of effective therapies, we focused our efforts in
the identification of novel potential therapeutic targets in ATC. We
found that the treatment with AMD3100 significantly suppressed
the development of tumors in different xenograft models of ATC
cells in nude mice.
The more dramatic biological effects of CXCR4 inhibition
observed in the animals with respect with those observed in cell
culture could be explained by the fact that SDF-1 can act, in
tumor microenvironment, at multiple levels. Indeed, tumoral
stromal cells, such as fibroblasts and bone marrow–derived cells,
express high levels of SDF-1 (34), which can directly enhance the
growth of epithelial tumoral cells and can recruit endothelial
progenitors, thus favoring angiogenesis. However, when we
analyzed xenograft tumors for CD31-positive tumor capillaries,
we found that there were no differences in vessel density of
AMD3100-treated versus untreated tumors. Preliminary data
suggest that AMD3100 activity in xenografts correlates better
with a proapoptotic than with an antiproliferative activity.7 Our
findings are in accord with previous reports about the use of
CXCR4 inhibitors in brain tumor models (40, 41). Although
treatment of ATC xenografts with AMD3100 did not induce a
complete regression of tumors, we observed a strong reduction in
growth rate, which was more dramatic in the case of BHT101
xenografts. It is conceivable that the combination of conventional
anticancer therapies with CXCR4 targeting would display a
stronger antineoplastic effect. Given the strong antitumor activity
of AMD3100, newer-generation compounds have been developed,
such as AMD3465. This compound differs from the bicyclam
AMD3100 in that it is a monocyclam endowed with greater
solubility in water, higher affinity for CXCR4, and a potent
antitumor activity (41). Although these compounds are effective in
inhibiting various cancers, long-term sustained dosing of
Figure 6. A, antitumorigenic effects of AMD3100 in ATC cell xenografts.
BHT101, ARO, and KAT4 cells (5  106 per mouse) were injected s.c. into the
right dorsal portion of BALB/c athymic mice. When tumors measured 40 mm3,
mice were randomized to two groups (10 mice per group) to receive AMD3100 or
vehicle (PBS) by i.p. injection. Treatment was given for 5 consecutive days per
week for 3 to 4 wk (day 1 is the treatment starting day). Tumor diameters
were measured with calipers and tumor volumes were calculated. Unpaired
Student’s t test (normal distributions and equal variances) was applied. All
P values were two sided, and differences were statistically significant at
P < 0.05. B, tumors were excised and photographed. Two representative
examples of BHT101 xenografts are shown.
6 F. Basolo and P. Faviana, unpublished observations.
7 V. Guarino et al., unpublished observation.
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AMD3100 displayed a certain toxicity (42). For this reason, further
studies, aimed at understanding the effects of long-term
administration of CXCR4 inhibitors, must be pursued. Despite
these considerations, our data, together with several other reports,
strongly indicate that the inhibition of this pathway should be
actively evaluated as a novel anticancer therapy.
In conclusion, in this report, we identify CXCR4 as another
potential target of ATC anticancer therapy and suggest that
AMD3100, or other specific CXCR4 inhibitors, should be developed
and tested for the therapy of human ATC.
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Some cancer types are strongly associated with chronic inﬂammatory or infectious diseases whereas
others are not, but an inﬂammatory component is present in most human neoplastic lesions. This review
focuses on various aspects of thyroid cancer and inﬂammation. The incidence of thyroid cancer, in par-
ticular of well-differentiated papillary thyroid carcinomas (PTCs), is increased in autoimmune thyroid
diseases such as Hashimoto’s thyroiditis. Thyroid cancer often has an inﬂammatory cell inﬁltrate, which
includes lymphocytes, macrophages, dendritic cells and mast cells, whose role in thyroid cancer is still
not completely understood. However, most experimental evidence suggests these cells exert a protu-
morigenic function. Moreover, oncoproteins typically expressed in human PTCs, such as RET/PTC, RAS,
and BRAF, trigger a proinﬂammatory programme in thyreocytes. These data suggest that inﬂammatory
molecules are promising targets for thyroid cancer therapy.
© 2009 Elsevier Ireland Ltd. All rights reserved.
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1. Thyroid cancer
Thyroid cancer, although a rare disease, is the most frequent
endocrine neoplasia, and its incidence is rapidly increasing. The
papillary histotype is the most frequent. Thyroid cancer can
derive from both the follicular and the parafollicular compo-
nent of the thyroid gland. Three malignant lesions may derive
from follicular cells: well-differentiated (WDTC), poorly differen-
tiated (PDTC) and anaplastic (ATC) thyroid carcinomas. WDTCs
are either papillary (PTC) or follicular (FTC). These two types are
characterized by speciﬁc histological features, and by the mainte-
nance of some differentiating features (Kondo et al., 2006). WDTCs
have a favorable prognosis thanks to the efﬁcacy of combined
surgical and radioiodine-based therapy. Nevertheless, 5–10% of
WDTCs progress to radioactive iodine refractory-disease. PDTCs
∗ Corresponding author at: DBPCM/IEOS, Via S. Pansini, 5, 80131 Naples, Italy.
Tel.: +39 0817463603; fax: +39 0817463603.
E-mail address: rosmelil@unina.it (R.M. Melillo).
and ATCs, which are thought to derive from pre-existing differenti-
ated tumors, do not accumulate radioiodine and respond poorly to
medical and surgical treatment (Rosai et al., 1992). Medullary thy-
roid carcinoma (MTC), which arises from the parafollicular C-cells
of the thyroid, is generally treatable by surgery. However, novel
chemotherapeutic agents like vandetanib,which target growth fac-
tor receptor, are showing promise in the treatment of MTC. This
tumorcanbe inherited in thecontextof autosomaldominantMEN2
(multiple endocrine neoplasia type 2) syndromes (MEN2A, MEN2B
and familial medullary thyroid carcinoma [FMTC]) (Roman et al.,
2009).
Non-overlapping mutations of the RET, TRKA, RAS and BRAF
genes are found in about 70% of PTCs. These genes encode activa-
tors of the mitogen-activated protein kinase (MAPK) cascade. RET
encodes the tyrosine kinase receptor of growth factors belonging
to the glial-derived neurotrophic factor (GDNF) family (Manie et
al., 2001). RET/PTC rearrangements are thought to be early events
in thyroid tumorigenesis since they are very frequent in clinically
silent small PTC (Fusco et al., 2002). Similar rearrangements of the
high afﬁnity receptor (TRKA) for nerve growth factor (NGF) are also
0303-7207/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.mce.2009.10.003
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found, albeit at a lowprevalence, inhumanPTC (Alberti et al., 2003).
Activating point-mutations in RAS small GTPases are found mainly
in the follicular variant of PTC (PTC-FV) (Zhu et al., 2003). Point-
mutations in BRAF are the most common genetic lesion in these
tumors (Kimura et al., 2003; Xu et al., 2003; Soares et al., 2003;
Cohen et al., 2003). BRAF is a member of the RAF family of ser-
ine/threonine kinases, which includes ARAF and RAF1, and it is a
component of the RAF–MEK–ERK signaling module.
FTCs are characterized by RAS point-mutations (Nikiforova
et al., 2002) or by the PAX8/PPAR rearrangement (Kroll et al.,
2000). PDTC and ATC can derive from pre-existing WDTCs. RAS
point-mutations and the V600E BRAF mutation are prevalent
in PDTC and ATC (Garcia-Rostan et al., 2003; Nikiforova et al.,
2003; Soares et al., 2004; Begum et al., 2004). Finally, p53 muta-
tions are often found in ATC (Donghi et al., 1993; Fagin et al.,
1993).
MTC can be sporadic or it could be one of the lesions that charac-
terize the autosomal dominantMEN 2 syndromes (MEN2A,MEN2B
and FMTC). MEN 2 syndromes are caused by germline point-
mutations that convert RET into a dominant oncogene (Santoro et
al., 1995). In all MEN2A cases, mutations target extracellular cys-
teine residues in RET. In more than 80% of cases, MEN2B is caused
by the Met918Thr substitution in the kinase domain of the recep-
tor. Roughly 40% of sporadic MTC cases harbor point-mutations in
RET (Leboulleux et al., 2004).
2. Chronic inﬂammation and cancer
Inﬂammation is a physiological, protective process used by the
organism in response to tissue damage. Several chemical signals
initiate and sustain the inﬂammatory response whose aim is to
ﬁght pathogens and to repair tissue damage. Several cell types
migrate to the sites of tissue damage. This migration is mediated
by chemotactic and adhesion proteins, including members of the
integrin and selectin family (Coussens and Werb, 2002). The ﬁrst
migrating cells are neutrophils, macrophages and mast cells, all of
which secrete reactive oxygen species (ROS), vasoactivemolecules,
such as histamine and leukotrienes, and cytokines, chemokines
and proteases that remodel the extracellular matrix (De Visser
et al., 2006). Inﬂammation is an auto-limiting process; however,
abnormal persistence of the stimuli that induced the inﬂammatory
response or the failure of the mechanisms that make it end, result
in chronic inﬂammation (Coussens and Werb, 2002).
A functional relationship between chronic inﬂammation and
cancer was ﬁrst proposed by Virchow in 1863, and has been
sustained by clinical and epidemiological evidence. The most com-
pelling evidence is the association between: (a) intestinal chronic
inﬂammatory diseases (Crohn’s disease and ulcerative rectocolitis)
and adenocarcinoma of the colon; (b) chronic HBV or HCV hep-
atitis and liver carcinoma; (c) Helicobacter pylori-induced chronic
gastritis and gastric carcinoma; (d) asbestosis and mesothelioma;
(e) chronic obstructive pulmonary disease (COPD) and lung can-
cer; and (f) chronic esophagitis and carcinoma of the esophagus
(Balkwill and Mantovani, 2001). Moreover, a 40–50% reduction in
the incidence of colorectal cancer is associated with the regular
use of non-steroidal anti-inﬂammatory drugs, the COX enzymes
that catalyze the synthesis of proinﬂammatory mediators, such as
prostaglandins (Baron and Sandler, 2000; Williams et al., 1999).
Further support for the concept that inﬂammation can cause
cancer comes from the observation that polymorphisms in genes
encoding proinﬂammatory chemokines are associated with an
increased risk of some forms of human cancer. For instance, IL1-
 polymorphisms are associated with an increased incidence of
gastric cancer (Gianfagna et al., 2008). Moreover, gastric-speciﬁc
expression of this cytokine in transgenic mice can induce gastric
inﬂammation and cancer (Tu et al., 2008).
Various inﬁltrating cells have been identiﬁed in tumors, namely,
tumor-associated lymphocytes, tumor-associated macrophages
(TAM), immature dendritic cells, mast cells and myeloid-derived
suppressor cells. The presence of speciﬁc inﬂammatory-immune
cells such as macrophages and mast cells in tumor site has been
associated with a poor prognosis of the disease (Fujimoto et al.,
2009; Maltby et al., 2009). Pollard and colleagues have shown
that transgenic mice prone to breast cancer develop less prolifer-
ating and invasive tumors when crossed with mice deﬁcient for
CSF1, a macrophage chemotactic factor (Lin et al., 2001). Other
cell populations also contribute, via distinct mechanisms, to tumor
growth. Indeed, mice deﬁcient in mast cells or CD4+ T cells dis-
play a reduction in tumor incidence and progression in models of
mice carcinogenesis (Daniel et al., 2003; Souceket al., 2007). Among
the cell populations recruited into tumor sites by cancer cells, a
peculiar role is played by bone marrow-derived precursors. These
include myeloid-derived suppressor cells that contribute to tumor
growth through tumor-induced immune tolerance (Marigo et al.,
2008), and bone marrow-derived stem cells, which are thought
to be recruited from the bloodstream and to repopulate areas of
epithelial destruction. Indeed, these cells constitute all the meta-
plastic, dysplastic and neoplastic areas in the Helicobacter-induced
gastric cancer model in mice. Again, IL1- plays an important role
in this process—indeed it seems to be required for both recruitment
and activation of bone marrow-derived stem cells (Houghton et al.,
2004; Tu et al., 2008).
Cancer cells secrete several cytokines and chemokines, thus sus-
taining cancer cell growth and recruiting leukocytes into tumor
sites. Leukocytes physiologically secrete ROS and reactive nitro-
gen species to eliminate pathogens. However, these highly reactive
metabolites induce the production of peroxynitrite and other
mutagenic agents; therefore, they can induce “DNA damage”, i.e.,
mutations in proliferating cells (Coussens and Werb, 2002). Thus,
in the case of persistent tissue damage, the O2 and N highly
reactive metabolites secreted by inﬂammatory cells induce point-
mutations, rearrangements and double-strand breaks in the DNA
(Colotta et al., 2009). This results in ahigherprobability of oncogene
activation or of tumor suppressor loss of function.
Proinﬂammatory cytokines produced in tumor sites are piv-
otal in cancer progression. The production of these cytokines by
inﬂammatory and epithelial cancer cells depends mainly on the
NFkB transcription factor. Through conditional deletion of theNFkB
upstream activator IKKb, in myeloid and epithelial cells, it has been
shown that NFkB plays a major protumorigenic role in an experi-
mental colitis-associated cancer (CAC) model (Greten et al., 2004).
Among the cytokines induced by NFkB, IL6 has been identiﬁed as
one of the most relevant myeloid-derived factors that promote
tumorigenesis. Moreover, activation of the IL6 pathway, in par-
ticular of the STAT3 transcription factor, which is a downstream
mediator of IL6 activity, is necessary for CAC initiation and pro-
gression (Grivennikov et al., 2009; Bollrath et al., 2009).
3. Thyroid cancer and autoimmune thyroid diseases
A link between thyroid cancer, in particular the PTC histotype,
and autoimmune thyroid diseases (AITD) has long been recognized,
although the precise relationship between the two diseases is still
debated. This group of diseases includes Hashimoto’s thyroiditis
andGrave’s disease.Hashimoto’s thyroiditis (HT) is anautoimmune
disorder in which the immune system reacts against a variety of
thyroid antigens. The overriding feature of HT is the progressive
depletion of thyroid epithelial cells, which are gradually replaced
bymononuclear cell inﬁltration andﬁbrosis.Multiple immunologic
mechanisms may contribute to the death of thyrocytes. Sensitiza-
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tion of autoreactive CD4+ T-helper cells to thyroid antigens appears
to be the initiating event. Hashimoto’s thyroiditis is character-
ized by proliferating nodules as well as by cytological alterations
and nuclear modiﬁcations similar to those of papillary carcinomas
(Weetman, 2004).
An epidemiological association has been identiﬁed between
Hashimoto’s thyroiditis and thyroid cancer (Di Pasquale et al.,
2001; Wirtschafter et al., 1997; Mechler et al., 2001; Segal et al.,
1985; Eisenberg and Hensley, 1989; Ott et al., 1987; Sclafani et
al., 1993; Pisanu et al., 2003). The increased incidence of car-
cinomas in patients with thyroiditis suggests thyroiditis might
be a precancerous condition. Most thyroiditis-associated carcino-
mas are papillary; however, also follicular, anaplastic, medullary
and squamous carcinomas have been reported in cases of thy-
roiditis. Thyroid follicular cells may have chromosomal defects,
such as the RET/PTC rearrangement, which is the hallmark of
many PTCs. Several authors found RET/PTC rearrangements in non-
neoplastic thyroid lesions, such as HT (Wirtschafter et al., 1997;
Sheils et al., 2000; Elisei et al., 2001). Additional evidence impli-
cating RET/PTC in the association between thyroiditis and cancer
comes from the ﬁnding that patients exposed to radiation from
the Chernobyl nuclear power plant disaster often develop not
only RET/PTC-induced papillary tumors but also autoimmune thy-
roiditis (Williams, 2002). Accordingly, transgenic mice engineered
to express RET/PTC develop papillary carcinomas and chronic
thyroiditis (Powell et al., 1998). Finally, Wirtschafter and col-
leagues detected RET/PTC expression in about 90% of the cases of
Hashimoto’s thyroiditis they analyzed (Wirtschafter et al., 1997).
However, these data partially contrast with other reports. Niki-
forova and colleagues detected RET/PTC rearrangements only in
PTCs not associated with Hashimoto’s disease (Nikiforova et al.,
2002). Rhoden et al. detected only a few follicular cells express-
ing very low levels of RET/PTC in Hashimoto’s thyroiditis, which
suggests that RET/PTC expression does not necessarily predict the
development of PTC in patients with thyroiditis (Rhoden et al.,
2006).
Two models can be hypothesized to explain the association
between Hashimoto’s thyroiditis and the RET/PTC rearrangement.
The ﬁrst suggests that inﬂammation might facilitate the rearrange-
ment. According to this hypothesis, production of free radicals,
cytokine secretion, cellular proliferation andother phenomena cor-
related with inﬂammation might predispose to the rearrangement
of RET/PTC in follicular cells. In support of this hypothesis, it has
been observed that the mutational rate in inﬂamed tissues is much
higher than in normal tissues (Colotta et al., 2009). It is also possi-
ble that the inﬂammatory microenvironment supports thyreocyte
survival in stress conditions. It is generally assumed that normal
humanepithelial cells donot tolerate oncogene expressionbecause
excessive growth signals induce DNA replication stress, which, in
turn, induces oncogene-mediated senescence or apoptosis (Lowe
and Sherr, 2003; Halazonetis et al., 2008; Evan and d’Adda di
Fagagna, 2009). Thus, evasion from apoptosis is required for neo-
plastic transformation and can occur through additional genetic
lesions that lead to activation of anti-apoptotic pathways, such as
those mediated by phosphatydilinositole 3-kinase. This concept is
supported by the ﬁnding that the ectopic expression of the RET/PTC
oncogene in a continuous rat thyroid cell line (PC Cl3) induces
apoptosis (Castellone et al., 2003; Wang et al., 2003). This effect
might be due to the strong RET-mediated mitogenic stimuli. It is
possible that cytokines and chemokines released by the inﬂamma-
tory tumoral stroma sustain the survival of those thyroid cells in
which RET/PTC rearrangements randomly occur, thereby allowing
the selection of clones that acquire additional genetic lesions and
thus become resistant to oncogene-induced apoptosis.
It has recently been suggested that tissue stem cells are the tar-
gets of malignant transformation. In the setting of chronic inﬂam-
mation, the pool of resident or bone marrow-derived stem cells is
thought to expand (Li et al., 2006). If this applies also to thyroid
cancer, AITD-mediated inﬂammation could cause the expansion of
stem cells in which a RET/PTC rearrangement has occurred.
An alternative hypothesis, which does not exclude the previous
hypothesis, is that theRET/PTC rearrangement itself, and the conse-
quent activation of the downstream signaling pathways can induce
thyroid inﬂammation. Accordingly, RET/PTC induces the synthesis
of many inﬂammatory proteins in epithelial thyroid cells (Table 1
) and a severe inﬂammatory response is observed in TG-RET/PTC
transgenic mice in which RET/PTC expression is conﬁned to the
thyroid gland (Powell et al., 2003; Melillo et al., 2005; Puxeddu et
al., 2005; Pufnock andRothstein, 2009). Indeed, RET/PTC transgenic
mice develop PTCs and chronic thyroiditis. However, RET/PTC itself
is not sufﬁcient to induce completeHashimoto’s thyroiditis in these
mice since this disease is characterized not only by lymphocytic
inﬁltration, but also by ahumoral autoimmune reaction that results
in the production of autoantibodies against thyroid antigens, and
by the formation of lymphoid follicles in the thyroid parenchyma.
These features are not present in TG-RET/PTC transgenic animals. In
conclusion, we favor the hypothesis that AITD creates a protumori-
genic microenvironment in which the RET/PTC rearrangement is
tolerated. The rearrangement itself then contributes tomaintaining
the inﬂammatory reaction.
4. Thyroid cancer and immune-inﬂammatory inﬁltrate
There are various reports of immune-inﬂammatory cell inﬁl-
trates in thyroid cancer. Not only are PTCs frequent in the context
of Hashimoto’s thyroiditis, but these carcinomas are often present
with a remarkable lymphocytic inﬁltrate in the absence of the
typical signs of autoimmune thyroiditis, such as autoantibody
production and tertiary follicle formation. The prevalence of lym-
phocytic inﬁltrate is generally signiﬁcantly higher in patients
with PTC than in patients with benign thyroid lesions (Okayasu,
1997), which indicates that these cells might favor cancer develop-
ment. However, the presence of chronic lymphocytic thyroiditis in
patientswith PTC correlateswith an improvedprognosis (Kebebew
et al., 2001). Moreover, thyroid carcinomas with a poor prognosis,
such as PDTCs and ATCs, are characterized by a strongly reduced
lymphocyte cell inﬁltrate comparedwithPTCs, thus suggesting that
these cells may play a protective role in thyroid cancer (Ugolini
et al., 2007). Macrophages and dendritic cells, mainly character-
ized by an immature phenotype, have been identiﬁed in human
PTCs (Scarpino et al., 2000). Again, PDTCs and ATCs are character-
ized by a greatly reduced dendritic cell inﬁltrate with respect to
PTCs, thus suggesting that these cell types also may play a protec-
tive role in thyroid cancer (Ugolini et al., 2007). Tumor-associated
macrophages are generally considered protumorigenic (Sica et al.,
2008). Ryder and colleagues found that the density of the TAM
inﬁltrate was higher in PDTCs and ATCs than in PTCs and FTCs.
Moreover, increased TAM inﬁltration in PDTCswas found to be pos-
itively correlated with capsule invasion, extrathyroidal extension
and poor prognosis (Ryder et al., 2008). Taken together, these data
support the concept that TAMmay favor themalignant progression
of thyroid cancer.
We compared the density of tryptase-positive mast cells in 96
PTCs versus normal thyroid tissue from 14 healthy individuals.
Mast cell densitywas higher in PTCs than in control tissue.Mast cell
inﬁltrate correlated with capsule invasion. We also observed that
mast cells promoted proliferation, survival and the invasive ability
of thyroid cancer cells, thereby contributing to thyroid carcinoma
growth and invasiveness (Melillo et al., unpublished observations).
The presence of inﬂammatory cells has been evaluated in
transgenic mice expressing RET/PTC3 in the thyroid gland by
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Table 1
The most relevant inﬂammatory molecules in thyroid cancer cells. The ofﬁcial symbol and full name, Gene ID, and known function for each molecule are listed. References regarding their role in thyroid cancer are also reported.
Inﬂammatory
molecules
Ofﬁcial symbol Ofﬁcial full name Gene ID Function References
M-CSF CSF1 Colony stimulating factor 1 (macrophage) 1435 Cytokine that controls the production, differentiation, and function
of macrophages.
Borrello et al. (2005)
G-CSF CSF3 Colony stimulating factor 3 (granulocyte) 1440 Cytokine that controls the production, differentiation, and function
of granulocytes.
Borrello et al. (2005)
GM-CSF CSF2 Colony stimulating factor 2
(granulocyte–macrophage)
1437 Cytokine that controls the production, differentiation, and function
of granulocytes and macrophages.
Russell et al. (2003, 2004), Borrello et al. (2005)
IL1- IL1A Interleukin 1, alpha 3552 Member of the interleukin 1 cytokine family. Pleiotropic cytokine
involved in various immune responses, inﬂammatory processes,
and hematopoiesis. It is mainly produced by monocytes and
macrophages.
Russell et al. (2003, 2004)
IL1- IL1B Interleukin 1, beta 3553 Member of the interleukin 1 cytokine family. It is produced by
activated macrophages as a proprotein, which is proteolytically
processed to its active form by caspase 1 (CASP1/ICE). This
cytokine is an important mediator of the inﬂammatory response.
Russell et al. (2003, 2004), Borrello et al. (2005)
IL6 IL6 Interleukin 6 (interferon, beta 2) 3569 Cytokine that functions in inﬂammation and the maturation of B
cells. The protein is primarily produced at sites of acute and
chronic inﬂammation, where it is secreted into the serum and
induces a transcriptional inﬂammatory response.
Russell et al. (2003, 2004), Puxeddu et al.
(2005)
IL8/CXCL8 IL8 Interleukin 8 3576 Member of the CXC chemokine family. It is one of the major
mediators of the inﬂammatory response. It is secreted by several
cell types, functions as a chemoattractant, and is also a potent
angiogenic factor.
Iwahashi et al. (2002), Borrello et al. (2005)
IL4 IL4 Interleukin 4 3565 Pleiotropic cytokine produced by activated T cells. This cytokine is
a ligand for interleukin 4 receptor.
Stassi et al. (2003), Todaro et al. (2006)
IL10 IL10 Interleukin 10 3586 Cytokine produced primarily by monocytes and to a lesser extent
by lymphocytes. It has pleiotropic effects in immunoregulation
and inﬂammation. It down-regulates the expression of Th1
cytokines, and enhances B cell survival, proliferation, and antibody
production.
Stassi et al. (2003), Todaro et al. (2006)
IL24 IL24 Interleukin 24 11009 Member of the IL10 family of cytokines. It can induce apoptosis
selectively in various cancer cells.
Shinohara and Rothstein (2004)
VEGFA VEGFA Vascular endothelial growth factor A 7422 Member of the PDGF/VEGF growth factor family, acts on
endothelial cells and mediates increased vascular permeability,
induces angiogenesis, vasculogenesis and endothelial cell growth,
promotes cell migration, and inhibits apoptosis.
Belletti et al. (1999)
OPN/IL28/SPP1 SPP1 Secreted phosphoprotein 1 6696 Cytokine secreted by immune and non-immune cells. Involved in
cell migration and adhesion, bone metabolism and immune
regulation of TH1 cells. Overexpressed in several cancer types.
Castellone et al. (2004a), Borrello et al. (2005)
TNFa TNF Tumor necrosis factor (TNF superfamily,
member 2)
7124 Proinﬂammatory cytokine that belongs to the tumor necrosis
factor (TNF) superfamily. It is mainly secreted by macrophages and
is involved in the regulation of cell proliferation, differentiation,
apoptosis, lipid metabolism, and coagulation.
Russell et al. (2003, 2004)
CCL2/mcp-1 CCL2 Chemokine (C–C motif) ligand 2 6347 Small cytokine belonging to the CC chemokine family that displays
chemotactic activity for monocytes and basophils but not for
neutrophils or eosinophils. Ligand for the CCR2 receptor.
Russell et al. (2003, 2004), Puxeddu et al.
(2005), Melillo et al. (2005)
CCL20 CCL20 Chemokine (C–C motif) ligand 20 6364 Small cytokine belonging to the CC chemokine family. It binds to
the CCR6 receptor and is strongly chemotactic for lymphocytes
and weakly attracts neutrophils. It is implicated in the formation
and function of mucosal lymphoid tissues.
Borrello et al. (2005)
CXCL1/GROa CXCL1 Chemokine (C–X–C motif) ligand 1 (melanoma
growth stimulating activity, alpha)
2919 Small cytokine belonging to the CXC chemokine family. It is
strongly chemotactic for neutrophils and has been shown to be a
major component required for serum-dependent melanoma cell
growth. Ligand for the CXCR2 receptor.
Russell et al. (2003, 2004), Melillo et al. (2005)
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Table 1 (Continued )
Inﬂammatory
molecules
Ofﬁcial symbol Ofﬁcial full name Gene ID Function References
CXCL10/IP-10 CXCL10 Chemokine (C–X–C motif) ligand 10 3627 Small cytokine belonging to the CXC chemokine family, ligand for
the receptor CXCR3. It has pleiotropic effects, including
stimulation of monocytes, natural killer and T-cell migration, and
modulation of adhesion molecule expression.
Puxeddu et al. (2005), Melillo et al. (2005)
CXCL12/SDF-1 CXCL12 Chemokine (C–X–C motif) ligand 12 (stromal
cell-derived factor 1)
6387 Small cytokine belonging to the CXC chemokine which activate
leukocytes and is often induced by proinﬂammatory stimuli.
Ligand for the CXCR4 and the CXCR7 receptors.
Borrello et al. (2005)
CXCR2 IL8RB Interleukin 8 receptor, beta 3579 Member of the G-protein-coupled receptor family. This protein is a
receptor for interleukin 8 (IL8) and for other CXC-chemokines. It
mediates neutrophil migration to sites of inﬂammation and has
angiogenic effects.
Melillo et al. (2005)
CXCR3 CXCR3 Chemokine (C–X–C motif) receptor 3 2833 Member of the G-protein-coupled receptor family. It displays
selectivity for three chemokines, CXCL10/IP10, Mig and I-TAC. It is
prominently expressed in effector/memory T cells, and in T cells
present in many types of inﬂamed tissues.
Melillo et al. (2005)
CXCR4 CXCR4 Chemokine (C–X–C motif) receptor 4 7852 Member of the G-protein-coupled receptor family. CXC chemokine
receptor speciﬁc for stromal cell-derived factor 1. It acts with the
CD4 protein to support HIV entry into cells and is also highly
expressed in cancer cells.
Castellone et al. (2004b), Borrello et al. (2005)
CD44 CD44 CD44 molecule (Indian blood group) 960 Cell-surface glycoprotein involved in cell-cell interactions, cell
adhesion and migration. It is a receptor for hyaluronic acid (HA),
osteopontin, collagens, and matrix metalloproteinases (MMPs). It
participates in a wide variety of cellular functions including
lymphocyte activation, recirculation and homing, hematopoiesis,
and tumor metastasis.
Castellone et al. (2004a)
mPGES1 PTGES Prostaglandin E synthase 9536 This protein is a glutathione-dependent prostaglandin E synthase.
The expression of this gene has been shown to be induced by the
proinﬂammatory cytokine interleukin 1 beta (IL1B).
Puxeddu et al. (2003)
COX2 PTGS2 Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
5743 It is the key enzyme in prostaglandin biosynthesis. This gene
encodes the inducible isozyme. It is regulated by speciﬁc
stimulatory events, suggesting that it is responsible for the
prostanoid biosynthesis involved in inﬂammation and
mitogenesis.
Puxeddu et al. (2003)
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means of a tissue-speciﬁc promoter. In this system, mice develop
PTC-like lesions, characterized by a leukocytic inﬁltrate, mainly
constituted by macrophages (Russell et al., 2004). This effect
seemed to be RET-speciﬁc because a similar oncogene, TRK-T1,
which also derives from a rearrangement of a tyrosine kinase
receptor with a heterologous gene, did not have the same effect.
Interestingly, the tumor incidence and burden in RET/PTC3 mice
were inﬂuenced by the genetic background of the animals. In
fact, tumors were signiﬁcantly larger in C57BL/6 mice expressing
RET/PTC3 than in C3H/HeJ animals. Cytokine expression was much
higher in large tumors, suggesting that these molecules play a role
in tumor growth. This effect could be due to the different polar-
ization of TCD4+ cells and consequently to the distinct cytokine
environment mounted by the C57BL/6 mice with respect to the
C3H/HeJ animals. Taken together, these data demonstrate that the
RET/PTC3 oncoprotein can induce recruitment of immune cells
into tumor sites, and that cytokines produced in a tumor site play
an important role in tumor progression.
In another set of experiments, Pufnock and Rothstein investi-
gated whether RET/PTC3 is involved in the recruitment of other
immune cell populations into tumor sites (Pufnock and Rothstein,
2009). In that study, RET/PTC3 and its mutant isoform (RET/PTC3
Y1062F), which is defective in the activation of the most rele-
vant RET-mediated signaling pathways, were transduced into a
mouse ﬁbrosarcoma cell line. Tumors were induced by inject-
ing RET/PTC3- and RET/PTC3 Y1062F-expressing cells in syngeneic
mice. RET/PTC3 tumors were signiﬁcantly larger than RET/PTC3
mutant tumors. CD4+ and CD8+ T cell inﬁltrate densitywas compa-
rable in both tumor groups. However, RET/PTC3, but not RET/PTC3
Y1062F tumors, displayed a remarkable leukocytic inﬁltrate char-
acterized by CD11b+, Gr1+ myeloid cells, previously described
as innate suppressive inﬂammatory cells (Marigo et al., 2008;
Gabrilovich and Nagaraj, 2009). These data suggest that RET/PTC3-
positive thyroid cancer, like other cancer types, can induce the
recruitment of CD11b+, Gr1+ cells. These cells can mediate tumor
escape from the immune response; this phenomenon is depen-
dent on the integrity of the Y1062 residue of RET. Whether other
mechanisms of immune evasion also operate in thyroid cancer is
unknown. Interestingly, the BRAF–MAPK signaling pathway has
been shown to induce the synthesis and secretion of immunosup-
pressive cytokines in melanomas (Sumimoto et al., 2006). These
factors include IL10, VEGF and IL6, which are cytokines that are
produced also by thyroid cancer cells (Stassi et al., 2003; Todaro
et al., 2006; Russell et al., 2004; Shinohara and Rothstein, 2004;
Belletti et al., 1999; Jo et al., 2006; Puxeddu et al., 2005).
5. Oncoprotein signaling in thyroid cancer and
inﬂammation
The activation of RET in PTC derives from a genetic rearrange-
ment between the RET tyrosine-kinase domain and heterologous
genes. The consequence of these rearrangements is the constitutive
activation of RET due to constitutive dimerization–oligomerization
of the oncoprotein induced by the different RET-fused genes. In
MEN2AandFMTC,RETactivation is achievedbyconstitutivedimer-
ization of RET through the replacement of an extracellular cysteine
and the formation of disulﬁde bonds (Santoro et al., 2004). Differ-
ently, mutations that affect the intracellular domain induce kinase
activation in the absence of dimerization, presumably through
a modiﬁcation of the kinase structure. For instance, the MEN2B
M918T point-mutation induces a change in substrate speciﬁcity
with respect to MEN2A mutants, which is reﬂected in the differ-
ent capability of MEN2B mutants to phosphorylate endogenous
tyrosines and signaling adaptors. These differences can account,
at least in part, for the phenotypic differences between the two
syndromes. Indeed, although both MEN2A and MEN2B are charac-
terized by the presence of pheochromocytomas and MTCs, MEN2B
MTCs occur earlier and are more aggressive. Furthermore, MEN2B
patients also present skeletal abnormalities and ganglioneuromas
(Hansford and Mulligan, 2000).
Both point-mutations and genetic rearrangements cause con-
stitutive activation of the tyrosine kinase activity of RET in the
absence of ligands. Several studies conducted in different labora-
tories have shown that activation of RET, either by physiological
ligands or by oncogenic conversion, results in the phosphorylation
of intracellular tyrosine residues that serve as docking sites for the
recruitment of signaling adapters. Among the tyrosines phospho-
rylated after RET activation, Y1062 has been shown to be important
for RET-mediated biological activity in thyroid cells. Y1062 is
a multi-docking site, being able to bind several PTB-containing
adapters, namely, ShcA, FRS2, IRS1, ShcC and dok. Substitution of
the Y1062 residue of Ret with a phenylalanine, both in the context
of a wild-type and of an oncogenically activated receptor, abro-
gates Ret-mediated signal transduction and biological activities
(Takahashi, 2001). We and others have shown that Ret can activate
the MAPK pathway in a Y1062-RAS- and BRAF-dependent manner
(Kimura et al., 2003; Melillo et al., 2005).
Several groups demonstrated that RET-induced transcriptional
activity depends almost entirely on the integrity of the Y1062
residue and on activation of the RAS/BRAF/MAPK pathway. Rus-
sel and colleagues reported that the expression of the RET/PTC3
isoform in a rat thyroid cell line (PC Cl3) induced an increase in
NFkB DNA-binding activity and a consequent increase in proin-
ﬂammatory cytokine secretion (Russell et al., 2003). CXCL1/Gro,
CCL2/mcp-1 and GM-CSF were up-regulated upon RET/PTC3
expression, and this increase depended on the integrity of residue
1062 of RET.
GDNF stimulation of the neuroectodermal tumor cell line SK-
N-MC, ectopically expressing the human wild-type RET, induced
the production of high levels of IL8. This cytokine has also been
found in the TT human medullary thyroid carcinoma cell line
carrying the RET/MEN2A oncogene and in the TPC1 human PTC
cell line (Iwahashi et al., 2002). IL8 is a proinﬂammatory, mito-
genic and proangiogenic chemokine that contributes to several
human cancers (Waugh and Wilson, 2008). Russel and colleagues
found that RET/PTC3 caused the expression of the proinﬂamma-
tory proteins IL1-, IL1-, IL6 and IL24 in thyroid cancer cells
(Russell et al., 2004; Shinohara andRothstein, 2004). Similar results
were obtained by Puxeddu and colleagues, who demonstrated that
prostaglandin E2 (PGE2), microsomal prostaglandin E synthase-
1 (mPGES1), cyclooxygenase2 (COX2) and several other genes
involved in immune response and inﬂammation were induced by
RET/PTC3 in PCCl3 cells (Puxedduet al., 2003; Puxedduet al., 2005).
To study the transcriptional changes associated with thyroid
transformation,we used an oligonucleotide-basedDNAmicroarray
(Affymetrix) on PC Cl3 cells engineered to stably express wild-
type and mutant isoforms of the oncogenic RET/PTC3 protein, or
the HRAS (V12) or BRAF(V600E) oncoproteins, respectively. When
transfected cells were compared with the parental cells, it was
evident that RET/PTC3 induced a complex pattern of gene expres-
sion that depended entirely on the integrity of the Y1062 residue.
The HRAS (V12) and BRAF(V600E) oncoproteins each modiﬁed the
expression of several genes, and 50% of these genes were com-
mon between the three oncoproteins. Furthermore, by using siRNA
and pharmacological inhibitors, we showed that most of these
gene changes depended on the ERK pathway (Melillo et al., 2005).
Our gene expression proﬁling studies also revealed the induction
of cytokine and chemokines and of their respective receptors in
PC RET/PTC3 cells (Fig. 1). Indeed, we found that RET/PTC3 cells
expressed high levels of osteopontin (OPN), VEGFA, CCL2, CXCL1
and CXCL10 (Melillo et al., 2005). Interestingly, CD44, CXCR2 and
CXCR3, the receptors for OPN, CXCL1 and CXCL10, respectively,
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Fig. 1. Cytokines and chemokines secreted by RET/PTC-transformed PC Cl3 rat thy-
roid cells:main biological effects. Transformation of PC CL3 rat thyroid cells through
activationof theRET/PTC–RAS–BRAF–MAPKsignalingpathway inducesaproinﬂam-
matory program that includes cytokines, chemokines and their receptors. Selected
mediators and their biological effects are indicated.
were also expressed by transformed cells. We also found the
expression of CXCR4, the chemokine receptor for the chemokine
CXCL12, in transformed cells with respect to the normal counter-
parts (Castellone et al., 2004b). These results were conﬁrmed by
Borrello and coworkers in human primary thyroid cells transduced
with the RET/PTC oncogene (Borrello et al., 2005).
Theproinﬂammatoryproperties of RET/PTC in the thyroidmight
have a dual effect: on one hand, molecules such as OPN, CXCL1,
CXCL10, CCL2 and GM-CSF can inﬂuence the immune response
to the tumor by recruiting and functionally regulating immune
cells. For instance, transplantation of RET/PTC3-expressing thyre-
ocytes into mice in vivo induced intense macrophage inﬁltrate and
neovascularization followed by cell death (Russell et al., 2003).
On the other hand, secreted cytokines and chemokines, such as
OPN, CXCL1, CXCL10 and IL24, can act as autocrine growth and
survival factors for thyroid tumor cells that express the cognate
receptors on their plasma membrane (Shinohara and Rothstein,
2004; Castellone et al., 2004a; Melillo et al., 2005). These data
are corroborated by studies conducted on human thyroid tumors.
Indeed, it has been shown that human thyroid samples express
most inﬂammatory genes (CXCR4, CD44, OPN, CXCL1, CXCL10 and
SDF-1) (Castellone et al., 2004a,b; Guarino et al., 2005; De Falco et
al., 2007; Melillo et al., 2005; Borrello et al., 2005).
Other studies support the concept that thyroid cancer epithelial
cells can produce inﬂammatory factors, and that these inﬂamma-
tory factors can sustain the resistance of thyroid cancer cells to
variousapoptotic stimuli. Stassi andcolleagues looked for cytokines
involved in the resistanceof thyroid cancer cells to chemotherapeu-
tic agents and identiﬁed IL4 and IL10. These cytokines are typically
secreted by T CD4+ cells polarized toward a TH2 phenotype. TH2
cytokines induce humoral immunity and promote thyreocyte sur-
vival in AITD by up-regulating levels of anti-apoptotic proteins
such as Bcl2 and Bcl-XL (Stassi et al., 2003). Moreover, the authors
demonstrated that IL4 and IL10 also induce resistance of thyroid
cancer cells to FAS/FASL-mediated apoptosis. This effect is medi-
ated by IL4 and IL10-induction of two anti-apoptotic proteins,
namely cFLIP and PED/PEA15 (Todaro et al., 2006).
6. Conclusions
The relationship between inﬂammation and thyroid cancer is
complex and still not completely understood. Like other cancer
types, thyroid cancer is inﬂuenced by andmodulates inﬂammation.
Epidemiological and histological data indicate that thyroid cancer
frequently occurs in the context of one of the most common AITDs,
Hashimoto’s thyroiditis, and that thyroid cancer is frequently inﬁl-
trated by inﬂammatory-immune cells.
The role of these cells is complex, and several studies indi-
cate that, depending on the speciﬁc cell population, the effect
can be either pro- or anti-tumorigenic. Speciﬁcally, the presence
of lymphocytes, which belong to the adaptive branch of immu-
nity, is signiﬁcantly higher in neoplastic than in non-neoplastic
lesions. However, lymphocytic inﬁltration seems to confer protec-
tion against cancer progression. On the other hand, the presence
of cells belonging to innate immunity, such as macrophages and
mast cells, enhances tumor progression and is associated with
an unfavorable prognosis. By activating the MAPK cascade, the
oncogenes activated in thyroid carcinomas (i.e., RET/PTC, RAS and
BRAF) can activate a cell-autonomous proinﬂammatory transcrip-
tional program that involves mainly cytokines, chemokines and
their receptors (Table 1). These molecules exert two main effects
in thyroid cancer. First, by acting in an autocrine fashion, they sus-
tain most of the malignant phenotypic features of thyroid cancer
cells namely, proliferation, survival and invasiveness. Second, by
acting in a paracrine and, possibly, in an endocrine manner, they
induce remodeling of the tumoral stroma by recruiting inﬂamma-
tory, immune, endothelial and bone marrow-derived cells. In this
way, cytokines can further enhance tumor progression through the
release of mediators from inﬁltrating cells, by stimulating angio-
genesis, and by inducing subversion of the anti-tumoral immune
response. Basedon these observations,we favor the concept that, at
least in the full blownphase, thyroid cancergrowthandprogression
are positively inﬂuenced by two major inﬂammatory components,
one dependent on the cells that are present in the cancer stroma,
the other dependent on activation, in epithelial cancer cells, of spe-
ciﬁc oncoprotein-mediated signaling. As a consequence, not only
oncoproteins, but also inﬂammatory molecules are promising tar-
gets for novel thyroid cancer therapeutical strategies. In support of
this, we have shown that the blockade of CXCR4 chemokine recep-
tor inhibits the growth of ATC cell xenografts in immunodeﬁcient
mice (De Falco et al., 2007).
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Abstract 
Mast cells function as effector cells during inflammatory and immune responses. Mast cell infiltrate 
is increased in several human tumors. We compared the density of tryptase-positive mast cells in 96 
papillary thyroid carcinomas (PTCs) versus normal thyroid tissue from 14 healthy individuals. Mast 
cell density was higher in 95% of PTCs (n=91) than in control tissue. Mast cell infiltrate correlated 
with capsule invasion (p= 0.0005). Conditioned media from thyroid cancer cells stimulated 
histamine release and cytokine synthesis in human mast cells and induced mast cell chemoattraction 
in vitro. The latter effect required vascular endothelial growth factor A produced by cancer cells. 
Conditioned media from two human mast cell lines (LAD2 and HMC-1), and from primary human 
lung mast cells induced thyroid cancer cell Matrigel invasion, survival and DNA synthesis in vitro. 
The latter effect was mainly mediated by three mast cell-derived mediators: histamine, and 
chemokines CXCL1/GROα and CXCL10/IP10. Co-injection of LAD2 and HMC-1 cells 
accelerated the xenograft growth of human thyroid cancer cells (8505-C) in athymic mice. This 
effect was mediated by increased vascularization and cancer cell proliferation. In conclusion, mast 
cells promote proliferation, survival and invasive ability of thyroid cancer cells, thereby 
contributing to thyroid carcinoma growth and invasiveness.  
Key words: chemokine, mast cell, thyroid cancer. 
 3
 
Introduction 
Inflammation was first linked to cancer in the nineteenth century consequent to observations that 
tumors often arose at sites of chronic inflammation and that inflammatory cells were present around 
tumors. Several chronic inflammatory diseases predispose to cancer. Cytokines, secreted by stromal 
cells can exacerbate the malignant phenotype of cancer cells. These, by producing chemoattractant 
molecules, recruit inflammatory cells into tumor sites, influencing them in a way that ultimately 
promotes cancer progression (Coussens and Werb, 2002; Balkwill, 2004; Mantovani et al., 
2008).  
 There are four types of thyroid carcinomas: differentiated papillary (PTCs) and follicular 
carcinomas, poorly differentiated carcinomas and rapidly growing undifferentiated carcinomas. 
PTC is the most common thyroid malignancy and it is usually associated with a good therapeutic 
response and prognosis. However, 10% of PTC patients develop recurrences and distant metastases. 
At somatic level, PTC is associated with four genetic lesions, namely, chromosomal aberrations 
affecting the RET or TRKA tyrosine kinase receptors and point-mutations in the RAS or BRAF 
genes (Kondo et al., 2006).  
 Inflammatory infiltrates have been found in human thyroid tumors. An association between 
PTC and lymphocytic thyroiditis has been reported in various studies starting from the 1950s (Di
Pasquale et al., 2001; Rhoden et al., 2006). Furthermore, macrophages and immature dendritic 
cells accumulate in PTCs, both in tumoral stroma and at the invasive front (Scarpino et al., 2000).  
 Mast cells are are bone marrow-derived immune cells widely distributed throughout 
vascularized tissues, and at interfaces with the external environment (Marone et al.., 2005; 
Kaleshnikoff and Galli, 2008). Mast cells are present in several tumors where they influence many 
aspects of tumor biology (Cousens et al., 1999; Nakayama et al., 2004; Soucek et al,  2007; 
Huang et al., 2008; Yang et al., 2008) such as  angiogenesis (Detoraki et al., 2009) and tumor 
invasion of the extracellular matrix by releasing cytokines and proteases (Coussens et al., 1999). 
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The role of mast cells in tumor growth is supported by the observation that carcinoma formation 
and expansion is greatly reduced in mast cell-deficient KitW-sh mutant mice (Cousens et al., 1999; 
Soucek et al,  2007;).  
 In this study, we investigated the possibility that mast cells and their mediators play a role in 
human thyroid cancer. We found that human thyroid carcinomas feature a remarkable mast cell 
infiltrate whose intensity correlates with the invasive phenotype and bilaterality. Using in vitro and 
in vivo assays, we show that thyroid cancer cells attract mast cells through the release of VEGF-A. 
Thyroid cancer cells stimulate histamine release and cytokine synthesis in human mast cells. Mast 
cell-released mediators enhanced the proliferation, survival and invasive behavior of thyroid cancer 
cells in vitro. Moreover, mast cells promote the growth of thyroid carcinoma xenografts in nude 
mice. Our data indicate that mast cell-derived chemokines and histamine are the major mediators of 
the growth-inducing effect of mast cells on thyroid cancer cells.  
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Materials / subjects and Methods 
Tissue samples and immunohistochemistry 
Retrospectively-collected archival thyroid tissue samples from 96 patients affected by papillary 
thyroid carcinomas (PTC) were retrieved from the files of the Pathology Department of the 
University of Pisa upon informed consent. Normal thyroid tissue samples, derived from enlarged 
neck dissection for tracheal or laryngeal carcinomas, were also retrieved from the files of the same 
Department. We used an anti-human tryptase antibody (DAKO, Glostrup, Denmark) for mast cell 
staining. Tryptase expression was counted in 10 high power fields and scored as follows: 0= 
absence of positive cells; + = 1-20 cells; ++ = 21-50 cells; +++ = > 50 cells. Anti-ki-67 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) and anti-CD34 (Novocastra Lab., Ltd Newcastle, UK) 
antibodies were used to evaluate cell proliferation and vessel density in xenografts.  
Cell lines  
Human primary cultures of normal thyroid cells were obtained and maintained according to F. 
Curcio (Curcio et al., 1994). Human thyroid cancer cell lines TPC1, 8505-C and NIM have been 
described and were maintained as previously described (Visconti et al., 1997; Salvatore et al., 
2006). HMC-1 and LAD2 mast cell lines were generous gifts of J.H. Butterfield and A.S. 
Kirshenbaum, respectively. These cells were grown as previously described (Butterfield et al., 
1998; Kirshenbaum et al., 2003). Jurkat cells were obtained from ATCC and cultured as described 
(Schneider et al., 1977). 
 
RNA extraction and reverse transcription polymerase chain reaction 
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley, West Sussex, UK) and subjected to 
on-column DNase digestion with the RNase-free DNase set (Qiagen). Primers were designed with a 
software available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi and 
synthesized by MWG Biotech (Ebersberg, Germany). Quantitative (real-time) reverse transcription 
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polymerase chain reactions (qRT-PCR) were performed as previously described (Melillo et al., 
2005). Quantitative RT-PCR for CXCL1 and CXCL10 was performed by using the pre-developed 
TaqMan assay reagent kit (“Assay on demand” from Applied Biosystems). 
 
ELISA assay 
Mast cells (70% confluent) were serum-deprived for 12 h and then treated with thyroid carcinoma 
cell conditioned medium (CM). Cells were incubated for further 12 h in serum-free media. CXCL1 
levels in culture supernatants were measured using a quantitative immunoassay ELISA kit 
(QuantiKine colorimetric sandwich assay, ELISA, R&D Systems Europe, Ltd, Abingdon, UK). 
Triplicate samples were analyzed at 490 nM with an ELISA reader and results were normalized for 
protein content (Model 550 microplate reader, Bio-Rad). 
 
Cell motility 
In vitro cell chemotaxis and invasiveness through Matrigel was assayed using transwell cell culture 
chambers as described elsewhere (Castellone et al., 2004). Briefly, 1X105 cells were added to the 
upper chamber of a pre-hydrated polycarbonate membrane filter of 8 μM pore size (Costar, 
Cambridge, MA) coated with fibronectin (Millipore Corporate, Billerica, MA) or Matrigel 
(Collaborative Research Inc., Bedford, MA). The lower chamber was filled with thyroid carcinoma 
or mast cell CM. When required, thyroid carcinoma cell CM was pretreated with VEGF-A blocking 
antibodies (1 μg/ml, Santa Cruz Clone C-1; Clone 147; Clone A-20). Plates were incubated at 37°C 
in a humidified incubator in 5% CO2 and 95% air for 24 h. Non-migrating cells on the upper side of 
the filter were wiped off and migrating cells on the reverse side of the filter were stained with 0.1% 
crystal violet in 20% methanol for 15 min. The stained cells were lysed in 10% acetic acid. 
Triplicate samples were analyzed at 570 nM with an ELISA reader (Model 550 microplate reader, 
Bio-Rad). The percentage of migrated cells was calculated with respect to total cell number.  
 
 7
S-phase entry  
S-phase entry was evaluated by BrdU incorporation and indirect immunofluorescence (5-bromo-2’-
deoxy-uridine Labeling and Detection Kit I, Roche Diagnostics, Indianapolis, IN). Cells were 
grown on coverslips, and serum deprived for 12 h. When indicated, thyroid carcinoma cells were 
treated with mast cell CM, PBL CM, Jurkat CM, CXCL1, CXCL10 (PeproTech, Inc. Rocky Hill, 
NJ) or histamine (Sigma-Aldrich, St Louis, MO for 48 h. For immunodepletion experiments, HMC-
1 CM was treated with 1 μg/ml CXCL1 (Clone 20326, R&D) or CXCL10 blocking antibodies 
(Clone 33036, R&D Systems, Minneapolis, MN). BrdU-positive cells were revealed with FITC-
conjugated secondary antibodies (Jackson Immuno Research Laboratories, Inc., Philadelphia, PA). 
Cell nuclei were identified by Hoechst 33258 staining (final concentration, 1ug/ml; Sigma-Aldrich). 
Fluorescence was visualized with a Zeiss 140 epifluorescent microscope. 
 
TUNEL assay 
For terminal desoxynucleotidyl transferase-mediated desoxyuridine triphosphate nick end-labeling 
(TUNEL), an equal number (5 x 103) of thyroid carcinoma cells was seeded onto single-well Costar 
glass slides. Cells were serum-deprived for 48 h or treated with HMC-1 or LAD2 CM, fixed in 4% 
(w/v) paraformaldehyde and permeabilized by the addition of 0.1% Triton X-100/0.1% sodium 
citrate. Slides were subjected to the TUNEL reaction (Roche). All coverslips were counterstained in 
PBS containing Hoechst 33258. The fluorescent signal was visualized with an epifluorescent 
microscope (Axiovert 2, Zeiss) (equipped with a 100X objective) interfaced with the image 
analyzer software KS300 (Zeiss).  
 
Xenografts in nude mice 
Three groups of 10 mice (4-week-old male BALB/c nu/nu mice, Jackson Laboratories, 
Bar Harbor, ME) were inoculated subcutaneously into the right dorsal portion with 8505-C cells 
(10x106/mouse), HMC-1 (1x106/mouse), or a mixture of both. Tumor diameters were measured 
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at regular intervals with a caliper. Tumor volumes (V) were calculated with the formula: V= A x 
B2/2 (A=axial diameter; B= rotational diameter). Mice were housed in barrier facilities that 
provided 12-h light-dark cycles and received food and water ad libitum. This study was 
conducted in accordance with Italian regulations for experimentation on animals. All 
manipulations were performed while mice were under isoflurane gas anesthesia. No mouse 
showed signs of wasting or other signs of toxicity. 
Isolation and purification of human lung mast cells
Macroscopically normal lung parenchyma was dissected free from pleura, bronchi, and blood 
vessels and minced into a single-cell suspension (de Paulis et al., 2006). Lung mast cells were 
purified by countercurrent elutriation (J2/21; Beckman) and by discontinuous Percoll density 
gradient and further purified by using an antibody anti-CD117 conjugated to magnetic beads 
(MACS system; Miltenyi Biotec, Bergisch Gladbach, Germany). The final preparations contained > 
95% viable cells, assessed by the Trypan blue exclusion method, and purity was > 98% mast cells.  
 
Histamine release
LAD2 cells were grown in complete medium, and serum-deprived for 1 h in DMEM without phenol 
red. LAD2 cells (1x104 mast cell/tube) were suspended in DMEM, placed in 12x75 mm 
polyethylene tubes and warmed at 370 C; each prewarmed releasing stimulus (TPC1 CM, 8505-C 
CM, or the Ca++ ionophore A23187, 1μg/ml) was added,  and incubation was continued at 370 C  
for 1 h. The reactions were stopped by centrifugation (1000 x g, 220 C, 2 min), and the cell free 
supernatants were assayed for histamine content by an histamine ELISA kit (IBL Hamburg, 
Germany).  
 
Purification of peripheral blood leukocytes  
 9
Human peripheral blood leukocytes (PBL) were purified from human healthy donors. Heparinized 
blood was centrifuged (300 × g for 30 min) in a gradient of ficoll-hypaque with a density of 1114. 
Peripheral blood leukocytes were suspended in RPMI 1640 plus 10% FCS and gentamycin (100 
?g/ml), and were washed three times in PBS. Cell viability (higher than 98%) was measured in all 
the samples by using the Trypan blue exclusion test. Lymphocytes were identified as 91–95% of the 
PBLs obtained. 
 
Statistical Analysis 
 To compare 8505-C versus 8505-C /HMC1 xenograft growth nude mice, we used the 
unpaired Student’s t test (normal distributions and equal variances). The clinico-pathological 
data and their correlation with mast cell infiltrate density were statistically evaluated with a two-
tailed Student’s t test; the chi2 test was used to establish the statistical significance of the 
distributions. Statistical analysis was done with the GraphPad Instat software, v.3.0b. 
Differences were statistically significant at P <.05.  
 
 10
Results 
Mast cell density is increased in human thyroid cancer and correlates with capsule invasion. 
Samples from normal and pathological thyroid tissues were evaluated by immunohistochemistry for 
mast cell infiltrate. We evaluated the density of tryptase-positive cells in PTCs (n=96) and in 
thyroid tissues from healthy individuals (n=14) whose average age and gender were comparable to 
PTC samples (Table 1). Mast cells were counted in each sample and cases were classified 
depending on mast cell number, as indicated in the Methods section. Mast cell infiltrate was present 
both within the tumors and at the invasive front but was virtually absent from normal tissues (Fig. 
1A): of the 14 healthy thyroid samples, 13 were negative for mast cells, and the remaining one was 
weakly (+) positive for tryptase. Instead, mast cell density was increased, to various degrees, in 
95% of PTCs (n=91) (Fig. 1A). Thus, the presence of mast cell infiltrate distinguished normal 
tissues from carcinomas (P=0.0001). A representative example of cell staining with tryptase 
antibody is shown in figure 1B. An isotype-matched non related antibody gave negative results for 
both normal and pathological samples (not shown). 
 We then looked for correlations between clinico-pathological features (Table 1), 
angiogenesis and mast cell infiltrate. To this aim, PTCs were divided into two groups, those with 
intense (+++, ++) tryptase staining, which represented 65% (63/96) of the samples, and those with 
weak tryptase staining, which represented 35% (33/96) of the samples. The group of PTCs with 
intense tryptase staining tended to be more invasive, i.e., capsule invasion was more frequent (P = 
0.0005, Table 2), as was bilateral disease (P < 0.05). Tryptase staining did not correlate with 
gender, age, PTC histological variant, tumor size, lymph node metastasis, multifocality or the 
degree of angiogenesis (data not shown). These results indicate that mast cells are present in PTCs, 
but not in normal thyroid tissues, and that their presence and intensity positively correlates with 
capsule invasion and bilateral occurrence. 
 
Recruitment of mast cells by human thyroid carcinoma cells: a role for VEGF-A 
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To evaluate whether the increased number of mast cells in a tumor site could be due to mast cell 
recruitment by thyroid carcinoma cells, we performed in vitro chemotaxis assays. For these 
experiments, we used two human mast cells lines, HMC-1 and LAD2, derived, respectively, from a 
patient with mast cell leukemia and a patient with mastocytosis (Butterfield et al., 1998; 
Kirshenbaum et al., 2003). We tested the ability of conditioned culture media (CM) from the 
thyroid carcinoma cell lines TPC1, NIM and 8505-C to induce migration of mast cells through a 
fibronectin matrix. Figure 2A shows that CM from each of the three thyroid carcinoma cell lines 
induced migration of both LAD2 and HMC-1 cells; non-conditioned CM was used as a negative 
control. CM from normal thyroid primary cultures did not induce mast cell migration (not shown). 
These data indicate that soluble factors secreted by thyroid cancer cells were responsible for the 
chemoattractant effect exerted on mast cells.  
 A likely candidate for the chemoattractant effect is vascular endothelial growth factor-A 
(VEGF-A), since we and others demonstrated that thyroid carcinoma cells produce VEGF-A 
(Viglietto et al., 1995; de la Torre et al., 2006) and human mast cells and basophils express the 
VEGF-A receptors VEGFR-1 and -2 (Detoraki et al., 2009; de Paulis et al., 2006). As shown in 
Fig. 2B, thyroid carcinoma, but not normal cells produced high levels of VEGF-A. We then 
blocked the activity of this cytokine in conditioned medium from TPC1 cells with three different 
neutralizing VEGF-A antibodies and found that mast cell chemotaxis was significantly impaired 
(Fig. 2C). These data indicate that human thyroid cancer cells secrete VEGF-A, and that this 
cytokine acts as chemoattractant for mast cells. 
Human thyroid carcinoma cells induce mast cell activation
 Human mast cells release a large array of mediators (Kaleshnikoff and Galli, 2008) among 
which is histamine, rapidly released upon mast cell activation. We stimulated LAD2 cells with  
thyroid carcinoma cell CM, and evaluated histamine release by ELISA assay. Figure 3 shows that 
both TPC1 and 8505-C CM concentration-dependently stimulated histamine release from LAD2,  
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being TPC-1 CM almost as powerful than the Ca++ ionophore A23187. Histamine concentrations in 
8505-C CM and TPC1 CM were undetectable (data not shown). Similar results were obtained when 
HMC-1 or primary mast cells purified from human lung (HLMC) were activated by both TPC1 CM 
and 8505-C CM (Supp. Fig. 1 and data not shown). 
 We verifyed whether thyroid carcinoma cell CM could induce also a transcriptional 
response in mast cells. After 24 hours of incubation with thyroid carcinoma cell CM, HMC-1 cell 
RNAs were extracted and subjected to quantitative RT-PCR. Figure 4A shows that treatment of 
mast cells with thyroid carcinoma cell CM significantly up-regulated the mRNA of cytokines (IL-6, 
GM-CSF, TNF-α) and of chemokines (CXCL1/Groα and CXCL10/IP10). As shown in Figure 4B, 
CXCL1 was abundantly secreted by HMC-1 and LAD2 cells stimulated with thyroid carcinoma cell 
CM. These data indicate that thyroid cancer cells produce soluble mediators that activate mast cells. 
Mast cell-derived mediators induce proliferation, survival and invasive ability of thyroid carcinoma 
cells
 We measured BrdU incorporation, as an indication of DNA synthesis, after 48 h of 
treatment of thyroid carcinoma cells (TPC1 and 8505-C) with HMC-1 and LAD2 CM. Figure 5A 
shows that HMC-1 and LAD2 CM increased BrdU incorporation by 2.5 fold in thyroid carcinoma 
cells compared with the non-conditioned medium. P5 normal thyroid primary cultures were not 
affected by treatment with HMC-1 and LAD2 CM. 
HMC-1 and LAD2 are neoplastic mast cell lines. Therefore, to exclude the possibility that the 
observed pro-proliferative effect was due to the neoplastic phenotype of the mast cell lines, we did 
the same experiment with HLMC. In the presence of HLMC CM, there was an increase in BrdU 
incorporation of TPC1 and 8505-C cells comparable to that induced by HMC-1 and LAD2 (Fig. 
5B). To ascertain that this effect was specific of mast cells, and not a common feature of human 
bone marrow-derived cells, we used peripheral blood lymphocytes (PBL) from different donors and 
the Jurkat cell line, which is derived from a human T-cell leukemia. Conditioned media of PBL and 
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Jurkat were significantly less efficient in inducing proliferation of TPC1 and did not induce any 
proliferation of 8505-C cells. Indeed, BrdU incorporation was increased 3 fold in the presence of 
HLMC CM, and 1.8 fold in the presence of PBL or Jurkat CM (Fig. 5B). We then evaluated 
whether mast cell CM inhibited apoptosis of thyroid carcinoma cells. To this aim, TPC1 and 8505-
C cells were serum-deprived for 48 h, a condition that induces apoptosis. Apoptosis was evaluated 
with TUNEL assays. Figure 5C shows that both HMC-1 and LAD2 CM strongly reduced the levels 
of serum starvation-induced apoptosis. Thus, soluble factor(s) secreted by mast cells are able to 
stimulate S-phase entry and inhibit apoptosis of thyroid carcinoma cells. 
 We evaluated whether mast cells could directly influence the invasive behavior of thyroid 
carcinoma cells through Matrigel chemoinvasion assays. Thyroid carcinoma cells were seeded on 
the top chamber of transwells, and their ability to invade a reconstituted extracellular matrix 
(Matrigel) toward mast cell CM was evaluated. As shown in Figure 6, mast cell CM, but not non-
conditioned media induced thyroid carcinoma cell migration in Matrigel.  
 
Mast cell-derived mediators involved in thyroid cancer cell proliferation  
 We next asked whether histamine could mediate mast cell-induced proliferation of thyroid 
carcinoma cells. We first verified the expression of the four principal histamine receptors (H1, H2, 
H3, H4) on thyroid carcinoma and normal thyroid cells using qRT-PCR. H1 and H2 receptors were 
markedly upregulated in four thyroid carcinoma cell lines. Normal thyroid cells were negative for 
each of the histamine receptors (Supp. Fig.2 A). Histamine H3 and H4 receptors were not detected 
in either normal or cancer thyroid cell lines (data not shown). We also confirmed, by western blot, 
that H1 and H2 receptors were expressed in thyroid carcinoma, but not in normal thyroid cells (Supp 
Fig. 2B). Then, we evaluated the ability of histamine to enhance the S-phase entry rate of thyroid 
carcinoma cells lines by performing BrdU assays using TPC1 and 8505-C cells. Consistent with the 
finding that thyroid carcinoma cells express H1 and H2 receptors, histamine (10-7 to 10-4 M) 
concentration-dependently enhanced S-phase entry in these cells. Moreover, the specific inhibitors 
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of receptors H1 (loratadine) and H2 (cimetidine) blocked this effect (supp. Fig. 3). Histamine (10-5 
M) induced an increase of S-phase entry (Fig. 7A).  
Because histamine could not account for the total DNA synthesis-stimulating activity of mast 
cell CM, we hypothesized that other mediators might be involved. We previously demonstrated that 
two chemokines, CXCL1/GROα and CXCL10/IP10, were important mediators of PTC cell 
proliferation and invasive ability (Melillo et al., 2005). Moreover, in the present study, thyroid 
carcinoma CM induced up-regulation of the expression and secretion of these chemokines in HMC-
1 and LAD2 cells (Fig. 4). Consequently, we evaluated whether CXCL1 and CXCL10 could be 
involved in the proliferative effect caused by mast cell CM, and found that both chemokines 
induced BrdU incorporation of TPC1 and 8505-C cells with a higher efficiency than histamine (Fig.
7A). Moreover, histamine enhanced CXCL1- and CXCXL10-induced proliferation. When all three 
mediators were added to the medium together, there was a 5-fold increase in BrdU incorporation 
(Fig. 7A). To verify these results, we used CXCL1- and CXL10 neutralizing antibodies to 
immunodeplete mast cell CM of the two ligands. Chemokine immunodepletion was confirmed by 
ELISA assay (not shown). The removal of each chemokine from mast cell CM caused the 
proliferation rate of TPC1 cells to return to basal level. The addition of the recombinant chemokines 
to the immunodepleted mast cell CM rescued the proliferation effect of the complete medium (Fig.
7B). These data suggest that CXCL1 and CXCL10 are the major mediators of the mast cell CM-
induced proliferation of thyroid carcinoma cells identified in this study. 
Mast cells enhance the xenograft growth of human thyroid cancer cells  in athymic nu/nu mice 
To verify if mast cells can tumor growth, we performed thyroid carcinoma cell xenografts in 
nude mice. Mice were randomly divided into three groups of 10 mice each and the cells were 
injected subcutaneously. The first group was injected with 10x106 8505-C thyroid carcinoma cells, 
the second with 1x106 HMC-1 cells, and the third was co-injected with 10x106 8505-C cells and 
1x106 HMC-1 cells. As shown in Figure 8A, HMC-1 cells alone did not induce tumor formation. In 
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contrast, 8505-C cell xenografts formed tumors with high efficiency. These tumors appeared 4 
weeks after injection and progressively increased up to 6 weeks. When 8505-C were co-injected 
with HMC-1 cells, tumors occurred earlier and the final tumor volume was consistently higher than 
those of 8505-C tumors (P< 0.001). Similar results were obtained with LAD2 cells (data not 
shown). 
End-stage tumors excised from the animals at 6 weeks postinoculation were immunostained 
for tryptase, CD34 and ki67, markers for mast cells, endothelial cells and cycling cells, respectively. 
Immunostaining for tryptase (Fig. 8B) revealed HMC-1 cells in mixed xenografts. Evaluation of at 
least 10 high magnification microscopic fields, showed that tryptase-positive cells represented 10-
20% of all cells. These data indicate that mast cells survive and proliferate in the presence of 
thyroid carcinoma cells. Immunostaining for ki67 (Fig. 8B) showed that mixed xenografts had a 
higher proliferative index than tumors induced by 8505-C cells alone. In the latter, 38% of cells 
were ki67+ versus 68% in mixed xenografts (Fig. 8C). Thus, the presence of mast cells enhanced 
the proliferation of 8505-C cells. We also evaluated vessel number and diameter in tumor tissues 
using the CD34 antibody. This analysis revealed a significant enhancement of vascularization in 
8505-C/HMC-1 tumors compared to 8505-C tumors (Fig. 8B). Thus, mast cells enhanced tumor 
formation by increasing 8505-C proliferation. This proliferation might be a consequence of 
increased vessel density. 
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Discussion   
Mast cells are present in several tumors, where they can mediate pro- or anti-tumorigenic activities 
by modulating tumor angiogenesis and invasiveness (Theoharides and Conti, 2004; Welsh et al., 
2005). Chronic inflammatory reactions occur in human PTCs and in genetically modified mice 
models predisposed to develop thyroid carcinomas (Rhoden et al., 2006; Pufnock and Rothstein, 
2009), and an inflammatory transcriptional response can be induced in normal thyroid epithelial 
cells upon the ectopic expression of PTC oncogenes. This inflammatory response involves 
chemokines and cytokines, including VEGF-A (Borrello et al., 2008). VEGF-A was identified also 
in human thyroid cancer samples, where it correlated with tumor aggressiveness (Klein et al., 2001; 
Jo et al., 2006), and it has been linked to activation of BRAF-ERK signaling also in melanomas 
(Sumimoto et al., 2006). Interestingly, VEGF-A induces human mast cell chemotaxis by activating 
VEGFR1 and VEGFR2 (Detoraki et al., 2009). We found that mast cell density is much greater in 
human thyroid cancer tissue than in normal thyroid tissue. This observation may be due to: 1) 
recruitment of mast cell precursors or 2) increased proliferation/survival of resident mast cells. We 
show that thyroid carcinoma cells are a potent chemoattractant for mast cells. This effect required 
thyroid carcinoma cell-derived VEGF-A because it was inhibited by an anti-VEGF-A antibody. In
vivo experiments showed that HMC-1 and HMC-1 cells inoculated in immunodeficient mice do not 
form tumors. Interestingly, when the two cell lines were co-injected, mast cells survived and 
proliferated, as shown by the immunohistochemical analysis of mixed xenografts. This finding 
indicates that thyroid cancer cells provide mast cells with a favorable environment that ultimately 
promotes their survival and growth. Consequently, the greater cell density in human thyroid cancer 
tissue could be due to both recruitment of mast cell precursors and increased proliferation/survival 
of resident mast cells.  
We also show that thyroid carcinoma cell CM induces mast cell activation (i.e., histamine 
release and cytokine synthesis). Human mast cells can be activated by immunologic and non-
immunologic stimuli through distinct signaling pathways (Gilfillian and Tzaczyc, 2006). How 
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mast cells are activated in our model system is not known, and will be the object of future 
investigation. 
We previously showed that thyroid carcinoma cells express CXCR2 and CXCR3, and their 
ligands, CXCL1 and CXCL10. These autocrinously produced chemokines sustain PTC cell 
proliferation and invasion (Melillo et al., 2005). In the same study, the addition of exogenous 
CXCL1 and CXCL10 to PTC cells further enhanced their proliferation and matrigel invasion, which 
suggests that the CXCR2 and CXCR3 receptors on PTC cells remain available for exogenous 
ligand binding. The results of the present study suggest that the mast cell-derived chemokines 
CXCL1 and CXCL10 are probably the mediators responsible for the mast cell CM-induced growth-
inducing effect on thyroid carcinoma cells. These findings support the hypothesis that mast cell-
derived CXCL1 and CXCL10 might be one of the sources of exogenous chemokines at tumor sites. 
Here we report that histamine, one of the mast cell preformed mediators, contributes to the 
growth inducing activity of mast cell CM on thyroid carcinoma cells. Although the role of 
histamine in cancer growth is still controversial, several studies identified H1 and/or H2 receptor 
expression in cancer cells and showed that histamine functions as a growth factor (Rivera et al., 
2000). In our system, histamine exerts an autonomous effect on cell growth and potentiates 
chemokine-induced cell proliferation. This effect appears to be mediated by the H1 and H2 
receptors expressed by thyroid carcinoma cells, since specific inhibitors of H1 and H2 reverted His-
induced BrdU incorporation. Both CXC and histamine receptors are G-protein-linked receptors 
(Tan et al., 2006; Raman et al., 2007; Parsons and Ganellin, 2007). Whether these receptors 
display typical coupling to signal transducers and how the different signaling pathways associated 
with these receptors integrate and induce cell proliferation will be the object of further 
investigation.  
Besides arguing for a role of mast cells in thyroid carcinoma growth and invasiveness, our 
data also raise several questions. First and foremost, are mast cells an absolute requirement for 
thyroid carcinoma formation or are they only necessary for tumor progression? We plan to conduct 
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experiments involving pharmacological depletion of mast cells and mice with genetically defective 
mast cell development to clarify this issue.  
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Figure legends 
Figure 1 
Immunohistochemical analysis of tryptase in human papillary thyroid carcinoma (PTC).  
A. Distribution of tryptase positivity in human normal thyroid tissue (NT) and in PTC. 98% of 
NT samples scored negative for tryptase-positive cells. 95% of the PTC samples displayed 
strong immunoreactivity to tryptase. Tryptase expression was scored as follows: 0= absence 
of positive cells; += 1-20 cells/10 fields 40x; ++= 21-50 cells/10 fields 40x; +++= > 50 
cells/10 fields 40x.  
B. Normal thyroid tissues (1, 4) were negative for tryptase staining. The degree of tryptase-
positive cell staining differed among PTC samples (see samples, 2, 3, 5, 6). No signal was 
detected after incubation of samples with isotype-matched antibodies (not shown). 
Figure 2 
Migration of LAD2 and HMC-1 cells in response to thyroid cancer cell line-conditioned media 
(CM). 
A. Mast cells were plated on the top of a transwell chamber pre-coated with fibronectin and 
incubated with thyroid carcinoma cell CM (TPC1, 8505-C, NIM CM) or non conditioned 
medium (-). Migrated cells were fixed and stained with crystal violet, and the percentage of 
migration was evaluated with an ELISA reader, and calculated with respect to total cell 
number (1x105). Top, representative micrographs. Bottom, average results of three 
independent assays 
B. VEGF-A expression in human thyroid cell lines was evaluated by ELISA. The TPC1, NIM 
and 8505-C cell lines released high levels of VEGF-A with respect to the normal primary 
thyroid P5 cells, as assessed in triplicate determinations (± S.D.)  
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C. Matrigel invasion of mast cells in response to TPC1 CM was performed in the presence and 
absence of three distinct anti-VEGF-A blocking antibodies. Each antibody, and the mix of 
them, inhibited mast cell migration. Top, representative micrographs. Bottom, average 
results of three independent assays. 
 
Figure 3 
Histamine release of human mast cells in response to thyroid carcinoma cell CM.
LAD2 cells were incubated 1 h at 370 C with the indicated dilutions of 8505-C CM, TPC1 CM,  or 
with the Ca++ ionophore A23187 (1μg/ml). The release of histamine in the supernatants of LAD2 
cells was evaluated by ELISA. Both 8505-C CM and TPC1 CM stimulated histamine release of 
LAD2 cells. Dilutions (> 1: 25)  of both thyroid cancer cell CM abrogated this effect. Histamine 
release was not detected in the presence of non conditioned medium.  
Figure 4 
Activation of HMC-1 in response to thyroid carcinoma cell CM. 
A. Quantitative RT-PCR was used to evaluate the mRNA levels of cytokines and chemokines 
of HMC-1 cells in response to the indicated thyroid carcinoma cell line CM. Non-
conditioned medium (-) was used as a control. Beta- actin mRNA detection was used for 
normalization. For each target (x-axis), the expression level values are calculated relative to 
the expression level in unstimulated HMC-1 cells, arbitrarily considered equal to 1. 
Experiments were performed in triplicate, and the average value of the results ± S.D. was 
plotted. 
B. CXCL1 expression in human mast cell lines was evaluated by ELISA. Both HMC-1 and 
LAD2 mast cell lines released high levels of CXCL1 in response to the indicated thyroid 
carcinoma cell line CM , as assessed in triplicate determinations (± S.D.) of CXCL1. 
Normal thyroid cell (NT) conditioned medium was used as negative control. 
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Figure 5 
Mast cells stimulate proliferation and survival of thyroid carcinoma cell lines. 
A. The indicated thyroid carcinoma cell lines were serum-deprived for 12 h and stimulated with 
mast cell conditioned culture medium (CM) or with non conditioned medium for 48 h. BrdU 
was added two hours before the reaction was stopped, and cells were processed for 
immunofluorescence. Mast cell CM stimulated S-phase entry of thyroid carcinoma cell 
lines, but not of the P5 normal primary thyroid cultures. The results are expressed as BrdU 
incorporation relative fold change with respect to unstimulated TPC1 cells, which were 
arbitrarily considered equal to 1. The average results and the standard deviations of three 
independent experiments in which at least 400 cells were counted are reported.  
B. TPC1 and 8505-C cells were serum-deprived and then stimulated with CM from human 
primary lung mast cells (HLMC), peripheral blood lymphocytes (PBL), and Jurkat T-cell 
leukemia cell line. Mast cell CM, but not CM from the other cultures, induced BrdU 
incorporation of thyroid cancer cells. The results are expressed as BrdU incorporation 
relative fold change with respect to unstimulated cells, which were arbitrarily considered 
equal to 1. The average results and S.D. of three independent experiments in which at least 
400 cells were counted is reported.  
C. The indicated thyroid carcinoma cell lines were serum-deprived for 48 h in the presence of 
mast cell CM or non conditioned medium. The percentage of apoptotic cells was evaluated 
with the TUNEL reaction. Mast cell CM, but not non conditioned medium, induced survival 
of TPC1 and 8505-C cells in condition of serum starvation. The results are expressed as 
apoptosis relative fold change with respect to unstimulated cells, which were arbitrarily 
considered equal to 1. The average results and S.D. of three independent experiments is 
reported. 
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Figure 6 
Mast cells stimulate the invasiveness of thyroid carcinoma cells.  
The indicated thyroid carcinoma cell lines cells were seeded in the upper chamber of Matrigel-
coated 8 μM pore transwells and allowed to migrate for 24 h towards HMC-1 CM or non 
conditioned medium. Top, a representative assay. Bottom, average results of three independent 
assays. SD is also shown. 
 
Figure 7 
The chemokines CXCL1 and CXCL10 and histamine mediate the proliferative effect of mast cell 
CM on thyroid carcinoma cell lines. 
A. BrdU-incorporation was measured to evaluate S-phase entry of TPC1 and 8505-C cells upon 
treatment with CXCL1 (60 pg/ml), CXCL10 (60 pg/ml), histamine (10-5 M) or the indicated 
combinations of these factors. As shown, histamine potentiated the effect of each 
chemokine. BrdU incorporation was highest when the three molecules were added together. 
The results are expressed as the relative fold change of BrdU incorporation with respect to 
unstimulated cells, which were arbitrarily considered equal to 1. Average results of three 
independent experiments ± S.D are shown. 
B. Neutralizing antibodies to CXCL1 and CXCL10 were used to deplete mast cell CM from 
chemokines. Immunodepletion was confirmed by ELISA assay (not shown). Chemokine-
immunodepletion abrogated the proliferative effect of mast cell CM on TPC1 cells, whereas 
mock immunodepletion did not. The add back of excess chemokine to immunodepleted 
media restored the effect of mast cell CM on TPC1 cells proliferation. The results are 
expressed as relative fold change of BrdU incorporation with respect to unstimulated TPC1 
cells, which were arbitrarily considered equal to 1. The average results of three independent 
experiments ± S.D is shown. 
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Figure 8 
Enhancement of 8505-C xenografts growth in nude mice in the presence of mast cells 
A. Xenograft growth of 8505-C thyroid cancer cells in the presence and in the absence of the 
HMC-1 mast cell line was monitored by measuring tumor size weekly. The addition of 
HMC-1 to 8505-C cells caused a marked increase in tumor volume. HMC-1 alone cells did 
not form tumors. 
B. The expression of tryptase, ki67 and CD34 in xenografts was evaluated by 
immunohistochemistry. Tryptase positivity indicated that mast cells survived in mixed 
xenografts. Ki67- and CD34-positive cells were more abundant in mixed than in 8505-C 
xenografts. 
C. Ki-67-positive cells were counted in 10 high magnification (40x) microscopic fields. The 
percentage of Ki67-positive cells was determined in 8505-C and 8505-C/HMC-1 xenografts. 
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 Table 1. Clinico-pathological features of normal and papillary thyroid carcinoma (PTC) patients   
Normal patients 
FEATURES Total (%) 
no. subjects  14 (100) 
   
Gender 
male  4 (29)
female  10 (71)
   
Age
<45y  6 (43)
>/=45y  8 (57)
PTC patients 
FEATURES Total (%) 
no. subjects  96 (100) 
   
Gender 
male  21 (22)
female  75 (78)
   
Age
<45y  51 (53)
>/=45y  45 (47)
   
Histotype 
PTC-CV  44 (46)
PTC-FV   41 (42)
PTC-TCV   10 (11)
PTC-WLV   1 (1)
   
Capsule invasion 
yes  58 (61)
no  38 (39)
Lymph-
node 
metastasis 
yes  23 (25)
no  73 (75)
Multifocality 
yes  28 (30)
no  68 (70)
Bilateral 
occurrence 
yes  20 (21)
no  76 (79)
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Table 2: Correlations between tryptase score and clinical features of papillary thyroid 
carcinomas 
Tryptase score Clinical features P value* 
 Capsule invasion - Capsule invasion +  
Intense tryptase 
staining 45% (17/38) 77% (46/58) 0.0005 
Weak tryptase staining 55% (21/38) 23% (12/58) 
 Bilateral occurrence - Bilateral occurrence+  
Intense tryptase 
staining 60% (46/76) 85% (17/20) 0.0403 
Weak tryptase staining 40% (30/76) 15% (3/20) 
* The chi2 test was used to establish the statistical significance of distributions. Mast cell infiltrate 
correlated with capsule invasion and bilateral occurrence.
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ABSTRACT 
 
 To search for CXCR4/SDF-1? transcriptional targets in thyroid cancer, 
we analyzed global gene expression profiles of CXCR4-expressing human 
papillary thyroid carcinoma cells (TPC-1) treated or not with SDF-1?. We 
identified two tyrosine-kinase receptors: TYRO3 and AXL: these proteins 
belong to the TAM family of receptors (TYRO3, AXL and MER), can be 
activated by two ligands, GAS6 and Protein S, are involved in the regulation of 
the immune response, and are overexpressed in some epithelial cancers. We 
found that TPC-1 cells constitutively express TYRO3 and AXL, but SDF-1 
stimulation increased their protein level and tyrosine phosphorylation. We 
found that most of the available thyroid cancer cell lines express both the 
receptors, albeit to different extent, and  AXL was always much more abundant 
than TYRO3. In most cell lines, the two receptors display high levels of  
tyrosine-phosphorylation, due to constitutive expression of GAS6. An 
exception to this rule was the TPC-1 cell line, in which AXL was highly 
phosphorylated despite the fact that GAS6 is absent. AXL and its ligand GAS6 
are also overexpressed in human thyroid carcinoma samples with respect to 
normal thyroid, as assessed by IHC. The inhibition of  TYRO3 and AXL by 
blocking reagents or RNA interference targeting each receptor or the ligand 
decreased cell proliferation and resistance to apoptotic stimuli in different 
thryoid cancer cell lines. In cell lines that expressed both receptors and ligand, 
the simultaneous blockade of these molecules dramatically affected cell 
viability. Accordingly, we show that the stimulation of  GAS6-negative TPC-1 
cells with GAS6 increased their proliferation and survival.  Moreover, we 
found that stable silencing of Axl reduces thyroid cancer cells invasiveness and 
inhibits experimental tumor growth in nude mice.. These results show that 
TYRO3/AXL-GAS6 axis sustain proliferation and survival of  thyroid cancer 
cells. For these reasons, targeting the Axl-Tyro3/Gas6 axis might be exploited 
as a novel therapy for thyroid cancer. 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Thyroid cancer is the most common endocrine malignancy, and its 
incidence is increasind worldwide. Thyroid cancer hystotypes include well-
differentiated lesions, such as papillary and follicular thyroid carcinoma (PTC 
and ATC), poorly differentiated thyroid carcinoma (PDTC) and anaplastic 
thyroid carcinoma (ATC). WDTC represents more than 90% of all thyroid 
cancers, while ATC accounts for approximately 2-5% of them (De Lellis et al., 
2004; Slough et al., 2006;  Sherman et al., 2003; Rosai et al., 2004). While 
WDTC can be cured in approximately in 90% of the cases, patients which 
present with PDC or ATC have a poor prognosis. Genetic rearrangements of 
the RET and TRKA tyrosine kinase receptors, point mutations of the BRAF 
serine-threonine kinase or, less frequently, mutations of the RAS family of 
small G-proteins, are  associated with PTC. Human FTC features 
rearrangements of the nuclear receptor PPAR? or RAS point mutations (Kondo 
et al., 2006; Nikiforova et al., 2004). Some specific genetic alterations, such 
as RAS or BRAF point mutations, are detected at low frequency in ATC, 
suggesting that some ATC may arise from a preexisting WDTC, while others 
may arise de novo (Nikiforova et al., 2004; Garcia-Rostan et al, 2005). ATC 
also displays inactivating point mutations of the p53 tumor suppressor and 
activating point mutations of the of ?-catenin or of the p110 PI3-Kinase 
(Garcia-Rostan et al, 2005; Garcia-Rostan et al, 1999).  
 Thyroid cancer also features overexpression of specific chemokine and 
their receptors. Among the different receptor-ligand couples, the CXCR4-SDF-
1 axis has been shown to have an important role in promoting cell growth, 
invasiveness and survival in thyroid cancer cell cultures (Melillo et al., 2005; 
Castellone et al., 2004). Importantly, it has been shown that AMD3100, a 
small molecular inhibitor of CXCR4, inhibits the growth of  xenografts of ATC 
in immunodeficient mice, suggesting that this receptor and its ligand(s) are 
required for tumor growth in vivo. These data prompted us to investigate the 
molecular mechanisms of the biological effects of CXCR4/SDF-1? in thyroid 
cancer cells. To this aim, we performed global gene expression profiling of the 
TPC-1 cell line, derived from a human PTC, and identified, as CXCR4 
transcriptional targets, the TYRO3 and AXL receptor tyrosine kinases. These 
receptors belong to a small Protein Tyrosine Kinase (PTK) subfamily, that 
includes three members, Tyro3, Axl and Mer, from which this family was 
named TAM. These receptors are frequently co-expressed in vascular, 
reproductive, nervous and immune system in adults, and their expression is not 
indispensable for life, since knockout of each receptor produces viable and 
fertile mice. Interestingly, when all the three receptors are deleted, several 
phenotypes arise few weeks after birth. Indeed, TAM-deficient mice are 
unfertile, display retinal degeneration, and develop a systemic autoimmune 
disease. Tyro3 (also named  Tif/Sky/Dtk/Rse) was first cloned from a human 
myelogenous leukemia cell line. Its expression is widely distributed, but it 
appears to be higher in the CNS. Axl (alternatively named Ufo/Ark) was 
originally identified in patients with chronic mielogenous leukemia; it is 
overexpressed in several cancer types and its levels correlate with cancer 
progression in some epithelial neoplasia. Human Mer (alternatively named 
Eyk) was firstly identified as the homologue of the avian retroviral v-eyk  
oncogene. It displays tissue specific expression and has a role in the 
phagocytosis of apoptotic cells by macrophages and in the homeostasis of the 
retina and of the immune system.  The three receptors share a common 
structure, being composed by an extracellular domain which contains two 
consecutive Ig-like and two FNII repeats, and a tyrosine kinase intracellular 
domain. The physiological ligands for TAM receptors are two homologous 
vitamin K-dependent proteins, namely Gas6 and protein S. Gas6 (Growth-
Arrest-Specific gene 6) was identified as a gene up-regulated in NIH3T3 
fibroblasts upon serum deprivation. Gas6 can bind, with distinct affinities, the 
three receptors. Protein S has been identified as a negative regulator of the 
blood coagulation process, and has a role in the engulfment of apoptotic bodies 
by phagocytic cells. It has been shown that Protein S can act as an agonist for 
Tyro3 and Mer, while there are no data available sustaining Axl/Protein S 
interaction; moreover, it is not clear whether ligands can bind as heterodimers 
and how receptor homo-heterodimers eventually respond to different 
combinations of ligands. These two proteins display 43% aminoacid identity 
and share a common structure, characterized by an N-terminal  domain rich in 
?-carboxyglutamic acid residues, a loop region, four Epidermal Growth Factor 
(EGF)-like repeats, and a C-terminal globular sex hormone binding globulin 
(SHGB)-like domain. This last region is both necessary and sufficient for 
receptor activation and biological activity. TAM receptors are endowed with 
transforming ability and also play an important role in cancer development and 
progression. In particular, Axl overexpression has been reported in several 
types of human cancer, including  myeloid leukemias, malignant gliomas, 
breast, colon, oesopageal and lung carcinomas. Relatively few data are 
available involving the expression of Tyro3 in cancer: it has been detected in 
myeloid leukemias, multiple myelomas and in human lung carcinoma cells. 
Gas6 is frequently co-expressed with Axl or Tyro3 in cancer cells; in some 
cancer types its expression levels correlate with a poor prognosis (Hutterer M 
et al., 2008).  
 Having identified Axl and Tyro3 as CXCR4 transcriptional targets in 
thyroid cancer, we aimed to study their involvement in these tumors. In this 
report, we show that SDF-1 treatment of PTC cells induces Axl/Tyro3 up-
regulation and tyrosine-phosphorylation. Human PTC and  ATC, but not 
normal thyroid cells consitutively express Axl, Tyro3 and their ligand Gas6. 
By using IHC, we show that human PTC and ATC, but not normal thyroid 
samples score positive for both Axl and Gas6 expression.We show that Axl, 
Tyro3 and Gas6 have a critical role in mediating thyroid cancer cell 
proliferation and resistance to apoptosis. Moreover, we show that stable 
silencing of AXL in an ATC cell line strongly affects tumor growth in 
immunodeficient mice. These data provide evidences that targeting the 
Axl/Tyro3/Gas6 axis might be exploited as a novel anticancer therapy for 
human thyroid cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Cell cultures 
 
Human primary cultures of normal thyroid and ATC cells were obtained 
from F. Curcio (Dipartimento di Patologia e Medicina Sperimentale e Clinica, 
University of Udine, Udine, Italy;) P5, P5-2N, P5-3N, P5-4N (hereafter “NT”) 
and U-HTH83/U-HTH7, and cultured as described previously (Salvatore et al., 
2006). Human thyroid papillary cancer cell lines TPC1 , BcPAP and NIM have 
been described previously (Carlomagno et al., 2003; Inokuchi et al., 1995). 
TPC1 cells harbor a RET/PTC1 rearrangement; BcPAP cells harbor a 
BRAF(V600E)mutation in homozygosis; NIM cells harbor a 
BRAF(V600E)mutation in heterozygosis. Primary cultures of ATC were also a 
kind gift of H. Zitzelsberger (Institute of Molecular Radiobiology, GSF-
National Research Center for Environment and Health GmbH, Neuherberg, 
Germany). The anaplastic cells FB1 cells harbor a BRAF(V600E) mutation in 
heterozygosis; 8505C and FRO harbor a BRAF(V600E) mutation in 
homozygosis (Salvatore et al., 2006); CAL62 cells express wild-type BRAF 
but mutant NRAS allele (Q61K); U-HTH83 cells express wild-tipe BRAF but 
mutant HRAS allele (Q61R) ; C643 cells express wild-type BRAF but mutant 
HRAS allele (G13R); SW1736 cells harbor a BRAF(V600E); U-HTH7 cells 
express wild-type BRAF but mutant NRAS allele (Q61R); OCUT-1 cells 
harbor a BRAF(V600E) mutation in heterozygosis; ACT-1 cells express a 
wild-type BRAF but mutant NRAS (Q61K). (Guida et al., 2005). Continuous 
cell lines were maintained in DMEM supplemented with 10% fetal bovine 
serum, 1% penicillin-streptomycin, and 1% glutamine. PC Cl 3 (hereafter 
"PC") is a differentiated thyroid follicular cell line derived from 18-month-old 
Fischer rats. PC cells were cultured in Coon’s modified Ham F12 medium 
supplemented with 5% calf serum and a mixture of 6 hormones (6H), including 
thyrotropin (TSH, 10 mU/ml), hydrocortisone (10 nM), insulin (10 μg/ml), 
apo-transferrin (5 μg/ml), somatostatin (10 ng/ml) and glycyl-histidyl-lysine 
(10 ng/ml) (Sigma Chemical Co., St. Louis, MO) (Fusco et al 1987). 
 
Tissue samples and immunoistochemistry 
 
Retrospectively-collected archival frozen thyroid tissue samples from 26 
patients affected by thyroid carcinomas (8 PTCs, 10 FTCs and 8 PDCs/ATCs) 
were retrieved from the files of the Struttura Complessa di Anatomia 
Patologica, Istituto Nazionale Tumori, Fondazione G. Pascale, of Naples, upon 
informed consent. Special care was taken to select cases whose corresponding 
histological samples were available for matched analysis. Sections (4-8 μM 
thick) of paraffin-embedded samples were stained with hematoxylin and eosin 
for histological examination to ensure that the samples fulfilled the diagnostic 
criteria required for the identification of PTC, FTC, PDC/ATC. Normal thyroid 
tissue samples were also retrieved from the files of the Struttura Complessa di 
Anatomia Patologica, Istituto Nazionale Tumori, Fondazione G. Pascale, of  
Naples. We used an anti-AXL (R&D Systems) and anti-GAS6 antibodies for 
the staining( R&D Systems?? 
 
RNA extraction and reverse transcription polymerase chain reaction 
 
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley, West 
Sussex, UK) and subjected to on-column DNase digestion with the RNase-free 
DNase set (Qiagen) according to the manufacturer’s instructions. Where 
indicated, cells were stimulated with SDF-1? (100ng/ml) (CXCR4 ligand) 
(Peprotech, Princeton Business Park, Rocky Hill, NJ) for 3h-6h-12h-24h-48h 
and treated with AMD3100 (1μg/μl) (CXCR4 antagonist) and harvested 24h 
after treatment. The quality of RNA was verified by electrophoresis through 
1% agarose gel and visualized with ethidium bromide. Random-primed first 
strand cDNA was synthesized in a 50 μl reaction volume starting from 2 μg 
RNA by using the GeneAmp RNA PCR Core Kit (Applied Biosystems, 
Warrington, UK). Primers were designed by using softwareavailable at 
http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi and 
synthesized by the MWG Biotech (Ebersberg, Germany). To exclude DNA 
contamination, each PCR reaction was also performed on untranscribed RNA. 
Quantitative (real-time) reverse transcription polymerase chain reactions 
(QRT- PCR) were performed by using the SYBR Green PCR Master mix 
(Applied Biosystems) in the iCycler apparatus (Bio-Rad, Munich, Germany). 
Amplification reactions (25μl final reaction volume) contained 200 nM of each 
primer, 3 mM MgCl2, 300 μM dNTPs, 1x SYBR Green PCR buffer, 0.1U/μl 
AmpliTaq Gold DNA Polymerase, 0.01U/μl Amp Erase, RNase-free water, 
and 2 μl cDNA samples. Thermal cycling conditions were optimized for each 
primer pair and are available upon request. To verify the absence of 
nonspecific products, 80 cycles of melting curve (55°C for 10 sec) were 
performed. In all cases, the melting curve confirmed that a single product was 
generated. Amplification was monitored by measuring the increase in 
fluorescence caused by the SYBR-Green binding to double-stranded DNA. 
Fluorescent threshold values were measured in triplicate and fold changes were 
calculated by the formula: 2-(sample 1 ?Ct - sample 2 ?Ct), where ?Ct is the 
difference between the amplification fluorescent thresholds of the mRNA of 
interest and the ß actin mRNA. 
 
RNA interference 
 
SMARTpool (custom-synthesized siRNA) system by Dharmacon was 
used for AXL, TYRO3 and GAS6 silencing. Cells were grown under standard 
conditions. The day before transfection, cells were plated in six-well dishes at 
the density of 3 x 10
5
. As transfection reagent, DharmaFECT was used. 
Transfection was performed by using 100nM of SMARTpool and 6 μl of 
DharmaFECT (Dharmacon). Cells were harvested at 24 and 48 h after 
transfection and analyzed for protein expression and biological activity. 
 
Generation of stable shRNA-expressing cell lines 
  
We obtained 5 lentiviral constructs (pLKO.1puro) containing custom 
synthesized, 21-mer short hairpin RNA (shRNA) directed to various coding 
region of AXL cDNA and with puromycin resistance locus (Mission shRNA, 
pLKO.1 puro) from Sigma-Aldrich, Inc. (Stewart et al., 2003). We transfected 
8505-C the plasmid shAxl pool or a pool of non-targeting vectors (control, 
shCTR) by electroporation. Stable transfectants were clonally selected in 
medium with 500ng/ml puromycin for 15 days, and cell colonies were 
screened for Axl silencing by Western blot analysis. 
 
Protein studies 
 
Protein extractions and immunoblotting experiments were performed 
according to standard procedures. Briefly, cells were harvested in lysis buffer 
(50 mM HEPES, pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 
mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM sodium pyrophosphate, 1 
mM Na3VO4, 10 μg of aprotinin/ml, 10 μg of leupeptin/ml) and clarified by 
centrifugation at 10,000 x g for 30 min. Protein concentration was estimated 
with a modified Bradford assay (Bio-Rad, Munich, Germany). Immune 
complexes were detected with the enhanced chemiluminescence kit (ECL, 
Amersham). Signal intensity was analyzed at the Phosphorimager (Typhoon 
8600, Amersham Pharmacia Biotech) interfaced with the ImageQuant 
software. Anti-AXL for Western Blot and immunoprecipitation analysis was 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); anti-phosphorilated 
AXL, specific for the active AXL phosphorilated at tyrosine 790, was from 
R&D Systems; anti-GAS6 for Western Blot was from R&D Systems.. Anti-
TYRO3 for Western Blot and immunoprecipitation was from Novus 
Biologicals. Anti-AKT and antiphosphoAKT, specific for the active AKT 
phosphorylated at serine 473, were from Cell Signaling (Beverly, MA). Anti-
phosphorylated p44/42 MAPK, specific for the active MAPK phosphorilated at 
threonin 202 and 204, and anti-p44/42 MAPK were from Cell Signaling 
(Beverly, MA) . Monoclonal anti-?tubulin was from Sigma Chemical Co. 
Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish 
peroxidase were from Bio-Rad; secondary antibody donkey anti-goat coupled 
to horseradish peroxidase was from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). Anti-phosphotyrosine antibodies were from Upstate Biotechnology 
Inc., (Lake Placid, NY, USA). 
 
 
 
 
ELISA assay 
 
Thyroid cells plated in 6-well dishes were allowed to grow to 70% 
confluency and then serum-deprived for 24h. Culture media were cleared by 
centrifugation at 2,000 RPM at 4°C to remove detached cells and debris. Gas6 
levels in culture supernatants were measured using a quantitative immunoassay 
ELISA kit (QuantiKine colorimetric Sandwich assay ELISA, R&D Systems, 
UK), following the manufacturer’s instructions. Triplicated samples were 
analyzed at 490 nM with an ELISA reader (Model 550 microplate reader, Bio-
Rad). ELISA results were validated on cell lysates by Western Blotting 
analysis by using an anti-GAS6 antibody (R&D Systems). 
 
Matrigel invasion 
 
In vitro invasiveness through Matrigel was assayed using transwell cell 
culture chambers according to described procedures. Briefly, confluent cell 
monolayers were harvested with trypsin/EDTA and centrifuged at 800xg for 10 
min. The cell suspension (1x10
5
 cells/well) was added to the upper chamber of 
a pre-hydrated polycarbonate membrane filter of 8 μM pore size (Costar, 
Cambridge, MA, USA) coated with 35 μg Matrigel (Collaborative Research 
Inc., Bedford, MA, USA). The lower chamber was filled with complete 
medium or 2.5% FCS (as indicated). After having plated stably-AXL-silenced 
cells on matrigel, cells were then incubated at 37°C in a humidified incubator 
in 5% CO2 and 95% air for 24h and 48h. Nonmigrating cells on the upper side 
of the filter and Matrigel were wiped off and migrating cells on the reverse side 
of the filter were stained with 0.1% crystal violet in 20% methanol for 15 min, 
and photographed. The stained cells were lysed in 10% acetic acid. Triplicated 
samples were analyzed at 570 nM with an ELISA reader (Model 550 
microplate reader, Bio-Rad). The results were expressed as percentage of 
migrating cells with respect to the sh-ctr silenced ones. 
 
Cell proliferation 
 
S-phase entry was evaluated by BrdU incorporation and indirect 
immunofluorescence. Cells were grown on coverslips and, when indicated, 
after 12h of starvation, cells were treated with recombinant human GAS6 
(200ng/ml) for 24h or with a blocking chimaeric protein (Dtk/FC) which 
contains the extracellular domain of Tyro3 fused to the FC portion of the IgG 
(R&D Systems) (2μg/ml) for 24h. Moreover, where indicated, cells have been 
silenced with siRNA (Dharmacon, CO); after 24h of silencing, cells have been 
serum-deprivated for 12h and then treated with recombinant human GAS6 
(200ng/ml) for 24h. In both cases, BrdU was added at a concentration of 10 
μM for the last 2h before the reaction was stopped.. Subsequently, cells were 
fixed in 3% paraformaldehyde and permeabilized with 0.2% Triton X-100. 
BrdU-positive cells were revealed with Texas-Red-conjugated secondary 
antibodies, respectively (Jackson Immuno Research Laboratories, Inc. 
Philadelphia, PA). Cell nuclei were identified by Hoechst staining. 
Fluorescence was visualized with a Zeiss 140 epifluorescent microscope.  
For growth curves, cells were plated at a density of 0.5 x 10
5
 with 
complete medium or in low serum conditions (2.5%) (as shown) and counted at 
the indicated time-points. 
 
TUNEL assay 
 
For terminal desoxynucleotidyl transferase-mediated desoxyuridine 
triphosphate nick end-labeling (TUNEL), an equal number (5 x 10
3
) of thyroid 
carcinoma cells from the different lines was seeded onto single-well Costar 
glass slides. Cells were treated with a proapoptotic substance DEM 
(DiEthylMaleate) at the concentration of 0.6 mM for 12h; then, where 
indicated, cells were treated with recombinant human GAS6 (200ng/ml) for 24 
h or with the blocking chimaeric protein (Dtk/FC). Moreover, where indicated, 
cells have been silenced with siRNA (Dharmacon, CO); after 24h of silencing, 
cells have been serum-deprivated for 12h and then treated with recombinant 
human GAS6 (200ng/ml) for 24h. Cells were fixed in 4% (w/v) 
paraformaldehyde and permeabilized by the addition of 0.1% Triton X-
100/0.1% sodium citrate. Slides were rinsed twice with PBS, air-dried and 
subjected to the TUNEL reaction (Roche). All coverslips were counterstained 
in PBS containing Hoechst 33258, rinsed in water and mounted in Moviol on 
glass slides. The fluorescent signal was visualized with an epifluorescent 
microscope (Axiovert 2, Zeiss) (equipped with a 100X objective) interfaced 
with the image analyzer software KS300 (Zeiss). 
 
Xenografts in nude mice 
 
Mice were housed in barrier facilities and 12-hour light-dark cycles and 
received food and water ad libitum at the Dipartimento di Biologia e Patologia 
Cellulare e Molecolare (University of Naples “Federico II”, Naples, Italy). This 
study was conducted in accordance with Italian regulations for experimentation 
on animals. All manipulations were performed while mice were under 
isoflurane gas anesthesia. No mouse showed signs of wasting or other signs of 
toxicity. BHT101 cells (5 x 10
6
 per mouse) were inoculated s.c. into the right 
dorsal portion of 4-week-old male BALB/c nu/nu mice (The Jackson 
Laboratory). When tumors measured 40 mm3, mice were randomized to 
receive AMD3100 (n = 10; 1.25 mg/kg/twice daily) or vehicle alone (n = 10; 
PBS) by i.p. injection for 5 consecutive days per week for 3 to 4 weeks. 
Moreover, three groups of mice (4-week-old male BALB/c nu/nu mice, 
Jackson Laboratories, Bar Harbor, ME) were inoculated subcutaneously into 
the right dorsal portion with 8505-C shCTR cells (10x10
6
/mouse), 8505-C 
shAXL CL1(1x10
6
/mouse), 8505-C shAXL CL2 (1x10
6
/mouse). Tumor 
diameters were measured at regular intervals with a caliper. Tumor volumes 
(V) were calculated with the formula: V= A x B2/2 (A=axial diameter; B= 
rotational diameter). Tumors were excised and fixed overnight in neutral 
buffered formalin and processed by routine methods. 
 
Statitical analysis 
 
To compare 8505-CshCTR versus 8505-CshAXL xenograft growth nude 
mice, we used the unpaired Student’s t test (normal distributions and equal 
variances). The clinico-pathological data were statistically evaluated with a 
two-tailed Student’s t test; the chi2 test was used to establish the statistical 
significance of the distributions. Statistical analysis was done with the 
GraphPad Instat software, v.3.0b. Differences were statistically significant at P 
<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
The Tyro3 and Axl receptors are transcriptional targets of the CXCR4/SDF-
1?  axis and are overexpressed in thyroid cancer cells 
 
To better understand the biological role of the SDF-1? chemokine and of 
its receptor CXCR4 in thyroid cancer, we performed global gene expression 
profiling of human TPC-1 cells, derived from a human PTC. By using an 
oligonucleotide-based array, representing the entire human genome, we found 
high expression levels for Tyro3 and Axl in SDF-1??treated  cells. Tyro3 and 
Axl mRNA levels were evaluated by Real-time RT-PCR (data not shown) and 
the corresponding proteins were assessed by using western blot analysis. As 
shown in fig.1A, Tyro3 basal levels were much lower than those of Axl in 
TPC1 cells, but SDF-1? treatment increased both Axl and Tyro3 protein levels 
in time-course experiments. Interestingly, tyrosine-phosphorylation of the two 
receptors also increased upon SDF-1? treatment.  
We then looked at Tyro3 and Axl levels by western blot analysis in a 
panel of thyroid cancer cell lines and in primary cultures of thyroid normal 
cells. As shown in Fig. 1B, Tyro3 and Axl protein levels were not elevated in 
normal thyroid cells, while most of the cancer cell lines featured high levels of 
the two receptors, being overall Axl consistently more expressed than Tyro3. 
This was also confirmed by RT-PCR experiments (data not shown). We also 
evaluated the expression of both the receptors in a rat thyroid cell line (PC Cl3) 
and in PC Cl3-derived cell lines transduced with different oncogenes. While 
we could not detect endogenous Tyro3, we were able to show that two 
RET/PTC isoforms, RET/PTC1 and RET/PTC3, the cooperation between E1A 
and RAF, and the v-mos oncogenes were able to induce Axl overexpression in 
these cells.  Since it has been reported that TAM receptors are activated in 
different cancer hystotypes (Craven et al.,1995; Nemoto et al., 1997; Ito 
2002; Zantek et al., 2001; Shieh et al., 2005; Gustafsson et al., 2009) , we 
evaluated the levels of phosphorylation of both Tyro3 and Axl in our cell lines 
by means of immunoprecipitation followed by western blot analysis with anti-
phosphotyrosine antibodies. As shown in fig. 1C, we then analyzed Axl 
tyrosine-phosphorylation and found that all the cell lines tested displayed Axl 
activation, being phosphorylation levels higher in Cal62, SW1736, 8505-C and 
Nim with respect to OCUT-1 and ACT1. The TPC1 cell line, derived from a 
human PTC featuring a spontaneous RET/PTC1 rearrangement, showed the 
highest levels of phospho-Axl relative to total Axl. We also evaluated the 
activation of Axl  by using an anti-phospho-Axl antibody, which specifically 
recognizes Tyr 779 (Y779), a residue of the carboxy-terminal tail that is 
phosphorylated upon Axl stimulation, as previously reported. As shown in Fig 
1C, CAL62, NIM and TPC1 cell lines diplayed the highest Y779 
phosphorylation levels. Axl-expressing PC Cl3  rat cell lines PC PTC3, PC663 
and PC E1A RAF were tested for Axl activation. As shown in fig. 1C, Axl 
phosphorylation was detected in all the three cell lines, with PC PTC3 
displaying the highest levels. Since it has been reported that Axl activation in 
tumor cells is due to autocrine or paracrine loops, we asked whether thyroid 
cancer cell lines expressed one of the Axl/Tyro3 ligands. RT-PCR experiments 
suggested that Gas6, but not ProteinS, was expressed by our cells (not shown). 
To confirm this finding, we evaluated Gas6 levels by using both ELISA 
immunoassay and western blot analysis. As shown in Fig. 2A, 8505-C, NIM, 
CAL62 and SW1736 secreted detectable levels of Gas6 in the culture medium. 
When we screened the cell lines for Gas6 expression by WB analysis, we 
found that all the cell lines produced Gas6, with the exception of TPC1 (Fig 
2B). Based upon these data, we identified cell lines, such as CAL62and 
SW1736, that produce different levels of Gas6, which is inefficiently released 
in the culture medium; cell lines, such as NIM and 8505-C, that produce and 
secrete high levels of Gas6; cell lines, such as TPC1, that did not produce 
detectable levels of Gas6, but, despite this, display high levels of Axl 
phosphorylation. These data indicate that thyroid cancer cells widely express 
Axl and Tyro3 receptors, being Tyro3 expressed at lower levels than Axl. In 
most cell lines Axl and Tyro3 are activated, as demonstrated by the high levels 
of phosphotyrosine content of the receptors. Receptor activation is probably be 
due to an autocrine effect, since all the cell lines, with the exception of the 
TPC1, express variable amount of the ligand, Gas6. 
 
 
Human thyroid cancer specimens express Axl and its ligand Gas6 
 
We analysed human thyroid cancer specimens for Axl expression. To 
this aim, we collected 26 thyroid carcinoma samples (8 PTCs, 10 FTCs and 8 
PDC/ATCs) (Table 1) and analysed them by using immunohistochemical 
staining with a specific  anti-human Axl antibody. Of  all the carcinoma 
analised, 73% (19/26) scored positive for Axl expression. These data are 
summarized in Table 1. Axl positivity was observed mainly in tumoral cells 
(Fig. 3A). Most of the samples display membrane positivity, but a small 
number of specimens were characterized by cytosolic staining. When Axl was 
cytosolic, it was found into perinuclear vescicles probably representing the 
Golgi apparatus. This pattern is typical of overexpressed transmembrane 
proteins. Tumoral stroma and non tumoral adjacent tissues were negative for 
Axl staining, with the exception of red blood cells, that were strongly 
recognized by anti-Axl antibody. This observation confirms previous findings 
indicating that this receptor is indeed physiologically expressed in eritrocytes 
(Tang et al., 2009). To assess whether thyroid carcinomas feature 
autocrine/paracrine loops involving Axl and its ligand, we also assessed Gas6 
expression by IHC in the same sample set. As shown in fig. 3B, most of the 
analysed specimens scored positive for Gas6 expression. Gas6 staining was 
cytosolic and was mainly found in carcinoma cells; some samples also 
displayed stromal positivity, suggesting that ligand can also be provided by 
other cells of the tumor microenvironment.  Table 1 summarizes the expression 
data of Axl and Gas6 in thyroid carcinoma samples. 
 
 
Axl/Tyro3-Gas6 axis blockade inhibits thyroid cancer cell proliferation and 
survival 
 
To investigate whether the Axl/Gas6 loop has a role in thyroid cancer 
biology, we selected two PTC cell lines, TPC-1 and NIM. As shown above, 
TPC1 cells express high levels of activated Axl in the absence of ligand. We 
analyzed the levels of DNA synthesis by BrdU incorporation assays in basal 
conditions (serum deprivation) and in the presence of Gas6. As shown in Fig. 
3A, 10% of TPC1 incorporated BrdU in conditions of serum starvation. When 
Gas6 was added, BrdU incorporation increased to 20%. Consistently, a 
chimaeric protein (Dtk/FC)which contains the extracellular domain of Tyro3 
fused to the FC portion of the IgG, that is able to suppress Gas6-mediated 
effects by sequestering this ligand, does not modify the rate of BrdU-positive 
cells grown in basal conditions, but inhibits the effects of Gas6 treatment. To 
further evaluate the role of Axl in TPC1 cell proliferation, we used RNA 
interference. Axl silencing was verified by western blot analysis (Fig 4C). As 
shown in Fig. 4A, when Axl was silenced, there was only a modest reduction 
of BrdU incorporation in basal conditions. This reduction was more dramatic 
in the presence of Gas6: BrdU-positive cell rate dropped from 27% to 8%. 
Gas6 silencing did not modify TPC1 growth rate, consistent with the 
observation that Gas6 is not produced by TPC1 cells (not shown).  To evaluate 
whether Axl blockade influences TPC1 survival, we first treated these cells 
with a proapoptotic substance, Diethylmaleate (DEM), for 24h, and performed 
TUNEL assays (Fig. 4B). In this condition, 48% of TUNEL-positive cells were 
obtained; Gas6 addition dramatically decreased this percentage. The blockade 
of exogenous Gas6  with DtkFC almost completely reverted this effect. 
Accordingly, DtkFC did not modify the percentage of  apoptotic cells when 
used in the absence of Gas6. We also performed apoptosis assays in the 
presence of Axl- or Gas6-targeting small interfering RNAs. In this case, 
apoptosis was induced by 24 h serum deprivation. In this condition, 10% of  
apoptotic cells were observed. This percentage decreased to 5% when Gas6 
was added. Axl silencing dramatically increased the rate of apoptotic cells to 
30%. Interestingly, when Gas6 was added to Axl-silenced cells, the pro-
apoptotic effects of Axl silencing were significantly inhibited (Fig. 4B). This 
effect is not likely to be due to incomplete Axl silencing, since western blot 
analysis of silenced cells showed a complete disappearance of the protein. A 
possible explanation is that the other receptor, Tyro3, can substitute Axl 
function. Again, Gas6 silencing did not modify the apoptosis rate both in the 
presence and in the absence of Gas6 (not shown). Since the additon of Gas6 
partially recovered the effects of Axl blockade in this cell line, we evaluated 
whether Tyro3 also has a role in thyroid cancer cell proliferation and survival. 
To this aim, Tyro3 was knocked down in TPC1 cells through RNA 
interference, and DNA synthesis and apoptosis were evaluated. As shown in 
figure 4A and B, Tyro3 silencing affected both BrdU incorporation and 
apoptosis. Silencing of both Tyro3 and Axl receptors increased the effect of the 
single knockouts; finally, Gas6 treatment did not modify the effect of the 
double knockouts. Similar experiments were performed by using the NIM cell 
line. As shown above, these cell express both Axl and Gas6. Exogenous 
addition of this ligand did not significantly modify  BrdU incorporation and 
apoptosis rate of NIM cells. Instead, the blockade of both endogenous Axl and 
Gas6 by using DtkFC or RNAi inhibited NIM DNA synthesis (fig.5A), and 
exogenous Gas6 addition reverted  these effects. Similar results were obtained 
when apoptosis was evaluated. DEM treatment induced 40% of apoptotic cells, 
and the blockade of Gas6 with DtkFC increased to 62% the percentage 
apoptotic cells. When cells were serum deprived, we observed  10% of 
apoptotic cells. This percentage was only slightly modified by Gas6 treatment. 
Axl or Gas6 silencing strongly enhanced NIM apoptotic rate, and these effects 
were again reverted by exogenous Gas6 (fig. 5B). Tyro3 silencing also affected 
NIM proliferation and survival, and Tyro3/Axl silencing was as effective as 
Gas6. Again, Gas6 treatment did not modify the effect of the double 
knockouts. Gas6, Tyro3 and Axl knockdown was verified by western blot 
analysis (fig. 5C). We also used siRNA-mediated silencing to verify whether 
Axl Knockdown could impair proliferation and survival of human ATC cell 
lines. To this aim, we used 8505-C and Cal62 cells. As shown in figure 6A 
and B, Gas6 stimulated cell proliferation and inhibited apoptosis of 8505-C. 
Consistently, Axl silencing slightly inhibited BrdU incorporation and enhanced 
apoptosis of  these cells. 
 
 
Effects of stable silencing of Axl in 8505-C ATC  cells 
 
To confirm that Axl silencing effectively inhibited the viability of thyroid 
cancer cells, we stably transfected 8505-C with a pool of vectors expressing 
five different shRNAs directed to Axl or expressing control non-targeting 
shRNAs. After antibiotic selection, cell clones were isolated and screened by 
western blot analysis for Axl expression: as shown in fig. 7A,  we identified 
several clones in which Axl expression was completely knocked down. Six 
Axl-knockout (shAxl Cl 1-6) and two control clones (shCTR Cl 1-2) were 
selected for further analyses. We first verified whether Axl knockdown could 
impair cell growth both in optimal (10% FCS) or in low serum (2,5% FCS) 
conditions by performing growth curves. As shown in Fig. 7B, shRNA-
mediated Axl silencing showed mild effects on cell proliferation in complete 
culture medium, while it was significantly more effective in low serum 
conditions. To  assess whether reduced cell growth was due to decreased DNA 
synthesis or increased cell death, cells were serum starved for 12h and we 
evaluated the percentage of BrdU- and TUNEL-positive cells. As shown in 
figure 7C, all shAxl clones displayed a significant reduction of BrdU 
incorporation and a significant increase in apoptosis when compared to control 
clones. Moreover, we asked whether stable AXL silencing on ATC cell lines 
could impair cell invasiveness through Matrigel. Invasive ability of cells was 
verified both in optimal (10%FCS) or in low-serum (2,5%FCS) conditions. As 
indicated in Fig. 8, shAXL clones showed a clear decrease of invasive ability 
with respect to shCTR, but only in low-serum conditions (Fig. 8). 
 
 
Axl silencing inhibits experimental tumor growth 
 
Next, we evaluated the role of Axl in tumor growth by using xenografts 
of ATC cells into (nu/nu) immunodeficient mice. To this aim, we choose 8585-
C as a model cell line because it expresses Axl  and it is able to efficiently form  
tumors when injected into nude mice. To study the role of Axl in tumor 
growth, we injected animals with parental, shCTR-transfected (shCTR Cl1), 
and shAxl- expressing (shAxl ClX and ClY) 8505-C cell lines, and compared 
their growth rate. Parental cells formed tumors with the same efficiency as 
shCTR-transfected cells did (not shown). As shown in fig. 9, the 
tumorigenicity of 8505-C shAxl Cl4 and Cl6 was dramatically reduced when 
compared with 8505-C shCTR control cells. when compared with 8505-C 
shCTR cells. At three weeks, shCTR tumor median volume was 34 mm
3
, while 
shAXL was < 10 mm
3
. At four, five and six weeks, shCTR tumors continued 
to grow, reaching a median volume of ~150 mm
3. 
shAXL tumors did not grow 
or regressed. At the end of the experiment, no shAXL tumors were available. 
This precluded histological analysis. 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Thyroid cancer is the most frequent endocrine neoplasia, and its 
incidence is rapidly increasing. We previously found that normal rat thyroid 
cells, transduced with Papillary Thyroid Cancer (PTC)-related oncogenes, 
display an inflammatory signature, that includes cytokines, chemokines and 
their receptors (Melillo et al., 2005). One of the chemokine receptor we 
identified, CXCR4, is frequently up-regulated in thyroid cancer. SDF-1, a 
CXCR4 ligand, induces proliferation, survival and invasive ability of PTC 
cells, and a CXCR4 blocking compound, AMD 3100, inhibits thyroid cancer 
growth (Castellone et al., 2004; De Falco et al., 2007). To better understand 
the molecular basis of  SDF-1 activity in thyroid cancer cells, we performed 
global genome expression profiling analysis on CXCR4-expressing human 
PTC cells upon SDF-1 stimulation,  and we identified two tyrosine-kinase 
receptors, TYRO3 and AXL, as transcriptional targets of this chemokine. 
TYRO3 and AXL belong to the subfamily of receptor tyrosine kinases 
(RTKs) that also includes Mer (from which the family name: TAM) (Lai and 
Lemke, 1991; O’Bryan et al., 1991). The ligands for TAM receptors are Gas6 
(Growth Arrest-Specific 6) and protein S, two vitamin K-dependent proteins 
that exhibit 43% amino-acid sequence identity and share similar domain 
structures (Stitt et al., 1995; Varnum et al., 1995). TAM activation and 
signaling has been implicated in multiple cellular responses including cell 
survival, proliferation, migration and adhesion (Hafizi and Dahlback, 2006). 
TAM receptor signaling has been shown to regulate vascular smooth muscle 
homeostasis (Korshunov et al., 2006, 2007), platelet function, thrombus 
stabilization (Angelillo-Scherrer et al., 2001; Gould et al., 2005) and 
erythropoiesis (Angelillo-Scherrer et al., 2008). TAM receptors are also 
implicated in the control of oligodendrocyte cell survival (Shankar et al., 
2006) and in the regulation of osteoclast function (Katagiri et al., 2001). 
Recent studies in knockout mice have revealed that TAM receptors play 
pivotal roles in innate immunity (Lemke and Rothlin, 2008). TAM receptors 
inhibit inflammation in macrophages and dendritic cells (Sharif et al., 2006; 
Rothlin et al., 2007), promote the phagocytosis of apoptotic cells (Lu et al., 
1999; Prasad et al., 2006) and stimulate the differentiation of Natural Killer 
cells (Caraux et al., 2006). In many of these instances, the primary 
downstream TAM signaling pathway appears to be PI3K/AKT pathway 
(Angelillo- Scherrer et al., 2001; Keating et al., 2006; Shankar et al., 2006); 
however, the Janus kinase-STAT pathway is essential for TAM-mediated 
immune responses (Rothlin et al., 2007). In addition, cooperative interaction 
between TAM receptors and cytokine receptor signaling network is required 
for many TAM-regulated biological functions (Budagian et al., 2005b; 
Rothlin et al., 2007).  
Several reports underlined the importance of TAMs receptor in cancer. In 
particular, AXL was first identified in patients with chronic myelogenous 
leukemia and, if overexpressed in non-transformed cells,  it induces neoplastic 
conversion (Janssen et al., 1991; O’Bryan et al., 1991). AXL overexpression 
has been reported in a variety of human cancers (Craven et al., 1995; Ito et 
al., 1999; Berclaz et al., 2001; Sun et al., 2004; Shieh et al., 2005), and is 
associated with invasiveness and metastasis in lung (Shieh et al., 2005), 
prostate (Sainaghi et al., 2005), breast (Meric et al., 2002), and gastric 
cancers (Wu et al., 2002) as well as in renal cell carcinoma (Chung et al., 
2003; Gustafsson et al., 2009) and glioblastoma (Hutterer et al., 2008). A 
recent study showed that AXL overexpression, through a ‘tyrosine kinase 
switch’, leads to resistance to the samll TK inhibitor Imatinib in 
gastrointestinal stromal tumors (Mahadevan et al., 2007). AXL expression is 
induced by chemotherapeutic drugs and it confers drug resistance in acute 
myeloid leukemia (Hong et al., 2008). These evidences suggest that AXL may 
be involved in the regulation of multiple aspects of tumorigenesis. For these 
reasons, we decided to investigate the biological role of TYRO and AXL 
receptors in human thyroid carcinomas. 
In this study, we found that TYRO3 and AXL expression can be induced 
by SDF-1-?. Axl and Tyro3 were expressed in human thyroid cancer cells and 
in rat thyroid cells neoplastically transformed by several oncogenes, but not in 
normal thyroid cells. AXL was also constitutively phosphorylated in most of 
these cells. This was due to the constitutive presence of the ligand Gas6; the 
only exception to this rule was represented by the TPC1 cell line, in which 
AXL was highly phosphorylated although ligands are absent. In this case, some 
other mechanisms, still not understood, may be active to keep the receptor in a 
constitutively active status. We showed AXL expression in a set of human 
thyroid carcinoma samples (8 PTCs, 10 FTCs and 8 PDC/ATCs), but not in 
normal thyroid specimens, by immunohystochemistry. Interestingly, we found 
that 73% of evaluated samples displayed strong AXL positivity which was 
confined to tumoral cells. Moreover, most of the analysed specimens scored 
positive for Gas6 expression; Gas6 staining was cytosolic and mainly found in 
carcinoma cells, thus suggesting the existence of  an autocrine loop.  
In cell lines that expressed both receptors and ligand, the inhibition of 
TYRO3, AXL or Gas6  reduced cell proliferation and increased  apoptotic rate. 
When either Tyro3 or Axl were silenced, Gas6 could partially recover 
proliferation and antiapoptotic activity, indicating that both the receptors are 
involved in Gas6-mediated biological activities. Instead, when both the 
receptors were inhibited, Gas6 had no effect on cell proliferation and survival. 
Accordingly, we show that the stimulation of  GAS6-negative TPC-1 cells with 
exogenous GAS6 increased their proliferation and survival. These data, taken 
together, indicate that the two tyrosine-kinase receptors are able to modulate 
two of the main features of malignant cells, proliferation and resistance to 
apoptotic stimuli.  
AXL expression is associated with invasiveness and metastasis in various 
cancers including breast (Meric et al., 2002; Zhang et al., 2008), lung (Shieh 
et al., 2005) and gastric (Sainaghi et al., 2005) cancers, as well as in 
glioblastoma (Hutterer et al., 2008). The involvement of AXL in promoting 
cancer cell migration and invasion has been demonstrated in vitro (Vajkoczy 
et al., 2006; Tai et al., 2008; Zhang et al., 2008). In breast cancer models, 
ectopic expression of AXL was sufficient to confer a highly invasive 
phenotype to weakly invasive MCF7 cells. Consistently, inhibition of AXL 
signaling by shRNA knockdown or an anti-AXL antibody decreased mobility 
and invasiveness of highly invasive breast cancer cells (Zhang et al., 2008). 
We also found that stable silencing of AXL in 8505-C ATC cells (8508-C 
shAXL) drammatically reduced thyroid cancer cell viability; we also observed 
that stable-AXL-silenced clones displayed a reduction of their invasive ability. 
Taken together these studies established a critical role of AXL in promoting 
cell migration and invasion. When we injected immunodeficient mice with 
8505-C shAXL clones, we observed a complete inhibition of tumor formation 
in vivo. Our data confirm previous studies showing that AXL expression is 
involved in  tumor growth of glioblastoma (Vajkoczy et al., 2006) and breast 
cancer models (Holland et al., 2005). It has been shown that activated AXL 
can interact with the p85? and p85? subunits of phosphatidylinositol 3-
kinase (Braunger et al., 1997)  and this mediates the strong the antiapoptotic 
effect mediated by the receptor. Furthermore, AXL can induce  angiogenesis, 
as confirmed by the observation that AXL and GAS6 are co-expressed in 
tumor associated vascular cells in gliomas (Hutterer et al., 2008) and that 
AXL knockdown is additive with anti-VGEF to inhibit endothelial tube 
formation (Li et al., 2009). Whether this is also the case for  thyroid cancer is 
still unknown. Unfortunaltely, the complete suppression of tumor growth of 
8505-C shAXL cells precluded further analysis of excised tumors. However, 
preliminary observations obtained by us indicate that Gas6 is a strong 
stimulator of the PI3-K/Akt pathway in thyroid cancer cells and that the 
blockade of Axl/Tyro3-Gas6 axis inhibits Akt phosphorylation. These data 
indicate that Axl blockade could impair tumor growth, at lea st in part,  by 
inhibiting of  the PI-3K pathway. 
In conclusion, our data strongly suggest that AXL/TYRO3-Gas6 axis can 
be considered as a novel potential target of thyroid anticancer therapy. Several 
compounds have been identifyed (small inhibitors and monoclonal antibodies) 
that could block AXL signaling by acting at different levels (Li et al., 2009). 
Our data indicate that these compound should be exploited to treat thyroid 
cancer. 
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FIGURE LEGENDS 
FIGURE 1 
Expression levels analysis of AXL and TYRO3 receptors in human cancer 
thyroid cells. 
A) Analysis of Tyro3 and Axl protein levels by western blot analysis 
on TPC1 cells stimulated with SDF-1? at different time-points. 
B) Evaluation of TYRO3 and AXL protein levels by western blot in a 
panel of thyroid cancer cell lines and in primary cultures of thyroid 
normal cells (NT). Equal amounts of proteins (50 μg) were 
immunoblotted with anti-TYRO3 and anti-AXL polyclonal 
antibodies. Anti-?tubulin monoclonal antibody was used as a 
control for equal loading. 
C) Analysis of AXL tyrosine-phosphorylation by immunoprecipitation 
followed by anti-phosphotyrosine and phospho-AXL western blot 
in a panel of human PTCs and ATCs cell lines and in a rat thyroid 
cell line (PC Cl3)-derived cell lines transduced with different 
oncogenes. AXL-phosphorilation levels were evaluated with an 
anti-AXL antibody by western blot with respect to the total AXL 
protein levels. 
 
FIGURE 2 
Analysis of AXL/TYRO3 ligand, Gas6 
A)  Evaluation of Gas6 levels by using ELISA immunoassay. 
B) Western blot analysis with specific anti-Gas6 antibody. Anti-
?tubulin monoclonal antibody was used as a control for equal 
protein loading. 
 
FIGURE 3 
Immunohistochemistry on human thyroid cancer specimens 
26 thyroid carcinoma samples (8 PTCs, 10 FTCs and 8 PDC/ATCs) were 
analysed by using immunohistochemical staining with a specific anti-human 
AXL antibody. AXL positivity was observed mainly in tumoral cells. Gas6 
staining was cytosolic and was mainly found in carcinoma cells but also a 
stromal positivity was displayed. 
 
FIGURE 4  
Axl/Tyro3-Gas6 axis blockade inhibits TPC1 cell proliferation and 
survival 
A) TPC1 cells were serum-deprived for 12h and, where indicated, 
treated with GAS6 (200ng/ml) and/or the blocking chimaeric 
protein Dtk/FC for 24h (left panel). As shown in the right panel, 
TPC1 were silenced for AXL or TYRO3 receptors; after 24h of 
silencing, cells were serum-deprived for 12h and then treated or not 
with GAS6 for 24h. Gas6 stimulated BrdU incorporation of TPC1 
cells and this effect was blocked by the Dtk/FC protein. 
Consistently, AXL and TYRO3 silencing inhibited TPC1 BrdU 
incorporation. BrdU was added two hours before the reaction was 
stopped, and cells were processed for immunofluorescence. The 
results are expressed as percentage of BrdU incorporation with 
respect to untreated and sictr-silenced TPC1 cells, respectively. The 
average results and the standard deviations of three independent 
experiments in which at least 400 cells were counted are reported. 
B) The indicated cell line was treated with a proapoptotic sunstance 
DEM (DiEthylMaleate) for 12h and then with GAS6 and/or Dtk/FC 
for 24h; in these conditions, Gas6 decreased the percentage of 
TPC1 apoptotic cells and Dtk/FC reverted this effect (left panel). 
Accordingly,  when TPC1 were serum-deprived and AXL, TYRO3 
or both were silenced, the percentage of apoptotic cells increased 
(right panel). The percentage of apoptotic cells was evaluated with 
the TUNEL reaction. The results are expressed as percentage of 
apoptotic cells. The average results and S.D. of three independent 
experiments in which at least 400 cells were counted is reported. 
C) Western blot analysis to verify AXL-TYRO3 silencing with anti-
AXL and anti-TYRO3 antibodies. Anti-tubulin monoclonal 
antibody was used as a control for equal protein loading. 
 
FIGURE 5 
Axl/Tyro3-Gas6 axis blockade inhibits NIM cell proliferation and survival. 
A) NIM cell lines were serum-deprived and then treated with GAS6 
and Dkt/FC as indicated in left panel. BrdU incorporation was 
evaluated in presence or absence of human recombinant GAS6. 
Dtk/FC inhibited DNA synthesis of NIM cells but exogenous Gas6 
didn’t modify the percentage of BrdU incorporation (left panel). 
Moreover, as shown in the right panel, NIM were silenced for AXL, 
TYRO3 and GAS6; AXL-, TYRO3- and much more evident Gas6-
silencing strongly affected NIM BrdU incorporation. BrdU was 
added two hours before the reaction was stopped, and cells were 
processed for immunofluorescence. The results are expressed as 
percentage of BrdU incorporation with respect to untreated and 
sictr-silenced NIM cells,respectively. The average results and the 
standard deviations of three independent experiments in which at 
least 400 cells were counted are reported. 
B) NIM cell line was treated with the proapoptotic sunstance DEM 
(DiEthylMaleate) and then with GAS6 and Dtk/FC (left panel). 
Gas6, as expected, did not modify  NIM apoptotic rate while the 
Dtk/FC protein increased the percentage of apoptotic cells and the 
addition of exogenous Gas6 reverted this effect. NIM cells were 
serum deprived after AXL, TYRO3( individually or both) and Gas6 
silencing. In these conditions,the prencentage of apoptotic cells 
increased and exogenous Gas6 reverted this effect (right panel). The 
percentage of apoptotic cells was evaluated with the TUNEL 
reaction. The results are expressed as percentage of apoptotic cells. 
The average results and S.D. of three independent experiments in 
which at least 400 cells were counted is reported. 
C) Western blot analysis to verify Axl- Tyro3-GAS6 silencing with 
anti-AXL, anti-TYRO3 and anti-GAS6 antibodies. Anti-tubulin 
monoclonal antibody was used as a control for equal protein 
loading. 
 
FIGURE 6  
Axl/Tyro3-Gas6 axis blockade also inhibits ATC cell proliferation and 
survival. 
A) 8505-C were silenced for AXL receptor and BrdU incorporation 
was evaluated. Gas6 stimulated 8505C BrdU incorporation while 
siAXL inhibeted. Gas6 reverted this effect. BrdU was added two 
hours before the reaction was stopped, and cells were processed for 
immunofluorescence. The results are expressed as percentage of 
BrdU incorporation with respect to sictr-silenced. 8505-C cells. The 
average results and the standard deviations of three independent 
experiments in which at least 400 cells were counted are reported. 
B) 8505C cell line was subjected to AXL silencing and serum-
deprivation. AXL silencing increased the percentage of apoptotic 
cells and Gas6 reverted this effect. The percentage of apoptotic cells 
was evaluated with the TUNEL reaction. The results are expressed 
as percentage of apoptotic cells. The average results and S.D. of 
three independent experiments in which at least 400 cells were 
counted is reported. 
C) Western blot analysis to verify Axl silencing with an anti-AXL 
antibody. Anti-?tubulin monoclonal antibody was used as a control 
for equal protein loading. 
 
FIGURE 7 
Biological effects of stable silencing of Axl in 8505-C ATC cells. 
A) Screening of cell clones (8505-C shAXL) by Western blot analysis with 
an anti-AXL antibody. Anti-tubulin monoclonal antibody was used as a 
control for equal protein loading. 
B) Growth curves on screened 8505-C clones. Cells were plated at a 
density of 0.5 x 10
5
 in complete (10% FCS) (left panel) or in low serum 
conditions (2.5% FCS) (right panel), harvested and counted at the 
indicated time-points. The average results of at least three independent 
determinations were reported. 
C) BrdU-incorporation was measured to evaluate S-phase entry of stably 
silenced clones. AXL silencing decreased the percentage of BrdU-
positive cells. Cells were grown on coverslips, and kept in serum-
deprivation conditions for 12h. BrdU was added two hours before the 
reaction was stopped, and cells were processed for 
immunofluorescence. The average results and the S.D. of three 
independent experiments in which at least 400 cells were counted are 
reported. 
D) TUNEL reaction was performed on cell clones to evaluated the 
proapoptotic effect of AXL stable silencing. Cells were serum-deprived 
for 12h and then processed for TUNEL assay. AXL silencing increased 
the percentage of apoptotic cells. The results are expressed as 
percentage of apoptotic cells. The average results and S.D. of three 
independent experiments in which at least 400 cells were counted is 
reported. 
 
FIGURE 8 
Matrigel invasion on 8505-C shAXL 
A) Cells were added to the upper chamber of a pre-hydrated 
polycarbonate membrane filter of 8 μM pore size coated with 35 μg 
Matrigel. The lower chamber was filled with complete medium or 
2.5% FCS (as indicated). Triplicated samples were analyzed at 570 
nM with an ELISA reader (Model 550 microplate reader, Bio-Rad). 
The results were expressed as percentage of migrating cells with 
respect to the unsilenced ones. 
B) Densitometric analysis of Matrigel invasion assay was reported. 
AXL silencing inhibited Matrigel invasion in low-serum conditions. 
 
FIGURE 9 
Tumorigenicity of 8505-C shAxl in ATC cell xenografts. 
Three groups of mice (4-week-old male BALB/c nu/nu mice) were inoculated 
subcutaneously into the right dorsal portion with 8505-C shCTR cells 
(10x10
6
/mouse), 8505-C  shAXL CL1(1x10
6
/mouse), 8505-C shAXL 
CL2(1x10
6
/mouse), respectively Tumor diameters were measured at regular 
intervals with a caliper. Tumor volumes (V) were calculated with the formula: 
V= A x B2/2 (A=axial diameter; B= rotational diameter). 8505C tumor growth 
was strongly impaired in shAXL clones with respect to shCTR. Unpaired 
Student’s T test (normal distributions and equal variances) was applied. All P 
values were two sided,and differences were statistically significant at P < 0.05. 
 
TABLE 1  
Percentage of AXL and GAS6 positivity in the panel of human thyroid cancer 
specimens analysed by immunohistochemistry.  
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